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 SUMMARY 
Helminth parasites may be regarded as intestinal symbionts that co-evolved with the immune system 
and are thereby essential for its proper maturation and functioning. According to the helminth therapy 
concept, the modulation that helminths exert on the immune system can counteract the dysregulation 
that occurs in different organic diseases.  
Clinical trials in inflammatory bowel diseases (IBD) have been performed mainly with T. suis ova 
(TSO). Despite the first promising open studies that showed a therapeutic effect in both Ulcerative 
Colitis (UC) and Crohn’s disease (CD), larger controlled, randomized multi-zentrische studies failed 
to show a significant effect of TSO in comparison to placebo in mild to moderate CD patients. The 
available evidence in support of its efficacy and safety is complicated by the lack of systematic 
studies in immunosuppressed individuals that constitute the majority of the IBD patients. 
Two major obstacles complicate translational research with T. suis. First, the parasites fail to colonise 
the intestine of mouse and rats. Second, in rabbits -where T. suis follows the life cycle observed in 
humans- a suitable IBD model was missing. 
To overcome these hurdles, we developed a novel protocol to induce a colitis in rabbits using dextran 
sodium sulphate (DSS). This model allowed the evaluation of the efficacy and safety of TSO 
treatment in immunocompetent and immunocompromised hosts. 
We show that TSO ameliorate the development of colitis in immunocompetent rabbits, by limiting 
weight loss and reducing the DSS-induced histopathology. Transcriptome analysis by RNAseq 
reveals that TSO strongly affect the response of LPMC to the DSS induced injury. In particular, TSO 
modulates innate inflammatory and cell-adhesion pathways. The weaker modulation exerted on 
intestinal epithelial cells (IEC) suggests that T. suis excretes or secretes molecules that bypass the EC 
barrier and directly interact with the lamina propria environment. 
The preventive immunomodulation is lost in immunosuppressed animals, where TSO treatment 
exacerbates the colitis. The presence of larvae in the caecum of immunosuppressed rabbits 
demonstrates a failure in the control of the helminth infection.  
Our findings highlight that TSO treatment can be detrimental to immunosuppressed patients as 
immunosuppression predisposes to adverse effects of helminth therapy. 
 
  
 
  1 
 
   
2 
 ZUSAMMENFASSUNG 
Die Besiedelung mit Helminthen löst eine Immunreaktion aus, die anti-inflammatorisch auf die 
überschiessende Immunreaktion während Immunerkrankungen wirken kann. Initiale Studien an 
Patienten zeigten dass die Verabreichung von Eiern des Schweinepeitschenwurms Trichuris suis 
(T. suis ova, TSO) zu einer deutlichen Verbesserung des Krankheits-Aktivitätsindex bei chronisch 
entzündlichen Darmerkrankungen führt. Randomisierte, kontrollierte Mulitcenter Studien konnten 
diesen Effekt jedoch nicht bestätigen.  
Genauere Untersuchungen zur Wirkungsweise einer TSO-Therapie konnten bislang aufgrund des 
Fehlens eines geeigneten Tiermodells nicht durchgeführt werden. Eine TSO-Infektion mit ähnlichem 
Verlauf wie er für den Menschen beobachtet wird, konnte nur für Kaninchen und Affen gezeigt 
werden. Die existierenden Kolitis Modelle in Kaninchen waren jedoch für die Untersuchungen zur 
Wirkungsweise einer TSO-Therapie nicht geeignet. Daher etablierten wir ein Dextran Sodium Sulfat 
(DSS) Modell einer akuten Kolitis im Kaninchen. Anhand dieses Modells konnten wir die Wirkung 
von TSO in einem präventiven, therapeutischen Ansatz in immunkompetenten und 
immunsupprimierten Tieren untersuchen.  
Wir konnten zeigen, dass TSO den Kolitis-assoziierten Gewichtsverlust verhindert und die Schwere 
der Entzündung im Cöcum reduziert. Eine Analyse des Cöcum-Transkriptoms zeigt einen 
dramatischen Effekt von TSO auf mononukleäre Zellen der Lamina Propria (LPMC). Im Besonderen 
hemmt TSO angeborene inflammatorische Prozesse (“innate immunity”) und Zelladhäsionsprozesse, 
welche durch DSS induziert sind. Der geringe Effekt auf cäcale Epithelzellen (IEC) weist darauf hin, 
dass exkretorische oder sekretorische Produkte von T. suis die Epithelbarriere überbrücken und die 
Lamina Propria Umgebung direkt modulieren. 
Unsere Versuche weisen jedoch auch nach, dass TSO die akute Kolitis in immunsupprimierten 
Kaninchen verschlechtert. Die Präsenz von adulten Trichuris im Cöcum deutet darauf hin, dass 
immunsuppriemierte Kaninchen eine T. suis Infektion nicht kontrollieren können. Unsere 
Erkenntnisse liefern wichtige Hinweise darauf, dass TSO-Behandlungen in immunsupprimierten 
Individuen zu unerwünschten Nebenwirkungen führen können. 
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1 INTRODUCTION 
1.1 Preface 
This thesis investigates the safety and efficacy of a therapy with T. suis ova in a rabbit model of 
inflammatory bowel disease (IBD).  
To contextualise our work, I firstly introduce the disease and the various animal models used in 
translational research. I touch the current available therapies and their limitations as well as the still 
unclear aetiology of IBD.  
The idea that a parasitic pathogen might treat an organic disease is fascinating. In chapter 1.3, I 
describe the rationale of helminth therapy from an epidemiological and evolutionary perspective. I 
then review the literature on the therapeutic and preventive use of helminths for organic diseases 
other than IBD. 
In chapter 1.4, I address helminth therapy in IBD. Afterwards, I summarise the experience in IBD 
models with several helminths species. In the final chapter, I present the particular case of T. Sui.  
Finally, I end by exploring the clinical studies with T. suis and the concerns about its safety and 
efficacy. 
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 1.2 Inflammatory Bowel Diseases: an Exemplary Post-industrial 
“Epidemic” Disease 
1.2.1 The History of IBD 
The term ulcerative colitis (UC) was first used by Wilks in 1859 to describe a case of a non-infectious 
severe and persistent diarrheal disease1. By the start of the 20th century, UC was widely recognized as 
a disease entity distinct from the intestinal inflammatory pathologies of known aetiology2. In 1761, 
Morgagni, citing the work of his mentor Antonio Maria Valsava-described the case of a 20 year old 
man who presented abdominal pain, diarrhoea and fever. Following a remission period, the patient 
developed acute fever, accompanied by stupor and hearing loss and died after two weeks. The 
Autopsy showed hallmarks that we nowadays can ascribe to Crohn’s disease (CD) such as 
perforations, gangrene, transmural inflammation and ulceration of the terminal ileum and proximal 
colon3.  
In 1932, Crohn, Ginzburg and Oppenheimer, accurately described cases of chronic terminal ileitis, 
occurring mainly in young adults, presenting symptoms often observed in ulcerative colitis patients4. 
Although the authors stated that the disease never affected rectum and colon, it was later recognized 
that the pathology can occur in all regions of the gastrointestinal tract5. In 1960, the term Crohn’s 
disease was firstly used to describe a chronic inflammatory bowel disease distinct from ulcerative 
colitis6. Later, the term indeterminate colitis was introduced for the cases where a clear distinction 
between UC and CD was not achieved7.  
From the initially sparse account, IBD incidence and prevalence experienced a dramatic increase, 
particularly in industrialized countries. An exemplary case is a retrospective study of IBD 
epidemiology performed in Rochester, NY: UC was the first disease to emerge in the 20ties (two 
cases), and CD followed in the 30ties with five cases. The incidence for both diseases rapidly 
increased and CD soon overtook UC: in the 80ties UC and CD annual incidence respectively reached 
23.19 and 39.02 cases/100’000 patients8. In Europe and North America the annual incidence currently 
ranges from 1.5 to 20.3 cases/100’000 patients for UC and 0.7 to 14.4 cases/100’000 patients CD9. In 
developing countries, IBD was practically absent but the incidence is clearly rising10; UC annual 
incidence is still generally greater than that of CD. However, recent studies suggest that, similarly to 
what is observed in industrialized countries, UC incidence reaches a plateau, while CD incidence 
continues to increase11.  
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 1.2.2 Pathophysiology of IBD 
Most of the early clinical observations presented above are still valid today. At present, UC is 
described as a relapsing-remitting chronic inflammatory disease involving a mucosal inflammation 
without the presence of granulomas. UC involves the rectum and a variable extent of the colon in a 
progressive and continuous manner (Figure 1.1). 
 
Figure 1.1: Distribution of lesions in ulcerative colitis and Crohn’s Disease. Adapted from Kaestner, et al 
200912. 
CD is defined as a chronic and progressive disease involving a nonspecific granulomatous 
inflammatory process transmural inflammation, strictures, and fistulas.  
Table 1.1: Clinical features of UC and CD 
Ulcerative Colitis Crohn’s Disease 
0.5-24.5 cases per 100,000 new persons-years 0.1-16 cases per 100,000 new persons-years 
Begin in the rectum with proximal, continuous 
extension  
No "skip areas" 
25% of cases confined to the rectum  
Any portion of the gastrointestinal tract Segmental 
involvement  
Inflammatory disease, strictures, and fistulas.  
35% of cases in the ileum and colon;  
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75%, proximally and contiguous spread.  
 
32%, solely in the colon;  
28%, in the small bowel;  
5%, in the gastro duodenal region 
Mucosa and the submucosa involved  
Thickening and dense infiltration of neutrophils, 
monocytes, macrophages, T cells typically on the 
mucosal layer 
Transmural, all intestinal layers involved  
Significant thickening 
Infiltration of macrophages, monocytes and T cells 
on the sub-mucosal layer 
Missing genetic contribution: 84% Missing genetic contribution: 77%  
 
CD can affect any region of the gastrointestinal tract in a segmented manner, from the mouth to the 
rectum (Figure 1.1). UC and CD patients suffer from severe diarrhoea, bleeding, abdominal pain, as 
well as fluid and electrolyte loss. UC and CD also share many extra intestinal manifestations, such as 
fever, sweats, malaise, and arthralgia.  
 
Figure 1.2: Comparison of the microscopic features of normal, UC, and CD mucosa. Active ulcerative colitis 
shows surface erosion, mucin depletion, crypt abscess, and crypt destruction (b, e). E: epithelium, LP: lamina 
propria, MM: muscularis mucosa, SM: submucosa, ME: muscularis externa. CD shows a micro granuloma 
(arrowhead), patchy colitis with irregular villi (c, f). a-c: schematic view, d-f: microscopic features, HE staining. 
Pictures from Geboes, 201414, Van Eyken 201415. 
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 The discrimination between the two forms of IBD is especially difficult when the pathology is 
localized in the colonic region. When it is not possible to reach a definitive diagnosis, the pathology is 
referred to as IBD unclassified, these cases represent 5-30% of all IBD13. An analysis of the 
histological features of intestinal biopsies is crucial for an IBD diagnosis (Figure 1.2). 
Histology also allows an assessment of the disease activity and an early detection of malignancy.  
Within the continuous lesion of UC patients, the crypts are scarce and distorted whereas the villi are 
shorter and stunted (Table 1.2)15. Immune cells infiltrate into the deeper level of the lamina propria and 
plasma cells accumulate in the inflamed mucosa.  
The lesions observed in CD are focal and scattered among the normal mucosa. The irregular mucosal 
morphology is characterised by a reduced density of the crypts that are shorter and dilated. 
Neutrophils and plasma cells infiltrate the lamina propria and basal lymphoid aggregates form in the 
susbmucosal layer. Often, monocyte/macrophage cells aggregate with other inflammatory cells in the 
mucosa to form a granuloma15. 
 
Table 1.2: Microscopic features of UC and CD 
UC CD 
Morphology 
Severe crypt architectural distortion Mucosal surface, normal, irregular, villous 
Severe widespread decreased crypt density Crypt atrophy (shortened, widely spaced 
crypts) 
Stunted villous surface Distorted, dilated, branching crypts 
Inflammation 
Heavy diffuse trans mucosal lamina propria 
cell increase 
Basal plasmacytosis, increase in cells in 
basal third of lamina propria 
Diffuse basal plasmacytosis Increased lamina propria cellularity (round 
cells and neutrophils) 
Neutrophils infiltration Basal lymphoid aggregates 
Miscellaneous 
Increased intensity of the alterations towards 
the distal colon 
Epithelioid granuloma 
Severe mucin depletion Basal giant cells 
Paneth-cell metaplasia distal to the hepatic 
flexure 
Excess Mac and DCs in lamina propria 
 
1.2.3 Aetiology of UC and CD 
The heritability of IBD is undeniable but limited: 6-15% of the UC and CD patients have a first 
degree relative with IBD. Further, in comparison to dyzygotic twins, monozygotic twins have a 
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higher concordance rate and also experience a similar disease phenotype. In the past decades, linkage 
studies and genome wide association studies (GWAS) later, allowed the identification of 163 risk loci 
that are mainly involved in both UC and CD (Figure 1.3). Interestingly, 40% of the IBD risk loci (66 
loci) are also found among the 154 loci that are associated with other immune-mediated diseases 
(Table 1.3)16. 
Table 1.3: IBD risk loci associated with other organic diseases.  
Disease # common loci Fold-enrichment Enrichment OR P-value 
Psoriasis 14 13.5 14.71 4.15.10-12 
Atopic dermatitis 3 12.1 12.32 2.05.10-3 
Rheumatoid arthritis 12 10.92 11.74 1.64E.10-9 
Celiac disease 16 10.57 11.64 4.56.10-12 
Type 1 diabetes 20 9.99 11.28 2.35.10-14 
Multiple sclerosis 17 8.19 9.06 5.11.10-11 
Asthma 7 7.61 7.91 4.90.10-5 
OR: odd ratios; CI: confidence interval (adapted from: Jostins, 201216). 
 
 
The discovered loci only account for a limited portion of disease variance (the amount of disease that 
can be explained by these loci): 7.5% in UC and 13.6% in CD16.  
This “missing heritability”, arises from a combination of host-intrinsic factors, such as genetic and 
epigenetic predisposition, immune system defects and environmental factors.  
 
Figure 1.3: Variance explained by the 163 IBD loci. 110/163 loci are associated with both UC and CD, 23 are 
UC-specific and 30 are CD specific. Each bar, ordered by genomic position, represents a locus and its width is 
proportional to the variance it explains in CD and UC. Bars are connected together if they are associated with 
both phenotypes. Labelled loci explain more than 1% of the total variance. Labels are either the best-supported 
candidate gene or the chromosome position of the locus. From: Jostins, 2012 
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 The complex aetiology also explains the evolving geografic distribution of IBD: the parallel between 
industrialisation processes and increasing incidence supports the importance of environmental factors. 
Among the various proposed risk factor, that range from sun-exposure to cornflakes consumption, 
only few have shown a strong association (Table 1.4)17; 18;19.  
 
Table 1.4: Selected environmental factors and risk for UC and CD 
  Ulcerative colitis Crohn's disease 
Risk factor West 17; 18 Asia + Aus19 West 17; 18 Asia + Aus19 
Smoking         
 Current smoker -   + + (Aus) 
 Ex-smoker + + + null 
 Never a smoker +   -   
Surgery/Medications         
 Appendectomy -   null   
 Oral contraceptive pills +   +   
 Antibiotics ?+ - ?+ - 
 NSAID +   +   
Diet         
 Sugars and fats ?+   ?+   
 Fibres, fruits, vegetables ?- - (muesli) ?- null (muesli) 
 Coffee (daily)   -   null 
 Tea (daily)   -   - 
 Juice   null   - 
Breastfeeding ?- - ?- - 
Hygiene standards         
 Sibship ?-   ?-   
 Urban environment ?+   ?+   
 Farm in childhood ?-   ?-   
 Pets   - (Fish)   - (Dog) 
 In-house water tap/ Hot water 
tap   -   null 
Infections/vaccinations         
 M, avium ?null   +   
 Pertussis vaccination   -   null 
 BCG vaccination      + 20 + 
 Dysbiosis  ?+21   +   
 Helicobacter pylori -   -   
 Helminths -   -   
 NSAID: Nonsteroidal anti-inflammatory drugs; M. avium: Mycobacterium avium paratuberculosis -: 
clear negative correlation; + clear positive correlation; ?-: weak negative correlation; ?+: weak positive 
correlation; null: no correlation. West: data for the environmental risk factors in western nations are 
derived from Molodecky, 201017; Frolkis, 201418 and Baron, 2005 20; Hold, 201421. Asia + Aus: data for 
Asian countries and Australia are derived from Ng, 201419. 
Several proposed factors, such as exposure to infections, antibiotic use, breastfeeding and sibship 
support the idea of a correlation between hygiene standards and IBD development 17; 18;20;21;19.  
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1.2.4 Disrupted Intestinal Homeostasis in IBD  
A delicate interaction between the epithelial barrier, the immune system and the microbial community 
governs intestinal homeostasis. Alternations of this balance, caused by a combination of host intrinsic 
and extrinsic factors, are considered responsible for the development of IBD (Figure 1.4). 
1.2.4.1 Intestinal Barrier Function 
The intestinal lumen is covered by a network of large highly glycosylated gel-forming mucins that are 
produced by specialized cells of the intestinal epithelium called goblet cells.  
 
Figure 1.4: Model of the key factors contributing to the disruption of intestinal homeostasis in IBD. Susceptible 
hosts present underlying genetic defects that affect barrier function, bacterial control and tolerance induction. 
Environmental triggers contribute to the initiation of aberrant responses toward translocated bacteria and 
luminal contents that result in progressive damage to the host's intestinal mucosa. The immune response cannot 
be controlled adequately due immune tolerance defects. Defects in the adaptive response contribute to a chronic 
immune response towards the microbiota and the host tissues themselves. CK: cytokines, DC: dendritic cells, 
Mac: macrophages, N: neutrophils, NK: natural killer cells, NKT: natural killer T cells, PAMPs: pathogen 
associated molecular patterns, T0: naïve T cells, Th: T helper cells, TJ: tight junctions, Treg: regulatory T cells.  
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 The mucous network covers the intestinal epithelium, which consists of a single layer of intestinal 
epithelial cells (IEC) bound together by a web of tight junctions (TJs). TJs are important regulators of 
barrier function and paracellular permeability.  
In IBD, a dysfunction of these two essential components leads increased barrier permeability. In both 
UC and CD, an aberrant expression and redistribution of the TJ-forming claudins combined with an 
increased epithelial apoptosis enhance the barrier dysfunction. In CD patients, GC hyper-proliferate 
causing a thickening of the mucous layer. Despite being thicker, the mucin network of CD patients 
shows dramatic changes in the posttranslational glycosylation that compromise its function27.  
Similarly, the mucins’ glycosylation pattern observed in UC patients is altered and the degree of 
distortion correlates with disease activity. In contrast to the hyper proliferation observed in CD 
patients, GCs of UC patients are depleted and their mucous layer is thinner28. Altered TJ structure 
contributes further to the impaired epithelial barrier function in UC29. Different GWAS studies 
highlighted the link between single nucleotide polymorphisms (SNPs) in TJ-associated genes and the 
development of IBD. One example is the transcription factor HNF4A that regulates the expression of 
cell-cell junction components including, adherens junctions, tight junctions and desmosomes30.  
A further contribution to the mucosal damage is caused by the increase matrix metalloproteinases 
(MMP) produced by fibroblasts, neutrophils and macrophages in response to pro-inflammatory 
cytokines31.  
1.2.4.2 Innate Immunity 
In a genetically susceptible individual, defects in the intestinal barrier function and in the immune 
response, led to aberrant reactions to luminal antigens and the intestinal microbiota32. The innate 
immune system recognizes microbes and luminal compounds through conserved pattern recognition 
receptors (PRRs) that allow a rapid and stereotypical response to pathogen associated molecular 
patterns (PAMPs) and damage associated molecular patters (DAMPs).  
PRRs include the membrane bound toll-like receptors (TLRs), C-type lectin Receptors (CLRs) and 
the cytosolic RNA helicases, DNA sensors and nucleotide-binding oligomerisation domain (Nod)-like 
receptors (NLR). Intestinal PRR are usually hypo responsive and compartmentalized to ensure that a 
response occurs only when a pathogen invades the mucosa or penetrate into a cell. Several PRRs have 
been associated with IBD, highlighting their role in the control of intestinal microbiota and the 
maintenance of gut homeostasis. For example, UC and CD patients have increased levels of TLR2 
and TLR433 and CD patients have an increased sensitivity to flagellin, recognized by TLR534. TLR5 
loss on IECs leads to an increase in flagellated bacteria, increased colitis susceptibility and metabolic 
syndrome35.  
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The two NLRs NOD1 and NOD2 mediate the response to different peptidoglycan moieties: NOD1 
recognizes γ-D-glutamyl-meso-diaminopimelic acid (iE-DAP) and recognizes muramyl dipeptide 
(MDP). Mutations in the NOD2 gene were the first identified susceptibility loci associated with CD, 
whereas they were later shown to confer protection from UC36. The NOD2 polymorphisms observed 
in CD cause a reduced NF-κB activation, yet CD patients have an increased NF-κB activation. 
Nod2-KO mice present a defective production of mucus, cryptidins and defensins, and are thus more 
susceptible to several pathogens. When the Nod2 gene in mouse is replaced with one of the CD-
associated variants, macrophages respond aberrantly to MDP by producing high amounts of IL-1β 
and exacerbating inflammation37. NOD2 also acts in DCs by priming a Th17 polarising phenotype 
through the release of IL-23 and IL-138.  
Both macrophages and DC numbers are increased in the lamina propria of IBD patients and their 
aberrant activation contributes to the induction of a pathologic adaptive response39. 
1.2.4.3 Adaptive Immunity 
Early studies suggest that UC and CD patients have an increased clonal expansion of CD4+ and CD8+ 
T cells in the intestine40. The spontaneous colitis observed in C3H/HeJBir mice, is mediated by CD4+ 
T cells that react to intestinal microbiota antigens41.  
The number of Th1 and Th17 cells is strongly increased in the intestine of CD patients42. Th17 cells 
are in devoted to the defence against intracellular pathogens and are associated with intestinal 
inflammation and mucosal damage. The levels of Th17 cells and the related cytokines correlate with 
the disease activity in IBD patients42. In the mouse, TGFβ and IL-6 initiate the polarisation of Th17 
cells, whereas IL-23 is required for the full effector function42. Il-23r is a CD susceptibility gene and 
the associated polymorphisms leads to the induction of a defective Th17 cell effector function43.  
In the T cell transfer model, expression of the gut homing α4β7 expression and intestinal antigen 
specificity are required for CD4+ T cells colitogenicity. In the same model, colitogenicity is enhanced 
by IL-23 responsive γδT cells that produce IL-1744.  
Ulcerative colitis patients have a different T-cell profile, characterized by an atypical type 2 response 
that lacks a clear association with IL-445. This response may be mediated by IL-5 and IL-13 
producing natural killer T cells (NKT)46. Additionally, imbalances of the homeostatic Treg functions 
contribute to the abnormal immunity observed in IBD. The differentiation in Treg and Th17 cells is in 
equilibrium that, when disrupted toward the latter, contributes to intestinal inflammation47. 
1.2.5 IBD and Intestinal Microbiota 
The human intestine is home of a complex community of bacteria, viruses and microbial eukaryotes 
that are referred to as microbiota. The number of bacteria, up to 100 trillion, is 10 times bigger than 
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 the number of cells in the human body. The intestinal bacteria genome contains 3.3 million microbial 
genes and is thus 150-fold bigger than the human genome48. In a healthy individual, 76% of the 
intestinal bacteria belong to the phylum Firmicutes, 16.4% to Bacteroidetes and the remaining 7% to 
Proteobacteria, Actinobacteria, Fusobacteria or Verrucomicroba49.  
Recent finding demonstrate a clear segregation between the microbiota communities in the lumen and 
in the mucous layer. It is important to consider this difference when interpreting microbiota data, 
since several human studies rely solely on faecal samples50. How the different communities affect 
intestinal homeostasis remains unclear. Evidence suggests that the larger luminal community exerts 
its influence through co-metabolism or metabolic exchange whereas the mucosal microbiota interact 
directly with the host epithelium and immune system51.  
 
Figure 1.5: Microbiota composition at the Phylum level in the colon and small intestine of IBD patients (UC 
and CD) and healthy controls. Bars represent percentages of cloned sequences in all samples of a particular 
category (cfr. legend, Firmicutes are subdivided into Bacillus, Lachnospiraceae, and other groups, Phyla of 
lower abundance were omitted). Hierarchical clustering of samples on the basis of their first two principal 
component scores separated the samples into two primary clusters: Control subset (includes most of the non-
IBD control samples as well as ca. 2/3 of CD and ca. 3/4 of UC samples) and IBD subset (dominated by CD and 
UC samples, 39/40 samples). From Frank, 200752. 
Antibiotics administration during childhood is thought to interfere with the development of tolerance 
towards commensals and is a known risk factor for both UC and CD18. Several pieces of evidence 
support the role of microbiota in IBD pathogenesis. An alteration of the luminal microbiota 
composition (termed dysbiosis) is often encountered in IBD patients. The changes observed in IBD 
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patients are diverse, but they mostly include a reduction in species diversity. A reduction in the 
number of Firmicutes and Bacteroidetes is frequently observed52.  
Of note, differences also occur among the microbiota associated with inflamed and non-inflamed sites 
of the same CD patient49,53,54. In CD patients, NOD2 and ATG16L1 risk alleles are associated with 
shifts in microbial compositions in particular among Clostridia species55.  
Obviously, these changes might be either a cause or a consequence of the intestinal pathology. 
Experiments in germ-free mice evidence the crucial role of intestinal bacteria in the maturation of the 
intestinal immune system. Germ-free mice suffer from an exacerbated colitis upon DSS treatment 
whereas Il-10 KO germ-free mice appear protected from the development of a spontaneous colitis56. 
Microbiota are essential for the proper formation of the intestinal mucosa and GALT (gut associated 
lymphoid tissues)57 and for the establishment of oral tolerance58.  
Further, microbiota stimulate the secretion of mucins by goblet cells and the thin mucus layer 
observed in germ-free mice can be restored to normal levels through exposure to LPS or 
peptidoglycans (PGN)59. Microbiota also influence the adaptive T cell populations both indirectly via 
modulation of antigen presenting cells (APC) cells and directly via PRR signalling60. Another 
adaptive cell population, NKT, appears to be controlled by neonatal microbial exposure. In the 
oxazolone colitis model, the pathogenic recruitment of NKT cells observed in germ-free mice is 
prevented by early colonisation, suggesting a role of this cross talk in the maintenance of mucosal 
homeostasis61.  
1.2.6 Current Therapies 
The complex and unclear aetiology of IBD implies that the therapy is symptomatic and non-curative. 
The goal of therapy in IBD is at first achieving a response or remission and subsequently maintaining 
the response or remission22. It is important, to carefully evaluate the benefits and side effects of every 
intervention, with thoughtful consideration of the long-term prospective22. The therapy is best tailored 
by considering both patient factors, such as lifestyle, family history and susceptibility as well as 
disease factors, such as classification, prior surgery, prognostic factory and disease activity. Further, 
medication related factors should be considered, for example by assessing the balance 
between efficacy and safety. The response to previous therapy should also be evaluated and an 
optimisation effort for the latter should be considered before testing a new one22,23. Table 1.5 
summarizes the medications commonly used for the therapy of UC and CD.  
The anti-inflammatory 5-aminosalicylic acid (5-ASA) exerts a local, topical therapeutic effect on the 
mucosa. 5-ASA is widely used for the induction and maintenance of remission in UC. The exact 
therapeutic mechanisms of amino salicylates is unclear; among the recognized properties 5-ASA 
inhibits intestinal macrophage chemotaxis, reduces antibodies secretions, attenuates the release of 
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 pro inflammatory cytokines and inhibit the arachidonate lipoxygenase and cyclooxygenase (COX) 
pathways. Corticosteroids are widely used for the achievement of remission in both UC and CD. 
They reduce NF-κB activation and down regulate pro-inflammatory cytokines, mainly through 
activation of the corticosteroid receptor. Conventional corticosteroids cause a wide range of adverse 
events, thereby alternative formulations (such as the synthetic prednisolone analogue budesonide) aim 
to reduce the systemic absorption and increase the therapeutic availability of the drug. Still, classical 
corticosteroid adverse events might occur especially following a prolonged use.  
 
Table 1.5: Common therapies in UC and CD 
Medication Indication for UC Indication for CD Side effects 
Anti-inflammatory    
5-ASA (oral, rectal) induction/maintenance colonic (mild): induction/maintenance Intestinal nephritis (rare), diarrhoea 
Corticosteroids (oral, i.v., 
rectal) induction induction 
Acne, moon face, truncal obesity, 
osteoporosis, osteonecrosis, diabetes, 
hypertension, cataract, infections 
Immunosuppressive    
6-MP/AZA 
corticosteroid 
withdrawal, 
maintenance 
corticosteroid 
withdrawal, maintenance 
Pancreatitis, fever, infection, leukopenia, 
hepatotoxicity, lymphoma 
Calcineurin inhibitors corticosteroid refractory  
Hypertension, nephrotoxicity, 
neurotoxicity 
Methotrexate under investigation induction/maintenance Nausea, fatigue, hepatotoxicity, pneumonitis 
Biologics    
anti-TNF induction/maintenance induction/maintenance 
Infusion/Injection site reaction, 
demyelination, infection, heart failure, 
lymphoma 
anti-integrin anti-TNF refractory; induction/maintenance 
anti-TNF refractory; 
induction/maintenance Joint pain, fever, PML (Natalizumab, rare) 
Antibiotics    
Metronidazole  
perianal and colonic 
disease Neuropathy, antabuse effect 
Ciprofloxacin  
perianal and colonic 
disease Arthropaty, tendon injury, sun sensitivity 
PML: multifocal leukoencephalopathy. Adapted from: ACP, 201225. 
 
Azathioprine (AZA) and its metabolite 6-Mercaptopurine (6-MP) can be administered to UC patients 
as an alternative to 5-ASA and/or in combination with steroids24. They are also used as adjunctive 
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therapy or as steroid-alternative in patients with active CD and for the remission maintenance in 
patients with extensive disease. AZA and 6-MP inhibit mitosis and cellular metabolism by 
antagonising purine metabolism and inhibiting the synthesis of DNA, RNA, and proteins. 
The calcineurin inhibitor Cyclosporine A (CycA) is a cyclic polypeptide that forms a complex with 
cytosolic cyclophilins that binds and inhibits calcineurin, thus preventing the dephosphorylation and 
nuclear translocation of the IL-2 inducing factor NF-AT. This mechanism mainly suppresses cell-
mediated immune responses and is used for the treatment of severe UC refractory to corticosteroids. 
Methotrexate is used in active or relapsing CD patients refractory or intolerant to azathioprine or anti-
TNF agents although the mechanisms of its anti-inflammatory effect are unknown.  
All currently used anti-TNF antibodies, such as infliximab and adalimumab, have similar efficacy and 
similar adverse effects. In UC they are used to induce clinical remission and mucosal healing. In 
addition, they are used in relapsing CD and for maintenance of remission CD. The Anti-integrin 
inhibitors are an emerging class of biologics that target cell adhesion molecules and their integrin 
ligands on leukocytes, thus reducing their migration into the site of inflammation. For example, the 
monoclonal antibody Vedolizumab targets the gut-specific interaction between the integrin α4β7 and 
MAdCAM-1, specifically blocking T cell homing in the gut26.  
Finally, broad-spectrum antibiotics such as Metronidazole and Ciprofloxacin show modest benefits 
for the therapy of colonic CD, either alone or in combination with other drugs.  
1.3 Helminth Therapy 
1.3.1 “Old Friends” Hypothesis 
In the early years of the 19th century, technological innovation and economic growth led to a 
substantial improvement of the health system, diminishing the exposure to infectious diseases, 
reducing mortality and increasing the average life span of the population especially in the urban areas. 
At the same time, industrialising countries experienced a constant rise in the incidence of immune 
related disorders62. Nowadays, a similar phenomenon is occurring in developing countries, and the 
correlation between increasing hygiene and the development of immune related disorders appears 
more and more clear. 
In 2004, Rook proposed and updated version of the “hygiene hypothesis” that focused on the 
diminished interaction between the immune system and the environmental microbiota63, 64. 
Partial deprivation of microbial stimuli that were previously abundant shaped the evolution of the 
human immune system. The immune system could not deal with the “old friends” responsible for 
these stimuli as it did with usual pathogens leading to the evolution of alternative response 
mechanisms (Figure 1.6).  
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 Several promising “old friends” candidates have been suggested. On the one hand, commensal 
organisms transmitted via the orofecal route are harmless, perform essential physiological roles for 
the host, and thus need to be tolerated. On the other hand, pathogens causing chronic carrier states or 
non-fatal subclinical diseases also need a customized response63. 
The evolution different subsets of T helper cells, such as Th2/Tregs impedes the complete removal of 
the chronic pathogens, avoids a destructive inflammatory response and ensures a constant antigen 
source and immune stimulus, resulting in striking immunity to re-infection65. 
 
Figure 1.6: Milestones of the immune system evolution in vertebrates occurred in presence helminth parasites. 
Plathyelminthic parasites colonized the early jaw fishes (Chondrichthyes) about 400 mya. Chondrichthyes were 
the first animals to develop BCR and TCR recombination (following the acquisition of the RAG gene) and with 
it a rudimental adaptive response. Nematode parasites colonized terrestrial vertebrates at different time points 
during the Palaeozoic (from 400 mya), when a fine tuning of the adaptive immune response such as polarization 
of the T helper cell response and immunoglobulins (Ig) class switch arose. BCR: B cell receptor, GALT: gut 
associated lymphoid tissues, LN: lymph nodes, PC: Precambrian, TCR: T cell receptor. (adapted from Rook, 
201069; Litman, 200570). 
A further millstone of the immune system evolution is the development of different Macrophage 
phenotypes, that are often encountered upon chronic infections66,67. Cytokines such as IL-4, IL-13 and 
IL-21 drive the polarization of alternatively activated Macrophages (aaMacs) that secrete the anti-
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inflammatory IL-10 and TGF-β, and contribute to extracellular matrix repair, wound healing and 
fibrosis68. 
Large parasitic worms (helminths) are a good example of pathogens that need a tailored immune 
response since a classical inflammatory response would merely cause undesirable immunopathology 
without antagonizing the parasite69. In order ensure the propagation of the species, helminths needed 
(and need) to escape the host defences and establish a prolonged colonization.  
Two groups of helminths evolved zoo-parasitism: Platyhelminthes (flatworms) parasitism probably 
arose from a common parasitic ancestor in the first jaw fishes71 whereas Nematodes (roundworms) 
parasitism emerged independently at least five times in terrestrial vertebrates72. Helminth parasites 
where thus present during the key periods in the evolution of the vertebrate immune system70, 73 
(Figure 1.6) and exerted a strong pressure for human genetic adaptation to local environments74. This 
led to the co-evolution of an intricate host-parasite relationship where helminths assumed an essential 
role in the development of tolerance and immune regulation pathways69,25. 
Epidemiological studies support a correlation between the decrease in soil-transmitted helminthiasis 
and the occurrence of several immune related disorders, including MS, IBD and allergies75. All these 
disorders share a complex aetiology and several genetic risk loci (Table 1.4), suggesting that similar 
mechanisms might be involved.  
 
According to the helminth therapy concept, reintroducing helminths-derived stimuli to the immune 
system might help restoring the aberrant immune responses occurring in immune related diseases. 
In the following chapter, I will give an overview of the different helminth species, address the use of 
helminth therapy for organic diseases and review the mechanisms of helminth-mediated immune-
modulation with a special focus on inflammatory bowel diseases. 
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 1.3.1 Parasitic Helminths 
Helminth parasites are large multicellular worms that colonise the intestine or the blood vessels of 
their host. Human helminthiasis belong to the neglected tropical diseases and infect about hundreds of 
millions of people worldwide76.  
 
 
Figure 1.7: General life cycles of Nematoda, Cestoda and Trematoda. Plain squares represent the definitive 
hosts harbouring the adult helminths; dotted squares the intermediate host harbouring larval stages. 
Generally, parasitic helminths have a slow maturation time and exert limited pathogenicity. The 
different helminth species are classified into cestodes and trematodes that belong to the phylum 
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Plathyhelminths and nematodes that constitute the phylum Nemathelminthes. Low burden helminth 
infections usually lead to chronic infection that can last several years and usually cause only a 
reduced morbidity. In order to colonise a great number of different environments, helminths evolved 
the capacity of maintaining homeostasis under a variety of environmental stress factors. Most species 
spend their life-cycle stages in different environments and need to adapt as they mature (Figure 
1.7).Key for the survival is the secretion of bioactive molecules involved in immune evasion, extra 
corporal digestion, moulting and tissue colonisation. Helminths also expel waste and products that 
cannot be digested by means of excretion. Since the distinction between the secreted and excreted 
molecules is complicated, they are collectively termed E/S products77 
Nematodes are non-segmented cylindrical worms and are the most numerous helminths in term of 
species diversity. The larval stage undergoes 4 moults to reach the adult form. Adult nematodes 
produce eggs that embryonate in utero or in the external environment78. The infectious stage is 
usually present in contaminated soil and thus the most common nematodes are known as soil-
transmitted helminths (STH)79. The nematodes of the genus Trichuris, that represent the focus of this 
thesis, are discussed in chapter 1.4.3.  
Cestoda are flat, ribbon like, hermaphroditic helminths (tapeworms). The adults are confined to the 
digestive tract of their hosts since they do not possess an alimentary canal. On the other hand, larvae 
occupy a greater variety of intermediate niches varying from insects to mammalian hosts. The 
transmission between different hosts occurs via ingestion of contaminated tissues. In the intermediate 
hosts the larvae invade the tissues and become encysted (metacestode form). Following ingestion by a 
definitive host, the larvae excyst and develop to the adult form. Among the human parasites five 
species belong to the Teniadee family and one to the Hymenolepidae family.  
Finally, Trematoda, or flukes, parasitize a wide range of hosts and undergo complex life cycle stages 
with both sexual reproduction and asexual reproduction. Most require a vertebrate or invertebrate host 
where the larvae proliferate and then colonise the digestive tract or its associated organ of vertebrates. 
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 1.3.2 Helminth Therapy in Organic Diseases 
To enhance their survival and reproduction in their mammalian hosts parasites have evolved a wide 
range of mechanisms to escape or divert the immune system. As we have seen in the previous chapter, 
different helminth parasites have different life cycle giving rise to a considerable variety in the 
interaction with the immune-system. Still, some common patterns can be observed. An increasing 
number of studies suggest that the immunomodulation exerted by helminths can be used to counteract 
an aberrant immune response and treat organic diseases. An ideal therapeutic helminth should have –
besides the essential immune-modulatory potential- a limited pathogenicity in the human host and a 
simple life cycle with no dissemination (Table 1.6).  
 
Table 1.6: The ideal therapeutic helminth.  
No dissemination 
Not pathogenic to human 
Self-limited infection 
No replication inside the host 
Not immediately infective 
Easy administration 
Effective anthelminthic available 
Production in SPF conditions possible 
Long term stability 
Adapted from Elliot, 200780 
 
The infection with the therapeutic helminth should be non-productive inside the host to ensure a 
control over the amplitude of the immunomodulation. In case of complications, it is important that the 
parasite can be easily eradicated using standard anthelminthic drugs. Further, the production in a 
specific pathogen free environment is needed to avoid eventual co-infections.  
As an alternative to live parasites, parasite extracts and parasite derived molecules can be used to 
avoid the risks of an uncontrolled infection (Table 1.7).  
 
The following chapter will review the studies on helminth therapy for different organic diseases and 
discuss the possible mechanisms of action.  
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Table 1.7: helminth derived molecules with immune-modulatory properties 
Molecule  Parasite Model tested Mechanism 
rCKBP chemokine 
binding 
protein 
S. mansoni air pouch, 
CXCL8- airway 
inflammation 
↓chemokines induced infiltration of 
neutrophils 
CPI-2 cystatine B. malayi - ↓endosomal/lysosomal proteases involved in 
antigen processing in a B-cell line, ↓MHC-II 
restricted antigen presentation 
Cystatine cystatine A. viteae OVA/grass 
pollen airway 
inflammation 
IL-10 producing macs 
Cystatine (cloned 
in E. coli Nissle) 
cystatine A. viteae DSS colitis ↓IL-6 and IL-17A (locally), ↑Tregs, cathepsin 
inhibition: ↓Ag presentation on APC 
rCsStefin-1 cystatine C. sinensis DSS colitis ↓ TNF in mLNs, ↑ IL-10 and IL-10+F4/80+ 
Macs in spleen and mLNs 
rOv17 cystatine O. volvulus - cathepsin L/S inhibition: ↓Ag presentation on 
APC, ↑ IL-10 by PBMC, ↓HLA-DR, CD86 
on monocyte 
MIF II cytokine A. simplex DSS colitis IL-10 by EC, DCs, and fibroblasts and TGFβ 
by fibroblasts 
MIF-II cytokine A. simplex OVA airway 
inflammation 
IL-10 production and Treg, IEC-TLR2 
dependent 
MIF-II cytokine T. trichiura - ↑ IL-10 and TNF from PBMC 
Glycans glycan T. suis - ↓LPS induced production of pro-
inflammatory CKs (via CTL, MR) on DCs  
LNFPIII glycan S. japonicum EAE ↑ Th2 response 
LNFPIII glycan S. japonicum Flaky skin mice Th2 priming DCs, via TLR4- NF-κB axis 
ω-1 glycoprotein  Schistosoma 
egg 
NOD mice ↑FoxP3 IL-4 
11a 12b PC A. viteae OVA induced 
airway 
inflammation 
↓mast cell degranulation, CK production, Eos 
infiltration 
PC moiety ES-62 PC A. viteae CIA ↓ IL-17/Il-22 in DC, γ/δ and CD4+ T (Th17) 
via MyD88 down-regulation (IL-1R/TLR 
axis) 
PC moiety of ES-
62 
PC A. viteae OVA induced 
airway 
inflammation 
↓ Th2 and Th17, ↑ Th1 
rDiAg polyprotein D. immitis NOD mice ↓ anti islet Th1 response, ↑IgE by B cells, 
CD40 agonist, NO by Macs 
rDiAg  polyprotein D. immitis Murine 
spontaneous 
abortion 
↓ IL-4, IL-23 and TNF 
Mr85 Mr105 porin  T. muris - ECM degradation (syncytial tunnel formation) 
TsTCI serpin T. suis - Inhibits Neutrophil elastase, the mast cell 
protease mMCP-1 and Cathepsin G.  
asparaginyl-
tRNA synthetase 
(rBmAsnRS) 
tRNA 
synthetase 
B. malayi T cell transfer 
colitis 
CD8+ response 
APC: antigen presenting cell, CIA: collagen induced arthritis; EAE: experimentally induced autoimmune 
encephalomyelitis; ECM: extracellular matrix; LPS: Lipopolysaccharide; mLN: mesenteric lymph nodes; NOD: non-obese 
diabetic, PC: phosphorylincholine (references in text). 
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 1.3.3 Helminth Therapy in Allergy 
Already in the first descriptions of hay fever (initially called catarrhus aestivus), the highest incidence 
was reported in upper class patients81. Despite this early recognition, it took almost three decades 
until the scientific community started realising that these income and regional differences could be 
ascribable to the occurrence of parasitic infections. The turning point was the discovery of IgE in 
196882 that was found to be up-regulated in both allergy and parasite patients83 The observation that 
patients suffering from hay-fever entered remission following Ascaris infection, led Preston to 
speculate that the atopic syndrome could be a consequence of good hygiene and the lack of nematode 
infections84.  
Whilst studying the role of IgE in allergic reactions, Jarret and colleagues85 noted that in rats infected 
with N. brasiliensis, subsequent passive skin test for systemic anaphylaxis and skin test reaction were 
strongly reduced. Confirming these observations, patients infected with different parasitic species 
were barely affected by passive skin sensitisation86.  
Shortly after, following his epidemiologic studies on asthma in rural and urban Gambia, Godfrey 
firstly suggested the treatment of allergic disorders with preparations of parasite antigens87. Turner 
promptly followed his advice and was successful in self-treating his allergic rhinitis by self-infection 
with 250 N. brasiliensis larvae at regular intervals88 (yet in a later article he reported severe gastro-
intestinal symptoms89).  
Ten year later, Emanuel listed the change in immunological status caused by the removal of parasitic 
infestations as one of the possible causes for the post-industrial increase in the prevalence of allergic 
rhinitis90. Afterwards, several epidemiological studies confirmed the preventive effect of parasitism in 
the development of allergies91;92.  
Several mouse studies have shown a protective effect of helminths against the development of 
allergies. In a mouse model of food allergy, intragastric administration of peanut antigen and cholera 
toxin induces the production of Ag-specific IgE and systemic symptoms of anaphylaxis. An IL-10-
dependent reduction in the allergic response occurs in H. polygyrus infected mice, where the down-
regulation of Ag-specific IgE is associated with a reduction of Ag-specific T cells secreting IL-1393. 
H. polygyrus also protects from OVA-induced lung inflammation, although it is not clear if IL-10 is 
necessary or if alternative pathways can be induced94;95. IL-10 appears essential in the prevention of 
OVA-induced lung inflammation by N. brasiliensis96 and in the protection from systemic fatal 
anaphylaxis by S. mansoni, where an increase in IL-10 producing B cells inhibits the IL-4 allergic 
response97. The important role of IL-10 is supported by studies with the filarial derived Cystatin that 
appears to supress both OVA and grass pollen allergen induced airways inflammation via induction of 
IL-10 producing macrophages98;99. 
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Another filaria derived product, the glycoprotein ES-62, protects from OVA-induced inflammation by 
reducing Th2 and Th17 responses and inducing Th1 responses100. ES-62 is a large molecule, highly 
glycosylated and decorated with a phosphorylcholine (PC) modification that possesses immune-
modulatory properties. PC was used as a template to design small, low weight analogues that were 
synthesized and tested for immune-modulatory properties101. Two of these molecules 11a and 12b, 
inhibit mast cell degranulation and cytokine production and prevent OVA-induced airway 
inflammation and eosinophil infiltration in the lungs102.  
The protective effects of O. dentatum extracts in a birch pollen allergy model and of T. suis E/S 
products in the OVA model further confirm that an infection with live parasites is not essential for the 
prevention of allergy development103;104. Schistosoma produce chemokine binding proteins (r-
smCKBP) that bind CXCL8 and reduce neutrophil infiltration in an air pouch model and in CXCL8-
induced airway inflammation. Through is blockade of Neutrophils’ infiltration, r-smCKBP is also 
protective in a contact hypersensitivity model105.  
These and other studies demonstrate the protective effect of helminths and helminth products against 
the development of allergies, yet whether helminths ameliorate an already established allergy is less 
clear. N. brasiliensis infection in sensitized rats does not prevent a subsequent hypersensitivity 
response106. N. brasiliensis also fails to protect mice from an established OVA allergy and from OVA 
anaphylaxis96.  
In contrast, Strongyloides venezuelanis infection following an OVA challenge protects rats against 
AHR induction two days later, when the larvae migrate through the lungs107. A therapeutic effect is 
also exerted by H. polygyrus in OVA sensitized mice95. Finally, A. simplex produces a MIF-
homologue that can suppress airway inflammation in mouse by inducing IL-10 production and Treg 
recruitment; this effect is strongly dependent on the expression of TLR2 by lung epithelial cells108. 
Following the initial success of helminth therapy in inflammatory bowel diseases, two double blind, 
randomized placebo controlled studies were performed in allergic rhinitis patients using Necator 
americans larvae 109;110 or T. suis ova (TSO)111-113. Yet, both studies failed to provide sufficient 
evidence on the efficacy and tolerability of helminth therapy in allergic rhinitis and a recent Cochrane 
review concluded that more preclinical studies should be performed to provide sufficient evidence on 
the efficacy of helminth therapy in the management of allergic rhinitis 114.  
1.3.4 Helminth therapy in Multiple sclerosis 
In 1966, an epidemiological study reported a correlation between the aetiology of multiple sclerosis 
(MS) and the level of sanitation in Israel115. The author proposed that increased levels of sanitation 
might postpone the encounter with the “causing infectious agent” later in life, when the central 
nervous system is more susceptible to demyelination.  
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 After the first successful experiments in IBD and diabetes, two studies investigated a treatment with 
S. mansoni ova in the murine EAE (experimental autoimmune encephalomyelitis) model116. Ova 
treatment decreased the incidence and delayed the onset of EAE in wild type mice, but not in STAT6 
deficient animals. Further, it reduced MOG-specific IFNγ, NO, and TNF production116;117. A soluble 
egg antigen from S. japonicum is also protective: among its components a glycan, Lacto-N-
fucopentaose III (LNFPIII), is sufficient to reduce EAE severity and induce a Th2 profile118. 
Similarly, F. hepatica promote tolerogenic DCs that induce parasite specific Treg cells. In turn, Treg 
produce IL-10 and TGFβ that supress Th1 and Th17 responses119. Moreover, T. crassiceps limits the 
production of IL-17 and TNF and the migration of T cells to the CNS120.  
A set of clinical studies121; 122 compared 12 MS patients with a mild, asymptomatic intestinal 
parasitism with 12 uninfected MS patients over a period of 7.5 years. The infected MS patients had a 
better clinical and radiological outcome. This protection was associated with the induction of Tregs, 
anti-inflammatory cytokine secretion, increased expression of TLR2 on B cells and DCs and of the 
MHC Class Ib molecule CD1d on IL-10 producing B cells.  
Both the MS-protection and the anti-inflammatory pattern reverted in four patients receiving anti-
helminth treatment. Additionally, two separate non-randomized studies have evaluated the use of 
T. suis ova (TSO) in the treatment of newly diagnosed relapsing remitting MS and secondary 
progressive MS123,124,125. In both studies TSO induced a modest shift toward a Th2 response and a 
mild eosinophilia. 
Unfortunately, TSO led to a transient reduction of the MRI lesions only in newly diagnosed MS 
whereas an effect on severe MS patients has not been shown to date.  
1.3.5 Helminth therapy in Rheumatoid Arthritis 
The first correlation between parasite and rheumatoid arthritis (RA) protection was the incidental 
finding that infection with the nematode Syphacia oblevata protects male rats (female rats show small 
differences only) from the development of complete Freund's adjuvant induced rheumatoid 
arthritis126. Following anti-parasitic treatment with piperazine the rats started manifesting the adjuvant 
disease. Parasite infections in other murine RA models lead to contrasting outcomes.  
Schistosoma infection reduces the severity of subsequent collagen induced arthritis (CIA) but 
exacerbates an already established CIA127;128. Further, Hymenolepis diminuta worsens a subsequent 
induced polyarthritis129 whereas Taenia crassiceps infection has no effect on the development of RA 
induced by adoptive OVA-specific T cell transfer130.  
More promising appears the treatment of collagen-induced arthritis severity with the filaria-derived 
glycoprotein ES-62131. The PC moiety of ES-62 possesses immune-modulatory activity132 and targets, 
DCs, γ/δ and CD4+ T cells to modulate the IL-17/IL-22 producing network133. The mechanism of 
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action appear to involve the down regulation of the adaptor MyD88 in Th17, mast cells and 
macrophages that lead to an inhibition of TLR/IL-1R signalling134;135.  
A small molecule analogue of the ES-62 PC moiety (11a) was successfully employed to prevent CIA 
in mice and caused a down-regulation of the IFNγ and IL-17 responses101.  
Early studies in mice136;137, showed that an A. suum infection or treatment with A. suum extracts can 
reduce the delayed type hypersensitivity to unrelated antigens through modulation of B and T cell 
responses. Similarly to ES-62, an extract from A. suum delivered parenterally or orally protects 
against the development of zymosan-induced arthritis in rats and therapeutic effect against CIA in 
mouse. A. suum extract reduced the levels of nitric oxide (NO), IL-1β (in rats), and IL-10138. 
1.3.6 Helminth therapy in Psoriasis 
Flaky skin BALB/c mice have a spontaneous skin phenotype that closely resembles human psoriasis 
and they develop skin lesions as early as 5 weeks of age, in humans, mutations in the gene 
responsible for this phenotype (TTC7) also result in a severe form of very early onset IBD. Treatment 
with the Schistosome LNFPIII prevented the development of skin lesions in 77% of the mice139. 
LNFPIII signals via TLR4 causing a rapid and transient NF-κB activation that leads to the activation 
of DC primed to induce a Th2 phenotype140.  
1.3.7 Helminth Therapy in Transplant Rejection 
BALB/C mice were infected with T. spiralis larvae per oral (p.o). 23 days prior to a body-skin graft 
from C57BL6 donors. Oral infection significantly prolonged the length of transplant retention from 
10.7 days to 24.5 days. Timing is crucial, as an infection performed 7 days before transplant, has a 
milder effect141. Injection of a soluble larval extract is sufficient to delay rejection, supporting a role 
of an E/S product142.  
In humans, Echinococcus infection might cause the development of hepatocellular carcinoma that 
eventually requires liver transplantation. Since the usual immunosuppression is inefficacious and 
leads to the exacerbation of the parasitic disease, milder immunosuppression regimens are used. Yet, 
the transplants are usually well tolerated and the rejection rates are low143. This effect has been 
reported in mouse models of both liver and heart transplants, indicating a systemic effect144. 
N. brasiliensis or its extract prolonged the survival of rat kidney and heart in both rat and mouse 
models and reduced the infiltration of CD8+ and to minor extents of CD4+ lymphocytes. N. brasilienis 
also diminished the allospecific cytotoxicity of spleen lymphocytes and polarized toward a type 2 
effector response145. The survival of heart allografts persists well behind the length of infection, 
further supporting a type 2 polarisation at the time of allograft-antigen presentation rather than a 
direct effect of the parasite.  
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 Schistosoma infections also appear to prolong the survival of skin-allograft in both humans146 and 
mice147. Interestingly, the protective effect is only observed in mice infected 60 days prior to the 
transplant, suggesting a role for the late Th2 response induced by Schistosoma. A recent study showed 
that infection of the recipients with H. polygyrus protects mice from graft versus host disease 
following a bone marrow transplant. H. polygyrus enhances the survival potential of TGFβ–
generating recipient Tregs after body irradiation and favoured a TGFβ–dependent increase of donor 
Tregs148.  
The mammalian foetus represents a semi allograft within the maternal uterus since it expresses (as do 
the extra embryonic membranes) paternal MHC transplantation antigens. From this point of view, 
pregnancy loss can be seen as a failure of tolerance induction at the maternal–foetal interface. Women 
suffering from repeated pregnancy loss have higher serum of IL-17 and IL-23 levels and increased 
expression IL-17, IL-23, and retinoid orphan receptor C (RORC) in the decidua in comparison to 
women with normal pregnancy149. In addition, they have a decreased number of Tregs in peripheral 
blood to nonpregnancy levels150. 
Using a murine model of spontaneous abortion151, Shihoko et al. could show that a filarial polyprotein 
significantly reduces the foetuses resorption rate from 42.9% in the control mouse to 11.1%. 
Interestingly, the reduction of pregnancy losses occurred in the absence of a Th2 CK up regulation 
and was characterised by diminished serum levels of IL-4, IL-23 and TNF whereas IL-17 levels were 
unchanged152. 
1.3.8 Helminth Therapy in Diabetes  
The parasite-induced shift of the T helper response was discovered in the last decade of the 20th 
century. Knowing that several auto-immune disorders were characterized by an aberrant Th1 
response, Cooke and colleagues decided to test S. mansoni to prevent or treat insulin dependent 
diabetes mellitus in non-obese diabetic (NOD) mice153.  
S. mansoni larvae first induce an initial Th1 response. 5-6 weeks later, the larvae start laying eggs that 
drive a marked Th2 response. Cooke showed that infecting 5-7 weeks old NOD mice with 
Schistosome larvae reduced the incidence of diabetes (described as blood glucose levels above 
12 mmol/l). Further, diabetes was also prevented by injection of Schistosome eggs in 5 weeks old 
mice, highlighting the importance of the Th2 response.  
Infection with a viable parasite is not necessary for the prevention of diabetes in NOD mice; filaria 
derived factor injected in 6-week-old NOD mice completely prevent insulitis and diabetes 
development by impairing the anti-islet Th1 cell response154;155. A similar experiment with soluble 
antigen from S. mansoni larvae or eggs, highlighted the importance of treating NOD mice at 4 weeks 
of age, when islet antigens presentation in pancreatic lymph nodes gradually cause the infiltration of 
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APC and lymphocytes156. S. mansoni eggs products induce Tregs, aaMacs, Th2 responses, and 
increase the numbers of NKT that are usually reduced in NOD mice157. Supporting a role of NKT, 
presentation of eggs glycoconjugates by dendritic cells (DC) to CD1d-restricted cells such as NKT is 
important for the induction of an adequate Th2 response158;159. Diabetes in NOD mice is also 
prevented by injection of the Schistosoma egg glycoprotein ω-1 that induces both FoxP3 and IL-4160. 
A preventive Th2 response is also observed in NOD mice infected with the gastrointestinal helminths 
T. spiralis and H. polygyrus161. H. polygyrus protection from diabetes also occurs in a Th2 deficient 
environment through an IL-10 dependent mechanism162. Rather than inducing a Th2 response, 
excretory/secretory products of the helminth Fasciola hepatica, supress the auto-antigen specific 
production of IFNγ and increase the numbers of IL-10 secreting B cells an aaMacs that might inhibit 
the initiation of auto reactive T cell responses163.  
Although a multitude of studies showed a protective effect of helminths or their derivatives in the 
prevention of diabetes in NOD mice, their clinical relevance is not clear. In fact, it is relatively easy to 
prevent diabetes in NOD mice even with nonspecific interventions 164. Another common model of 
type 1 diabetes in rodents implies the administration of streptozotocin (STZ) a cytotoxic glucose 
analogue that causes the destruction of β-cell. The pathology caused by multiple low doses of STZ is 
immune-mediated and can be reduced by infection with H. polygyrus 165 that protects pancreatic islets 
and reverses the increase of pro-inflammatory mediators in a STAT6 and IL-10 independent manner. 
In contrast, the hyperglycemia induced by single high dose STZ is immune-mechanism independent 
and is not affected by H. polygyrus infection. 
1.3.9 Helminth Therapy in Autoimmune Hepatitis 
Autoimmune hepatitis (AIH) is a chronic hepatocellular inflammation and necrosis that, if left 
untreated, predisposes to cirrhosis and to hepatocellular carcinoma.  
In the mouse AIH model, i.p injection of Concavallin A leads to a massive Th1 lymphocytes 
activation and infiltration into the liver parenchyma. Treatment with the adult worm extract from A. 
suum (Asc) 30 minutes before Concavallin A reduced the extent of liver damage, induced a type 2 
response and increased the survival rate form 38% to 100%. Instead, treatment 2h after Concavallin 
had only a limited efficacy. Unfortunately, both the preventive and the therapeutic treatment with Asc 
exacerbated liver fibrosis, an adverse effect that might limit the translation of Asc use into the clinic 
both for AIH and for other immune related diseases166. 
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 1.3.10 Helminth Therapy in H. pylori-induced Gastritis 
Helicobacter pylori is a component of the gastric flora in approximately 50% of the world population. 
It is well established that chronic helicobacter infection causes gastritis and peptic ulcer disease and 
predisposes to metaplastic changes.  
In mouse, pre-treatment with H. polygyrus appears to limit the extent of Helicobacter felis induced 
atrophy of the glandular epithelium, reduced mucosal hyperplasia and mucosal metaplasia 16 week 
post- infection167. A similar study in the Mongolian Gerbils model of helicobacter-induced gastritis 
showed that, at 21 weeks post-infection, gastritis indices were lower in co-infected gerbils and were 
inversely proportional to worm burden.  
However, the protective effect was lost by week 42 and the initial protective overexpression of anti-
inflammatory mediators was transient and followed by a down regulation at week 42168. Male insulin 
gastrin (INS-GAS) transgenic mice suffer from a moderate chronic gastrinemia and develop gastric 
intraepithelial neoplasia 5-7 months after H. pylori infection.  
A recent study showed that INS-GAS mice preventively infected with H. polygyrus were less 
susceptible to H. pylori induced gastric atrophy and dysplasia and were resistant to gastric 
colonisation with enteric microbiota, a phenomenon that is thought to contribute to gastric-
carcinogenesis in humans and mice169. 
1.3.11 Celiac Disease 
Preliminary trials were performed in 10 celiac disease patients in remission. In a first small double 
blinded placebo controlled trial, patients were treated with infective N. americanus larvae170. In a 
subsequent crossover study, 7 of patients previously enrolled in the control group received the 
infected larvae171. Although the symptom severity following gluten challenge remained unchanged, N. 
americanus reduced IFNγ and IL-17production by intestinal tissues. Additionally, the response to 
gluten challenge acquired a Th2 profile.  
A subsequent open label trial showed that a combination of N. americanus and desensitization 
immunotherapy by micro challenge with deamidated gluten prevent histology and serology changes 
following gluten challenge172. The study enrolled 12 patients with diet-managed celiac disease. 
Among them, two subjects withdrew after microchallenge with 1g gluten. This promising study calls 
for a larger, double-blinded trial testing the efficacy and safety as well as the relative importance of N. 
americanus infection and gluten microchallenge172. 
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1.4 Helminth therapy in IBD 
1.4.1 Animal Models of IBD 
Although it is impossible to reproduce the complexity of IBD in a laboratory animal, colitis models 
have contributed largely to our understanding of the human disease. Table 1.8 summarizes the criteria 
that a relevant IBD model should possess. 
A relevant IBD model should resemble the human pathology both in its clinical manifestations and in 
its pathogenicity. Further, the induction protocol should be simple and the outcomes highly 
reproducible173 (Table 1.8). 
Table 1.8: Criteria for a relevant IBD model 
easy induction 
similar clinical manifestations 
similar pathogenesis 
respond to establish therapy 
reasonable time course  
reproducible results 
available species with well-defined strain 
Adapted form Bylund-Fellenius, et al, 1994173  
 
Most models are performed in rat and mouse and can be divided according to the induction method 
(Figure 1.8). Chemically induced models are widely distributed, cheap and simple models that imply 
the application (oral or rectal) of a chemical compound. Congenic models include mouse strains that 
spontaneously develop intestinal pathology (colitis and ileitis). Genetically engineered models 
comprise knock-out or transgenic mice that develop colitis or ileitis spontaneously.  
Adoptive transfer models require the transfer of T cells (usually CD4+ CD45RBhigh T cells) into an 
immunodeficient recipient. Finally, spontaneous colitis is observed in cotton-top tamarins kept in 
captivity174. The different models are summarized in Figure 1.6 and the most common are described in 
further details in this section.  
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Figure 1.8: Animal models of IBD, classified according to the method of induction. The listed models are 
representative of the induction categories. 
1.4.1.1 DSS 
The chemical induction of colitis with dextran sodium sulphate (DSS) is among the most used mouse-
models of IBD. One reason is the simple induction protocol that implies the administration of DSS in 
the drinking water. Furthermore, this model does not require anaesthesia of the animals that is 
necessary e.g. when applying an enema. Acute and chronic colitis can be achieved by varying doses 
and dosage and other protocols are used to study colitis associated carcinogenesis.  
Clinically, DSS colitis manifests with weight loss and diarrhoea that might lead to the death of the 
animals.  
To date, the mechanism by which DSS penetrates into the cells is unclear175. In the colon, DSS 
associates with medium-chain fatty-acids and form nano-lipocomplexes that can disrupt epithelial 
permeability176. DSS leads to a disruption of tight and adherent junctions by inducing the loss of 
ZO-1 and claudins. It also exerts a direct toxic effect on IEC and causes erosions that can lead to the 
complete loss of surface epithelium177. Following the epithelial damage, luminal contents leak into 
the mucosa and activate innate immunity causing a Th1 response.  
Bacterial products are recognized by TLR4 and TLR2 and other PRRs that direct the recruitment of 
neutrophils and regulatory T-cells to the intestinal site. In acute DSS colitis bacteria and bacterial 
products are essential for the initiation of inflammation178. Several studies reported higher number of 
bacteria in the mucosa following DSS administration179, which is in agreement with the increased 
number of bacteria found in biopsies of UC patients180. 
Similarly to the changes observed in UC patients, an increased presence of pro-inflammatory species 
- such as Bacteroidaceae and Clostridium spp. and a decrease of the probiotic Lactobacillus species 
was found to correlate with acute and chronic colitis179;180. Adaptive immunity plays a secondary role 
since DSS induces colitis in SCID, Rag KO and other mice that lack T cells and B cells181.  
Single doses of DSS (2-4% weight/volume) induce acute colitis, with weight loss and signs of loose 
stool or diarrhoea, characterized by a Th1 Th17-mediated acute inflammation. The pathology features 
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hyperemia, ulcerations, submucosal edema, and histopathological changes which include disruption 
of crypt architecture, inflammatory cell infiltration, muscle thickening and goblet cell depletion.  
Multiple, lower doses of DSS (1-2% weight/volume) cause chronic colitis and in some cases lead to 
the development of malignancy. Chronic colitis leads to a Th2-mediated inflammatory response, with 
an increase in IL-4 and IL-10 and a concomitant decrease in TNF, IL6, IL-17182.  
1.4.1.2 TNBS 
Trinitrobenzene sulfonic acid is a haptenising compound that is applied intra-rectally in an alcoholic 
solution. TNBS haptenizes autologous or microbial proteins and renders them immunogenic. This 
leads to a delayed hypersensitivity response and to the development of a Th1/Th17 mediated immune 
response. In mouse, TNBS causes a progressive weight loss, diarrhoea and faecal blood. TNBS colitis 
exhibits a diffuse colonic inflammation with transmural leukocyte infiltration (in particular 
CD4+ T cells), oedema and ulceration.  
For these characteristics, TNBS colitis is usually considered a CD like model183. 
1.4.1.3 Oxazolone 
Intrarectal application of the haptenating agent oxazolone in ethanol damages the epithelium. The 
leakage of oxazolone and haptenized bacterial antigens initiate a self-limiting Th2 characterized by an 
increased IL-4 and IL-5 secretion.  
Critical for the colitis development is the production of IL-13 by Th cells and NKT cells. The 
infiltration of NKT cells seems mediated by the gut-homing interaction between CCL25 and CCR9 
that are up-regulated in both oxazolone colitis and human UC184. The induced histopathology also 
resembles the damages observed in UC patients185 and is characterized by edema, infiltration of 
granulocytes in the superficial layers of the mucosa and ulceration of the epithelial layer. 
1.4.1.4 Acetic Acid 
Acetic acid is infused into the rectal lumen of a lightly anesthetized mouse, rat or rabbit and causes an 
initial mild epithelial necrosis and oedema that later variably extends into the lamina propria, 
submucosa, or external muscle layers, depending of the dose and dosage applied.  
Other features include the infiltration of Neutrophils into the mucosa, vascular dilation and 
submucosal ulceration. Colitis is initiated by the acetic acid induced damage of the intestinal 
epithelium, which subsequently activates the immune response.  
The pathology is probably related to an increased oxidative stress and the inflamed mucosa shows an 
increased ROS production and lipid peroxidation186. 
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 1.4.1.5 Il-10 KO Spontaneous Colitis 
In 1993, Kühn et al reported that mice deficient in Il-10 (Il-10 KO mice) spontaneously develop a 
chronic enterocolitis187. Il-10 KO mice suffer from weight loss and anaemia and develop skip lesions 
that are typically most severe in the caecum and the proximal colon. The pathology includes 
increased neutrophil infiltration, erosions, transmural, mononuclear to granulomatous inflammation 
similar to CD, and diminished gut associated lymphoid tissue.  
Intestinal microbiota are the trigger of colitis in the Il-10 KO model and the development of colitis is 
abolished when Il-10 KO nice are maintained under germ-free conditions. Interestingly, MyD88 
expression in the mononuclear phagocyte compartment is needed for colitis development, suggesting 
a role for the signalling of commensals through the TLR-MyD88 axis188.  
Luminal antigens lead to a sustained production of pro-inflammatory cytokines that cannot be 
controlled due to the absence of IL-10. 
1.4.1.6 Transfer Colitis 
The adoptive transfer of CD4+CD45RBhigh naïve T cells from healthy wild-type mice into syngeneic 
SCID recipients, lacking T and B cells, causes severe colitis in approximately 6 to 12 weeks189. In 
absence of CD4+CD25+Foxp3+ Tregs cells, the naïve T cells are activated and expand in response to 
intestinal antigens and produce colitogenic Th1 and Th17 cells. Therefore, colitis can also be induced 
by transfer in Rag KO, Cd3 KO, Nod KO and Tcrα Tcrβ KO recipients190. The pathology features 
transmural inflammation, IEC hyperplasia, leukocyte infiltration, crypt abscesses, and epithelial cell 
erosions191. Transfer colitis models are used to investigate the initiation of adaptive immunity in 
colitis and were crucial for the study of Tregs and their role in maintaining homeostasis into the 
intestinal mucosa192.  
1.4.1.7 Citrobacter Colitis 
The Gram-negative, non-invasive mouse pathogen C. rodentium has been extensively used to 
investigate the contribution of intestinal commensals and pathogens to the development of IBD193. 
C. rodentium colonises the caecum and the colon causing a transient and self-resolving mild colitis 
with crypt hyperplasia, loss of goblet cells and infiltration of mononuclear immune cell infiltration194. 
The infection changes the composition of both adherent and luminal microbiota and increases the 
numbers of Proteobacteria, Clostridia, whilst reducing the abundance of Lactobacillus spp.195.  
C. rodentium induces a chronic colitis in mice with a compromised intestinal barrier and in 
immunocompromised mice (e.g Rag KO). Studies in KO mice revealed the importance of the 
TLR2/MyD88 axis for the maintenance of the epithelial barrier function196 and of B cells for the 
recognition and clearance of the pathogen197. 
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1.4.1.8 Spontaneous Colitis in the Cotton-Top Tamarin 
Captive cotton-top tamarins (Saguinus oedipus) develop a colitis featuring periodic flares, whose 
histological appearance involves diffuse mucosal inflammation and crypt abscess formation.  
The pathology resembles UC and presents an increase in various inflammatory mediators such as 
prostaglandins, interleukins and myeloperoxidase. Chronic colitis also leads to the development of 
colorectal cancer rendering the tamarin a good model for both diseases.198.  
1.4.1.9 Post-Weaning Syndrome 
Young piglets often develop a post-weaning intestinal inflammation characterized by an increase of 
both CD4+ and CD8+ T cells as soon as 2 day post weaning. The pathology is accompanied by an 
increased expression of IL-1β, IL-6, and TNF and an increased permeability in the intestine199. 
1.4.2 Helminth Therapy in Animal Models of IBD  
The first animal studies in IBD were performed with some delay with respect to the early pioneer 
studies in RA, allergic rhinitis and MS.  
In 1991, Urban noticed that a concurrent enteric helminth infection could modulate the inflammation 
and gastric immune responses induced by H. pylori 200. One year later, Elliot and Weinstock showed 
that exposure to H. polygyrus reduces intestinal inflammation in Il-10 deficient mice, starting a long 
series of studies with different helminths in different models of IBD201.  
The intestinal nematode H. polygyrus has now shown protective and therapeutic potential in several 
models of murine colitis including chemically induced colitis (TNBS and DSS), T cell transfer colitis 
and antigen driven colitis. However, the beneficial modulation of the immune response exerted by 
H. polygyrus also dampens protective responses such as the recruitment of intestinal phagocytes. This 
leads to impaired resistance to C. rodentium and Salmonella and enhances the infectious colitis202;203. 
The results with the cestode H. diminuta are less clear. Administration reduces the severity of a 
subsequent DNBS colitis in mice via the induction of alternatively activated macrophages, IL-10 
producing T cells and TGFβ producing regulatory B cells204. In contrast, preventive or therapeutic 
administration of H. diminuta larvae to DSS mice failed to improve the histological damage, despite a 
shift of the immune response toward a Th2 response205. The enhanced Th2 response and the 
consequent eosinophilia are probably the reason for the detrimental effect of H. diminuita observed in 
the Th2-biased model of oxazolone colitis206.  
The trematode Schistosoma was first tested in a TNBS model of colitis. BALB/C mice injected 
intraperitoneally with freeze-killed S. mansoni eggs 4 days prior to the induction of colitis show a 
STAT-6 dependent attenuation of colitis, with an augmented Treg and Th2 response207. Freeze-killed 
S. japonicum eggs also protect from TNBS colitis preventing the disruption of tight junctions and 
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 reducing the TNBS induced TLR4 and NOD2 up-regulation, leading to a Th2 polarisation208. The 
integrity of the egg is not a requisite for the protective effect: intraperitoneal injection of S. japonicum 
soluble egg antigen protects mice from T cell transfer colitis by reducing the Th1 and Th17 responses 
in favour of TH2 responses209. In contrast, injection of either live eggs or soluble eggs antigen fail to 
protect from acute DSS colitis despite inducing a Th2 shift210,211. Also, in the DSS model, egg-laying 
infections with S. mansoni have no preventive effect and increase the symptoms of the colitis. The 
noxious effect is ascribable to the laid eggs, as non-productive infections with male larvae attenuate 
the DSS colitis and diminish both Th2 and Th1 cytokines levels.  
Another nematode, T. spiralis, induces a Th2 response and attenuates a subsequent TNBS colitis212. 
As for other parasites, protection is reproduced using a T. spiralis-derived antigen213, with a down 
regulation of iNOS expression and IL-1β production and an up-regulation of colonic Th2 and aaMacs 
markers. In vitro experiments support an alternative activation of macrophages, that in response to 
T. spiralis antigens upregulate Arg1, Mr, Ym1 and Il-10 in a STAT6 dependent, IL-4R independent 
manner214.  
Recent studies tried to substitute the live parasite with immune-modulatory parasite components or 
secreted products. The MIFII homologue produced by A. simplex that is protective in a murine asthma 
model also reduces the severity of a subsequent DSS colitis. In vitro, A. simplex MIF II induces in 
vitro expression of IL-10 by EC, DCs, and fibroblasts and TGFβ by fibroblasts215.  
The E/S products of the filarial nematode A. vitae also possess immune-modulatory activity. One of 
its components is a cysteine protease inhibitor (cystatine) that acts on macrophages and attenuates 
DSS colitis. Interestingly, A. vitae cystatin as well as cystatins from other helminthic parasites such as 
Onchocerca volvulus216, Clonorchis sinensis217 and Brugia Malayi218 target antigen-processing cells 
whereas the cystatin produced by the free-living C. elegans does not98. Cystatins secreted by 
helminths during the mammalian phase, mimic the mammalian cystatins that modulate cathepsin 
activities and antigen presentation218.  
To directly target the site of inflammation, A. vitae cystatin was cloned in the probotic E. coli Nissle 
and administered to DSS feed mouse. Attenuation of colitis was associated with a decrease in 
macrophages, an increase of Tregs in the colon and a local decrease in the production of IL-6 and 
IL-17A219.  
The cystatin produced by B. malayi (CPI-2) inhibits endosomal/lysosomal proteases involved in 
antigen processing in a B-cell line and has been shown to inhibit MHC-II restricted antigen 
presentation in a peptide-specific manner218.  
Besides cystatins, B. malayi also produces the excretory/secretory protein asparaginyl-tRNA 
synthetase (rBmAsnRS) that attenuates T cell transfer colitis and induces a CD8+ response220. 
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 1.4.3 Trichuris suis as an Ideal Therapeutic Helminth 
Trichuris species are widespread helminths that parasitize several mammals including both wild and 
domestic animals. Among the different Trichuris, T. trichiura, T. muris and T. suis are the human, 
mouse and pig parasites. A Trichuris infection is initiated by the ingestion of embryonated eggs 
(Figure 1.9).  
 
 
Figure 1.9: Trichuris life cycle. Infection occurs by the ingestion of soil contaminated with embryonated eggs. 
The eggs hatch in the caecum in response to bacterial stimuli. The larvae (L1) penetrate the caecum and 
proximal colon wall, dwell in the epithelial layer and mature to L2 stage. L3 larvae protrude the posterior end 
into the intestinal lumen, whilst the stichosome is anchored in an IEC tunnel. The larvae mature further to L5 
stage and, after reaching sexual maturity, produce eggs that are expelled with the faeces. The eggs require an 
incubation time in the soil for embryonation to the infective stage. 
Throughout its maturation in the hosts, Trichuris remains confined to the intestine and no 
dissemination to the lungs or other organs occurs. In a compatible host, the eggs hatch freeing L1 
larvae that first attach to the villi and then move distally toward the caecal and proximo-colonic 
mucosa. L1 invade the intestinal epithelium on the crest of crypts, bringing with it luminal bacteria 
and antigens. The larvae remain embedded and develop in the mucosa gradually moving through 
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 adjacent epithelial cells. At approximately 2 weeks post infection (in T. suis infected pigs) L3 larvae 
protrude the posterior end into the intestinal lumen, whilst the thin anterior end (called stichosome) is 
anchored in an inert tunnel composed of dead epithelial cells221. Within the tunnel Trichuris secretes 
digestive enzymes and immune-modulatory molecules and intakes nutrients through its absorptive 
bacillary cells.  
 
Figure 1.10: Colonisation of the caecal mucosa by T. muris. (a) Portion of the caecum of a T. muris infected 
mouse; the posterior ends of Trichuris extending into the lumen are visible (day 33 post infection). (b) Light 
micrograph of an adult female T. muris (day 42 post infection). Multiple transverse sections of anterior worm 
can be seen embedded within the epithelium, with transverse section of the posterior worm free in the lumen. 
Eggs are visible inside the worm uterus. (c) SEM of a portion of caecum on which the Trichuris stichosome is 
burrowed into the mucosal epithelium. From Artis, 2008221. 
 
The larvae mature locally to the L5 stage and, after reaching sexual maturity (T. suis: day 37 
p.i/T. trichiura: day 60 p.i), produce eggs that are expelled with the faeces. Of note, the eggs are not 
immediately infective, and require an incubation time in a warm humid soil over a period of 3-6 
weeks to embryonate222. Once embryonated, the eggs can be stored at 4°C for at least 1 year, without 
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compromising the larvae infectivity. The life span of the adult Trichuris depends on the species: 
T. trichiura infection can last 1 year whereas T. suis infection can last up to 2 years222. In humans, 
T. trichiura represents the third most common parasitic nematode and infects approximately 500 
million people worldwide223. The morbidity of trichuriasis is low and the occurrence and severity of 
the symptoms depends largely on the worm burden. Trichuris causes usually causes mild 
gastrointestinal symptoms such as loose stools and abdominal discomfort. Still, dysentery, anaemia 
and rectal prolapse might occur in heavily infested patients224.  
Table 1.9: T. suis as an ideal therapeutic helminth 
Intestinal colonisation, no dissemination 
Not pathogenic to human 
Self-limiting infection 
Eggs are not immediately infective 
Effective single-dose anthelminthic available 
Production in SPF conditions possible 
Long term stability of TSO 
 
Trichuris spp, and more generally helminths, are usually species specific; for example T. suis ova fail 
to colonise the murine intestine. Occasionally, zoonotic transmission to humans can occur for some 
species including T. vulpis and T. suis225;226. The first reports of an experimental T. suis infection in 
human subjects resulted in a detectable infection after 5-8 weeks227. In two other cases cases, the 
infection was only transient and led to the production of eggs for approximately 10 and 16 days228. 
Only 11% of the recovered eggs could embryonate (indicating successful mating), whereas the 
reported rate for infections in pigs is 84-86%. Importantly, the subjects showed no adverse effects and 
no alterations in the leukocyte counts227;228. These findings confirm that man is not the normal host of 
T. suis. To our knowledge, there is no report of pathology attributable to T. suis in healthy individuals. 
Moreover, Trichuris infection can be eradicated with a single dose of antihelmintic drugs such as 
albendazole plus oxantel pamoate or mebendazole229. Lastly, T. suis ova for helminth therapy can be 
obtained from specific-pathogen free pigs, thereby minimising the possible risks associated to a 
coinfection with pathogenic viruses or bacteria. In light of these considerations, T. suis appears a safe 
helminth therapeutic candidate for IBD and other diseases (Table 1.9). The evidence supporting its 
efficacy and the immune-modulatory properties of the Trichuris spp. are discussed in the next chapter. 
1.4.3.1 Trichuris in the Healthy Intestine 
Whole genome sequencing revealed a high conservation of genes in Trichuris, we can thus speculate 
that different Trichuris species employ similar mechanisms to colonise the gut mucosa (Figure 
1.11)230;231. 
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Figure 1.11: Modulation of the intestinal niche by Trichuris spp. Names in italics are molecules secreted by 
Trichuris. Red arrows represent inhibitory effects. B: B cells, DC: Dendritic cells, ECM: extracellular matrix, 
GC: Goblet cells, IEC: intestinal epithelial cells, ILC: innate lymphoid cells, LN: lymph nodes, Mac: 
Macrophages, MCPI: mast cell protease I, N: Neutrophils, NE: neutrophil elastase, Plasma: plasma B cells 
SLPI: serine leukocyte protease inhibitors, T: T cells, Th2: Type 2 T helper cells. Black arrows indicate 
stimulatory pathways, red diamond-tipped arrows indicate inhibitory pathways.  
As the other helminths, Trichuris spp. secrete an E/S products to interact with its host. A recent 
analysis in T. suis has identified 618 genes encoding putative E/S products that constitute 10% of the 
whole transcript231. Proteases are highly represented in the secretome of Trichuris spp.232;230;231 and 
might be involved in the colonisation of the caecal mucosa. For example two serine proteases from 
T. muris (Mr 85 and Mr 105) possess ECM degrading activity and have been implicated in the 
formation of syncytial tunnel233. 
Other proteases are homologues known mammalian secretory leukocyte protease inhibitors230;232 
(SLPIs), that are not found in other helminth lineages and seem unique to the Trichuris spp. In 
mammals, SLPIs act as Neutrophil elastase inhibitors, anti-microbial peptides, and inhibitor of NF-κB 
in response to microbial products. Of note, SLPIs are strongly enhanced in inflamed versus non-
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inflamed UC regions and SLPIs expression increases during resolution of DSS colitis234;235. SLPI 
seems to regulate the balance between host defence and tissue regeneration, and is crucial to mucosal 
healing of inflammation-mediated damage236. T. suis produces serine protease inhibitors (serpins) 
including the low weight TsTCI that inhibits a variety of proteases including Neutrophil elastase, the 
mast cell protease mMCP-1 and Cathepsin G. Other portions include channel and transporters such as 
the T. trichiura porin TT47, which induces ion-conducting pores in the lipid membrane and is 
involved in the formation of syncytial tunnels233.  
The T. suis transcriptome also includes homologues of macrophage migration inhibitory factor 
(MIF)232, similar to the immune-modulatory proteins found in A. simplex237. A MIF homologue is also 
a component of a T. trichiura extract that stimulates the production of IL-10 and TNF from peripheral 
blood mononuclear cells (PBMC)238. T. muris is a natural mouse pathogen and is a widely used model 
to study Trichuriasis. The outcome of a T. muris infection depends on the mouse strain: most strains 
successfully expel T. muris, although with various efficacy. In contrast, strains that are more prone to 
a Th1 response, fail to mount a protective immune response and suffer long term chronic infections. 
Infections with low numbers of eggs (less than 100) usually cause no symptoms and lead to persistent 
infection whereas higher doses cause a more acute response that usually results in parasite 
expulsion239.  
Efficient hatching is a critical process for the establishment of Trichuris and is probably triggered by 
the optimum temperature and the increased bacterial numbers found in the caecal region. Treatment 
of mice with antibiotic reduces the worm-burden of a subsequent T. muris infection, but has no effect 
on an already established infection. Noteworthy, incubation of the embryonated eggs at 37°C with 
dead E. coli is sufficient to trigger hatching through the interaction with type I fimbriae. Bacteria 
lacking type I fimbria also trigger TSO hatching, suggesting the presence alternative recognition 
mechanisms240.  
Early studies have shown that parasite clearance is associated to a Th2 response, with the cytokines 
IL-4 and IL-13 playing a critical role. In contrast, susceptibility is associated with a Th1 response241. 
T cells play a crucial role in the control of Trichuris infections: T cell transfer form T.muris infected 
donors is sufficient to transfer immunity to naïve mice242. Yet, the interaction with the host immune 
system is more complex than a simple effect on T cell polarisation, with effects on both the innate and 
the adaptive immune response.  
An acute T. muris infection causes goblet cell hyperplasia and an increased secretion of MUC2 and 
MUC5A, two mucins necessary for worm expulsion. In turn, T. muris secretes proteases that target 
MUC2 for degradation leading to the depolymerisation of mucin nets243. In resistant mouse strains, 
the host secretes higher levels of serpins that prevent the disruption of the mucous layer allowing 
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 worm expulsion. In susceptible strains, chronic infections are accompanied by alterations of mucins 
modification such as lower D-GalNAc glycosylation and higher Sialylation. The altered mucin 
composition affects the intestinal microbiota composition and its interaction with the underlying 
epithelium243. Another expulsion mechanism observed in resistant strain is an increase in epithelial 
cells turnover. Epithelial proliferation functions as an epithelial escalator moving the parasite 
embedded in the epithelium from the bottom of the crypt to its top244. This process is IL-13 dependent 
and is enhanced by members of the epidermal growth factor (EGF) family such as Amphiregulin that 
is expressed by activated Th2 cells in response to T. muris infections245.CD4+ T cells and NK cells are 
the major producer of IL-13 in response to T. muris. Interestingly, IL-13 mediated protection is 
dependent on CD4+ T cells and IL-18 signalling246. 
In susceptible strains, chronic infection causes a IFNγ, TNF mediated increase in IEC apoptosis and a 
down-regulation of the IEC turnover that on the one hand reduces worm expulsion and on the other 
hand might protect the host since it counters infection-induced IEC hyperplasia247. E/S products of 
T. suis enhance epithelial permeability by diminishing the expression of the tight junction proteins 
EMP-1 and Claudin-4. This effect is mediated by the glycan moieties and allows other components of 
the E/S product to cross the epithelium and affect cells on the basolateral side248.  
Further, in vitro studies have shown that T. suis E/S products elicit the production of IL-6 and IL-10 
from IECs249. Epithelial cells of resistant animals also show enhanced levels of chemokines that lead 
to a rapid recruitment of DCs in the mucosa248. A prompt and increased recruitment of DCs might 
facilitate antigen sampling from the epithelium and the lumen and thus a rapid priming of T cells in 
the mesenteric lymph nodes (mLN)250. DCs differ from intestinal macrophages in expressing higher 
levels of MHC-II and CD11c and by lacking CD64. The murine gut DCs can be subdivided into 
CD103+ CD11b+ DCs, CD103+ CD11b− DCs and CD103− CD11b+ DCs251. In resistant strains, DCs 
express higher levels of the maturation markers CD80/86, MHC-II and CCR7 and possess lower 
endocytic activity than DCs in susceptible strains.  
In vivo experiments with human monocyte derived DCs, revealed that glycans from Trichuris suis 
excretory/secretory antigen signals via C type lectins (CTL) and mannose receptors (MR) on 
immature DCs and supress LPS induced production of pro-inflammatory cytokines252. The 
recruitment of MHC-IIhi CD11chi CD103+ DCs (mostly CD11b+) in response to T. muris is dependent 
on NOD2: The IECs in Nod2 KO animals are unable to produce chemokines essential for the 
recruitment of DCs to the colonic epithelium. Nod2 KO have a reduced T cell expansion, supporting 
the importance of DCs for T cell priming and gut homing. The defective T cell response might 
explain the delayed worm expulsion observed in Nod2 KO mice250. 
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Despite these findings, T. muris infections in Cd103 KO mice showed that these cells are dispensable 
for the resistance to T. muris 253 suggesting the existence of alternative mechanisms.  
Important mediators of the early response to Trichuris are the innate cytokines (alarmins) thymic 
stromal lymphopoietin (TSLP), IL-25 and IL-33. Tslp is constitutively expressed by IEC in the 
caecum and colon. Exposure to T. muris excretory/secretory antigen (but also to viruses, bacterial 
pathogens, Th2 and Th1 cytokines) leads to an IKKβ mediated increase in TSLP production248. TSLP 
reduces the production of IFNγ, IL-12/23p40 and IL-17A by DCs and induces the production of type2 
cytokines by CD4+ T cells254. In addition, TSLP mediate the accumulation of mast cells, and 
basophils that also contribute to the anti-inflammatory response255.  
IL-25 is constitutively expressed in strains resistant to T. muris, and its production increases in 
response to nematode infection256. IL-25 appears to promote a type 2 response mainly by reducing 
type 1 inflammation257 and also stimulate type 2 cytokine production by a population of MHC-IIhigh, 
CD11cdull Linn- innate immune cells258.  
IL-33 is transiently produced in the caecum of T. muris infected mice in the early phase of the 
infection. IL-33 enhances TSLP production by IEC, induces Th2 polarisation, enhances the numbers 
of goblet cells and increases the production of IgE259. The production of type 2 cytokines in response 
to Trichuris is fast, although the parasite specific T cell response needs several days to develop. The 
fast response toward helminths is mediated by type 2 innate lymphoid cells (ILC) that are elicited by 
TSLP, IL-25 and IL-33. IL-25 simultaneously stimulate a distinct population of ILC named 
multipotent progenitor type 2 (MPPtype2) cells. MPPtype2 accumulate in the mucosa following a 
T. muris infection; they induce an early type 2 response and can differentiate in to innate cells such as 
Macs, Mast cells and basophils capable of producing IL-4 and IL-13260;261. Mast cells and eosinophils 
are not essential for T. muris expulsion but they might play a supportive role262. IL-9 is a growth 
factor involved in the recruitment and survival of mast cells that is produced in response to T. muris.  
Recent studies suggest that a distinct subset of Th2 cells produces IL-9 in response to TGFβ during 
T. muris infections and is required for parasite clearance263. Retinoic acid signalling via the retinoic 
acid receptor (RORyt) is essential for CD4+ T Cell effector responses and the generation of Th1 and 
Th17 and Th2 cells that reduced in the intestine of vitamin A deficient (VAI) mice. VAI mice also 
have less intestinal RORyt+ ILC3 cells and a diminished production of ILC-derived IL-22 and IL-17 
that results in enhanced susceptibility and pathology to acute bacterial infection. In turn, they show 
increased numbers of intestinal ILC2 producing IL-13 that can compensate for the defective Th2 
immunity and rescue the control of a T. muris infection264 
The production of retinoic acid is reduced in a high-dose chronic T. muris infection due to a 
diminished numbers of ALDH+ macrophages and DCs. In acute infections the reduction in ALDH+ 
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 cells is transient and is restored following the expulsion of the parasite. This indicates a role of 
retinoic acid in the modulation of immune responses265.  
A classic response to helminth infection is the differentiation and the accumulation of aaMacs. 
Despite this phenomenon, there is no clear evidence supporting an essential role of this cell 
population. In T. muris infections, aaMac, usually rare in the gut, increase in numbers at around 3 
weeks post infection. Presence of arginase (ARG1) producing Macs is superfluous for the control of 
T. muris and no changes in the cytokines and antibodies responses occur in Arg1 KO mice266. In vitro 
studies with T. suis soluble products, revealed that in human macrophages the anti-inflammatory state 
is induced via TLR4267. Macrophages deficient in the phosphatase SHIP are more sensitive to IL-4 
mediated aaMacs polarisation. Despite the increase in aaMAc numbers, Ship KO mice are susceptible 
to T. muris infections and develop a polarized Th1 response due to an increased production of 
IL-12p40 by macrophages, ephasizing the role of a proper macrophage response268.  
T. muris-specific antibody production in the mLN peaks two weeks post infection in both resistant 
and susceptible strains. Afterwards, the levels gradually decline in both susceptible and resistant 
strains, but remain above the naïve levels only in susceptible strains269. Underlining the importance of 
the antibody response, B cell deficient C57BL/6 mice fail to control T. muris infections, but can be 
rescued by reconstitution with splenic B cells or by treatment with Trichuris-specific IgG1 from 
resistant mice 270. Of note, T. muris and other parasites (H. polygyrus and S. mansoni) can induce the 
production of IgE even in absence of the Ig μ- and δ-chains, suggesting the existence of an 
evolutionary old mechanism for the antibody response towards helminthic infections271.  
A modulation of the intestinal microbiota by Trichuris has been observed in pigs. T. suis infection 
alters the composition of the proximal colon microbiota and causes a shift in its metabolic potential 
affecting carbohydrate metabolism, lysine biosynthesis and fatty acid absorption272.  
In contrast, the effect of T. trichiura on the human intestinal microbiota is unclear273;274. An 
Ecuadorean study found no difference between the microbial composition in faeces from children 
infected with T. trichiura (n=17) and local uninfected controls (n=30). On the other hand, a similar 
study performed in Malaysia revealed an association between helminth colonization and increased 
microbial diversity in the faeces, which seems driven by Trichuris infection. 
1.4.3.2 Trichuris Therapy in IBD Models 
T. muris is a natural mouse parasite. Hence, it is not surprising that a concomitant infection in the 
Il-10 KO model worsens the spontaneous colitis. T. muris exacerbates the Th1 and Th17 responses 
and increases the expression of the IL-13 decoy receptor (IL-13Rα2) resulting in a diminished IL-13 
activity. IL-13Rα2 seems to prevent Th2 polarisation since Il-10, Il-13rα2 double KO mice are 
resistant to colitis and develop a less severe chronic colitis in response to T. muris275.  
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T. muris also increases colitis severity in Mdr1a KO mice that spontaneously develop a Th1 colitis 
due to an epithelial barrier defect276. A concurrent T. muris infection also exacerbates colitis in the 
DSS model. Yet, when DSS colitis is induced after the expulsion of T. muris (from day 27 post 
infection), mice are protected and develop a milder colitis. In particular prior T. muris infection 
appear to favour re-epithelialisation and regeneration of the colonic mucosa277. T. trichiuria has 
shown positive effects in treating idiopathic chronic diarrhoea in macaque monkey. This small study 
showed an attenuation of colitis in 4 out of 5 treated animals, with the 5th requiring euthanisation due 
to progressive weight loss and diarrhoea. The attenuation of colitis coincided with a Th2 response and 
expression of genes characteristic a type 2 response. Further, T. trichiuria reduced the attachment of 
bacteria to the intestinal mucosa and induced changes in the microbiota composition278.  
1.4.4 Clinical Studies and Case Reports with Trichuris 
The first small open label trial with Trichuris suis ova (TSO) was performed by the Weinstock group 
in 2003 with 4 CD and 3 UC patients (Table 1.10). The patients were treated with a single dose of 
2500 TSO and were monitored regularly for 12 weeks. Importantly, no adverse effects were reported 
and no changes in laboratory parameters were observed. The results were promising: 6 of 7 patients 
achieved clinical remission at week 8 according to the IBD quality of life index. Yet, this effect was 
temporary and 3 of the patients relapsed within 4 weeks. In 2 CD and 2 UC patients the transient 
effect of TSO could be prolonged by repeated administration of TSO every 3 weeks for 28 weeks279. 
A later open-label trial enrolled 29 CD patients, with a mean CD activity index (CDAI) of 
287.1±47.8, who received 2500 TSO every three weeks. At week 12, the CDAI improved in 22 
patients (ΔCDAI>-100 points or reduction to CDAI<150) and 19 entered remission (CDAI<150). The 
improvement was maintained and the mean CDAI reached 99.9±35.6 at week 24280. A larger, 
randomized, double blind, placebo-controlled trial involved 54 UC patients with an UCDAI of 
8.7±0.3. Of the 54 patients, 13/30 patients receiving 2500 TSO every 2 weeks experienced a response 
after 12 weeks ΔUCDAI >-4) versus only 4/24 patients receiving placebo281. Following this first 
phase, a crossover was performed by switching the therapy to the patient that still had UCDAI≥4. 
After additional 12 weeks, 56.3% of TSO treated patients responded relatively to 13.3% of the 
placebo patients. Unfortunately the number of patients included in this analysis is not clear, but the 
authors reported a significant effect282.  
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 Table 1.10: Clinical studies and case reports with Trichuris suis ova (TSO) and Trichuris trichiura ova in 
inflammatory bowel diseases, multiple sclerosis and allergic rhinitis. 
Citation Nematode Dose and dosage 
Baseline medication 
allowed n/placebo 
Kind of 
trial Severity Outcome Adverse effects 
IBD 
Summers, 
2003279 T. suis  2500TSO 
Prednisone, 
antibiotics, 5-ASA, 
AZA, 6-Mp 
4 CD, 3 UC open label  
CD 
(CDAI>180) 
and active 
UC 
+ w8:86% remitted‡ no 
Summers, 
2005280 T. suis  
2500 TSO 
every 3w 
for 24w 
14/29 on 
corticosteroids 29/0 open label 
CD (CDAI: 
220-450) 
+ w12: 75% 
responded, 65% 
remitted 
w24: 79% responded 
72% remitted• 
no 
Summers, 
2005281 T. suis  
2500 TSO 
every 2w 
for 12w 
Mesalamine, 
corticosteroids/AZA/6
-Mp 
54/24 randomized, double blind 
UC (UCDAI 
>=4) 
12w: 43.3% 
responded with TSO 
vs 16.7% placebo 
(P = 0.04)* 
no 
Elliot, 
2005282 T. suis  
2500 TSO 
every 2w 
for 12w 
Mesalamine, 
corticosteroids/AZA/6
-Mp 
? 
randomized, 
double 
blind, 
crossover of 
Summers, 
2005 
UC (UCDAI 
>=4) 
12w: 56.3% 
responded with TSO 
vs 13.3% placebo 
(P = 0.02)* 
no 
Kradin, 
2006283 T. suis 
5x1500 
TSO 
Refractory to 
corticosteroids, 
thalidomide, AZA, 
and α-TNF 
1/0 case report CD No benefits Worms reached adult stage 
Broadhurst, 
2010284 T. trichiura 
3x eggs 
(500, 1000, 
2000) in 3 
years 
Refractory to 
mesalamine 6-MP and 
steroids.  
1/0 case report Severe UC Induction of remission No severe adverse events 
Sandborn, 
2013285 T. suis  
500, 2500 
and 7500 
TSO 
5-ASA, prednisone, 
azathioprine, 6-Mp 27/9 
sequential 
dose-
escalation 
randomised, 
double-
blind. 
mild-to 
moderate CD na 
Adverse events in 
37% TSO vs 44% 
placebo patients; no 
dose dependency 
Multiple sclerosis 
Benzel, 
2012123; 
Rosche, 
2013124  
T. suis  
TSO every 
2w over 6 
months 
2/4 received 
methylprednisone 4/0 
non-
randomized, 
pilot study 
secondary 
progressive  
Moderate immune-
modulatory effect  
1/4 mild 
gastrointestinal 
symptoms 
Fleming 
2011125 T. suis  
TSO every 
2w over 3 
months 
2/5 previously 
received 
corticosteroids. 
Declined standard 
treatment. 
5/0 
baseline 
versus 
treatment 
relapsing 
remitting 
,newly 
diagnosed 
Reduction of new 
gadolinium-enhancing 
MRI lesions (n-Gd+). 
 
3/5 mild transient 
gastrointestinal 
symptoms 
Allergic rhinitis 
Bager, 
2010111; 
Bager 
2011112; 
Bourke, 
2012113 
T. suis  
8x 2500 
TSO every 
21 days 
No use of systemic 
steroids during the last 
2 months and no 
immune therapy in the 
last 2 years. 
96/47 
double-blind, 
placebo-
controlled 
na No therapeutic effect 
Moderate to severe 
gastrointestinal 
disorders (76% 
TSO vs 49% 
placebo). Especially 
from d0-d42.  
TSO: embryonated Trichuris suis ova; 5-ASA: 5-aminosalicylic acid, AZA: Azathioprine, 6-Mp: 6-Mercaptopurine; CDAI: Crohn's disease activity index; UCDAI: 
ulcerative colitis disease activity index. na: not assessed. 
‡ Remission defined according to the IBD quality of life index. Among the CD patients 3/4 remitted and 4/4 responded (ΔCDAI> 150). All the UC patients 
responded (SCCAI>4). 
* Response defined as ΔUCDAI> -4 point. Calculated according intention to treat. 
• Response defined ad ΔCDAI> - 100 points, Remission defined as CDAI < 150 
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To our knowledge, no other studies of T. suis in IBD have been published. In 2010, Brodhurst 
reported the case of a UC patient who improved its clinical symptoms by self-infecting with multiple 
doses of T. trichiura eggs. Along with the symptomatic remission following the T. trichiura treatment, 
a reduction in neutrophils infiltration and a mucosal regeneration characterized by the presence of 
CD4+ IL-22+ Th cells were observed284. To date, there is not conclusive evidence of the efficacy of the 
TSO therapy in IBD and further randomized, double-blind, multicentre studies are needed286.  
1.4.4.1 Concerns on the Safety of Trichuris Therapy 
Although T. suis infections are presumably transient, self-limiting and do not cause adverse effects in 
healthy subjects, their outcome in IBD patients is not clear286. IBD patients have a compromised 
barrier function that could favour the invasion of the larvae in the mucosa. Further, the concomitant 
infection could enhance the inflammatory reaction as observed in T. muris infections in colitic mice 
(Chapter 1.4.3.2). Another major concern is the safety of TSO in immunocompromised host. This is a 
major concern, since the standard treatment for IBD patients is immunosuppression.  
The initial studies performed in IBD patients did not report any adverse effect that could be attributed 
to the TSO treatment, even in immunosuppressed patients281. The larvae reportedly colonised the 
hosts only transiently for few weeks and no eggs were observed in the faeces of the treated patients, 
suggesting that the larvae did not reach sexual maturity279;280;281. These studies included patients 
undergoing standard immunosuppressive treatment that did not seem to affect the responsiveness to 
TSO281.  
A later study, explicitly addressed the concerns on TSO safety with a sequential, dose-escalation, 
double-blind test on patients suffering from a mild to moderate CD. A similar rate of adverse effects 
was observed in both TSO and placebo groups and no dose-dependency was noted285.  
Although the initial studies indicate that a T. suis infection in humans is not invasive, the parasite 
might be actually able to invade the intestinal mucosa of the human hosts as it does in the pig. T. suis 
larvae were found in the caecal mucosa of a CD patient treated with TSO. In this case, treatment had 
no therapeutic efficacy and the mucosa presented a lymphoplasmacytic infiltrate with substantial 
numbers of eosinophils even in sites not actively infected with T. suis283.  
The IBD studies, never found eggs in the faces of the patients, suggesting that T. suis never reached 
sexual maturity287. Still a productive infection is possible and was observed once at approximately 
day 24 in one TSO treated MS patient115. 
The nature of IBD itself might mask the presence of TSO induced symptoms, thereby complicating 
the assessment of the TSO-treatment related effects. Supporting this concerns, multiple sclerosis (MS) 
and allergic rhinitis patients developed gastrointestinal symptoms when treated with TSO. In the two 
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 studies with MS patients, 4 out of 9 patients developed transient gastrointestinal effects, that where 
mild even with concomitant immunosuppression288;125.  
A double-blind, placebo-controlled study confirmed the occurrence of gastrointestinal disorders 
following TSO administration. Symptoms included moderate to severe flatulence, diarrhoea, and pain 
in the upper abdomen. The symptoms were transient and occurred particularly up to day 42 post 
infection112. 
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 2 OBJECTIVES 
2.1 Study Rationale and Aim of the Project 
Ulcerative colitis and Crohn’s disease frequency increased dramatically in the last 60 years. 
According to the old friend hypothesis, improved hygienic condition reduced the interaction with 
organisms that co-evolved with our immune are thus essential for its proper functioning. Several 
studies have addressed the possibility of reintroducing these missing stimuli to treat inflammatory 
bowel diseases (IBD) and other disorders. 
The whipworm parasite Trichuris suis is a promising therapeutic agent, since it colonizes and 
interacts with the host intestine without causing major pathogenicity. In pigs, the natural host, 
infection is initiated by the ingestion of embryonated eggs (Trichuris suis ova, TSO). In the last two 
decades, few clinical studies have addressed the safety and efficacy of T. suis in IBD and in other 
immune related diseases. The evidence in support of TSO therapy in IBD is inconclusive. 
Furthermore, the safety of helminth therapy in immunosuppressed individuals that constitute the 
majority of the IBD patients is a major concern, and systematic studies are missing.  
Basic research is complicated by the absence of an animal IBD model that would allow studying a 
TSO treatment. In rabbits the course of a TSO infection resembles the one in humans with 
colonisation of the gastrointestinal tract for 2-3 weeks without reaching sexual maturity.  
For this reason we chose to use New Zealand white (NZW) rabbits as an in vivo model to study 
T. suis.  
 
The overall aim of this work was to develop a rabbit model of colitis and use it to evaluate the 
efficacy and safety of TSO therapy in immunocompetent and immunosuppressed animals.  
 
This work pursued the following specific aims: 
 
1) Establish a rabbit colitis model suitable for the in vivo study of T. suis 
a. Is it possible to develop a colitis model in rabbits analogous to the DSS colitis in 
mouse? What are the optimal conditions for induction DSS colitis in rabbits? 
b. What criteria can be identified to monitor and assess the development and severity of 
the induced colitis? 
 The colitis model was developed on the basis of the well-established dextran sodium 
sulphate (DSS) model. 
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Figure 2.1: Experimental layout for the establishment of a DSS induced colitis suitable for the in 
vivo study of T. suis in the rabbit. Study 1.1, 1.2, 1.3 were performed in White Himalayan rabbits 
(WH). Study 1.4 was performed in New Zealand White Rabbits. DSS: Dextran Sodium Sulphate, 
administered in daily beverage; # euthanasia and analysis. 
Preliminary studies showed that the dose and dosages used in the murine protocols (3% 
DSS in drinking water for 10 day) are inadequate for the induction of acute colitis in 
rabbits as they lead to a fulminant colitis. 
We thereby tested different protocols with a considerably reduced DSS concentration and 
administration length. Figure 2.1 summarises the steps that led do the development of the 
optimal acute colitis protocol. Clinical symptoms were monitored daily to develop an 
adequate clinical scoring system. The intestinal tract was examined to identify the sites 
and the characteristics of the DSS induced pathology. Several biomarkers were analysed 
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 at different time points to identify suitable parameters for the assessment of the colitis 
severity. 
 
2) Examine the therapeutic effect, the safety, the pharmacodynamics and the mechanisms of 
action of viable T. suis eggs in the colitis model in immunocompetent rabbits 
a. What are the optimal doses, dosages and administration of TSO? 
b. How do TSO interact with the mucosal immune system and which consequences can 
be observed on a systemic level? 
 We hypothesized that in healthy, immunocompetent rabbits T. suis prevents the onset 
of a chemically induced colitis or reduces its severity.  
 
 
Figure 2.2: Experimental layout for the preventive treatment with TSO ova in a model of DSS 
induced acute colitis. Studies were performed in New Zealand White Rabbits. DSS: Dextran 
Sodium Sulphate, administered in daily beverage. TSO: 2500 T. suis ova, administered intra 
gastrically ; # euthanasia and analysis. 
We tested the effects of TSO administration before the induction of acute colitis. The 
dose and dosage were chosen on the basis of the protocols utilized in the published 
human studies (Figure 2.2). The clinical symptoms and colitis severity were monitored on 
the basis of the previously identified parameters. A transcriptome analysis of immune 
cells isolated from caecal tissues was performed to investigate how T. suis modulates the 
mucosal niche. We investigated the effects of T. suis on the intestinal microbiota by 
characterizing the microbial composition of the faeces and caecal contents at different 
time points during the experiments. 
 
3) Examine the therapeutic effect and the safety of viable T. suis eggs in the colitis model in 
immunosuppressed rabbits 
a. Which consequences of a TSO therapy can be observed in immunocompromised 
subjects? 
b. Can an immunosuppressed rabbit control a T. suis infection?  
c. Is a functional immune system a prerequisite for the therapeutic effect of TSO? 
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 We hypothesized that in immunosuppressed rabbits T. suis escapes the control by the 
immune system and leads to an exacerbated colitis. 
 
 
Figure 2.3: Experimental layout for the preventive treatment with TSO ova in a model of DSS 
induced acute colitis in immunosuppressed rabbits. Studies were performed in New Zealand White 
Rabbits. Immunosuppression was induced with a combination of Cyclosporine A (CycA) and 
Methylprednisolone (MP) administered per oral. DSS: Dextran Sodium Sulphate, administered in 
daily beverage. TSO: 2500 T. suis ova, administered intra gastrically; # euthanasia and analysis. 
Cyclosporine and methylprednisolone were used for the establishment of an immune 
suppression protocol in rabbits. The preventive TSO administration established 
previously was applied to the immunosuppressed rabbits (Figure 2.3). Samples were 
collected from different organs to test for a systemic migration of the larvae. The 
intestinal microbiota of immunosuppressed rabbits was characterized and compared with 
the composition of immunocompetent rabbits. 
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 2.2 Contribution to Further Projects During the Time of the Dissertation  
(not addressed in detail within this written thesis) 
2.2.1 Protective Role of Helicobacter pylori in DSS-Induced Chronic Colitis 
Similarly to helminths infections, infections with H. pylori have been inversely linked to various 
allergic and chronic inflammatory conditions. We showed that experimental infection with H. pylori, 
and administration of regular doses of H. pylori extract, both alleviate the clinical and 
histopathological features of DSS-induced chronic colitis. 
Publication 
Engler DB, Leonardi I, Hartung M, Kyburz A, Spath S, Becher B, Rogler G, Müller A. 
Helicobacter pylori-specific protection against inflammatory bowel disease requires the NLRP3 
inflammasome and IL-18, Inflamm Bowel Dis. 2015 Feb 11. [Epub ahead of print] 
Own contribution to the publication: 
Euthanasia of mice and sampling  
Determination of the murine endoscopic index of colitis severity  
2.2.2 Influence of Isotretionin in Chronic DSS-Induced Colitis and T-cell Transfer 
Colitis 
Various studies discuss a potential adverse effect of isotretionin that is used in the treatment of severe 
forms of acne, in the development of IBD. The role of isotretionin in a chronic DSS-induced colitis 
and a T-cell transfer colitis model has been assessed. 
Publication 
Frey-Wagner I, Fischbeck A, Cee A, Leonardi I, Gruber S, Becker E, Atrott K, Lang S, Rogler G.  
Effects of retinoids in mouse models of colitis: benefit or danger to the gastrointestinal tract? Inflamm 
Bowel Dis. 2013 Oct;19(11):2356-65. 
Own contribution to the publication: 
Animal care, treatment, recording of weight curves 
2.2.3 pH Receptors in Intestinal Inflammation 
A local acidification in the gut lumen as well as in the mucosa occurs during intestinal inflammation 
and is implicated in the pathogenesis and progression IBD. We investigated whether GPR4, a 
prototype pH-sensing receptor, is involved in intestinal inflammation. Our data demonstrate that 
deletion of GPR4 is associated with ameliorated DSS and Il-10 KO colitis and thus pH sensing plays 
an important role in the pathophysiology of IBD. 
Publication 
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Wang Y*, de Valliere C*, Leonardi I, Gruber S, Gerstgrasser A, Weber A, Leucht K, Wolfram L, 
Hausmann M, Krieg C, Thomasson K, Boyman O, Frey-Wagner I, Rogler G, Wagner CA 
The proton-activated receptor GPR4 modulates intestinal inflammation 
Submitted, 2015, * Shared first authors. 
Own contribution to the publication: 
LPMC isolation 
Design, performance and analysis of the Flow cytometry experiments 
2.2.4 Role of Transcriptional Factor Nfr2 in Mucosal Inflammation and Cancer 
The transcription factor Nrf2 is a major modulator of the cellular antioxidative response. In IBD the 
regulation of reactive oxygen species (ROS) is of high interest, as the mucosa of patients is infiltrated 
by macrophages leading to a massive production of ROS. Transgenic mice conditionally expressing a 
constitutively active form of Nrf2 (caNrf2) were used to study the effects of Nrf2 overexpression in 
acute DSS colitis and chronic Il-10 KO colitis. Mice overexpressing Nrf2 in epithelial cells or myeloid 
cells lost more weight during acute colitis, had a more pronounced shortening of the colon and an 
elevated histological score. The worsening of inflammation in an acute model could not be confirmed 
in a chronic Il-10 KO model, where even a tendency towards reduced prolapse rate in female mice 
was observed.  
Publication 
Cee A, Leonardi I, Atrott K, Kopf M, Schäfer M, Werner S, Rogler G, Frey-Wagner I 
Cell-specific activation of the Nrf2 antioxidant pathway increases mucosal inflammation in acute but 
not in chronic colitis. Submitted, 2015. 
Own contribution to the publication: 
Euthanasia of mice and sampling  
Determination of the murine endoscopic index of colitis severity  
Histological scoring  
Isolation of murine IECs 
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In our manuscript Leonardi et al,  “Oral administration of dextran sodium sulphate induces a caecum-
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The correct figure 7, along with the accompanying figure legend, is: 
 
 
Figure 7: Quantitative RT-PCR showing expression of COX-2 (a, d), IL-6 (b, e) and MMP-1 (c, f) in intestinal 
epithelial cells (IEC, upper panel) and lamina propria mononuclear cells (LPMC, lower panel) of DSS and 
control rabbits at day 10 post colitis induction. Expression is shown relative to GAPDH in the distal colon, n = 
4–9. Values are given as mean ± SD and difference between groups was tested by two-tailed Student's t-
test. 
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SUMMARY
Trichuris suis ova (TSO) have shown promising results in the treatment of inflamma-
tory bowel disease (IBD) but the mechanisms which underlies this therapeutic effect
cannot be studied in mice and rats as T. suis fails to colonize the rodent intestine,
whilst hatching in humans and rabbits. As a suitable rabbit IBD model is currently
not available, we developed a rabbit colitis model by administration of dextran
sodium sulphate (DSS). White Himalayan rabbits (n = 12) received 0.1% DSS in the
daily water supply for five days. Clinical symptoms were monitored daily, and rab-
bits were sacrificed at different time points. A genomewide expression analysis was
performed with RNA isolated from caecal lamina propria mononuclear cells (LPMC)
and intestinal epithelial cells (IEC). The disease activity index of DSS rabbits
increased up to 2.1  0.4 (n = 6) at day 10 (controls <0.5). DSS induced a caecum-
localized pathology with crypt architectural distortion, stunted villous surface and
inflammatory infiltrate in the lamina propria. The histopathology score reached a
peak of 14.2  4.9 (n = 4) at day 10 (controls 7.7  0.9, n = 5). Expression profil-
ing revealed an enrichment of IBD-related genes in both LPMC and IEC. Innate
inflammatory response, Th17 signalling and chemotaxis were among the pathways
affected significantly. We describe a reproducible and reliable rabbit model of DSS
colitis. Localization of the inflammation in the caecum and its similarities to IBD
make this model particularly suitable to study TSO therapy in vivo.
Keywords
Crohn’s disease, DSS colitis, rabbit model of inflammatory bowel disease, RNA
sequencing, Trichuris suis, ulcerative colitis
Inflammatory bowel diseases (IBD) can be regarded as a
‘postindustrial revolution epidemic’ as the frequency of these
diseases has increased dramatically in the last 60 years
(Molodecky et al. 2012). Initially, this increase was
explained on the basis of the hygiene hypothesis that linked
the improved hygienic conditions and the consequent reduc-
tion of childhood infections to an increase in the prevalence
and incidence of immune-related diseases (Strachan 1989).
Today it is assumed that the increase in hygiene standards
reduces the interactions with micro-organisms that co-evolved
with the immune system and influences the balance between
immune-regulatory and effector mechanisms (Rook 2011).
In 2000, Elliot and colleagues focused their attention on
the complementarity between the distribution of IBD and of
helminth infections (Elliott et al. 2000; Weinstock et al.
2002). In their work they set the basis for the clinical appli-
cation of a helminth therapy and proposed the whipworm
parasite Trichuris suis as a therapeutic agent (Summers et al.
2003). Overall, the treatment with T. suis ova (TSO) proved
to be safe with only mild and transient gastrointestinal
effects reported (Scholmerich 2013). Those early results for
efficacy in IBD were promising. However, two recent large
multicenter trials in mild to moderate Crohn’s disease with
or without immunosuppression could not demonstrate a
significant benefit of TSO treatment over placebo. Further
clinical trials in ulcerative colitis are still under discussion.
So far most studies have focused on the clinical efficacy and
safety, and the mechanisms underlying the TSO treatment
© 2015 The Authors.
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effects remain unsolved. The discussion on whether further
clinical studies should be undertaken (i.e. in ulcerative
colitis) has given rise to a request for a better understanding
of potential mechanisms and this implies establishment of
suitable animal models.
Animal models of colitis are essential for the understand-
ing of the aetiology and pathophysiology of IBD and consti-
tute an essential tool in the development of new therapies.
Currently, more than 66 different IBD models have been
developed in several species including mouse, rat, rabbit and
tamarin (Wirtz & Neurath 2000). Generally, IBD models
can be subdivided into four categories of experimental
colitis depending on the method of induction: congenital,
genetically engineered, chemically induced and cell transfer
induced (Mizoguchi 2012).
Most methods are used successfully in both mouse and
rat. Unfortunately, research on the therapeutic application
of T. suis in model organisms is complicated by the
unsuccessful hatching of the ova in the mouse and rat
intestine (unpublished data). In contrast, the life cycle of
these parasites in the human and rabbit intestine is simi-
lar. In both hosts, T. suis hatch and establish in the distal
intestine region where the larvae seem to die prematurely
without reaching sexual maturity (unpublished data).
Therefore, a colitis model in the rabbit would be a valu-
able tool to investigate the mechanisms underlying T. suis
therapy.
Thus far the established rabbit IBD models have several
drawbacks that limit their use for translational research.
Rectal application of acetic acid causes severe acute inflam-
mation, ischaemia and erosion within one day postapplica-
tion, but fails to induce chronic inflammation (Hathaway
et al. 1999; Murthy 2006). Similarly, trinitrobenzene sul-
phonic acid (TNBS) dissolved in ethanol is also applied in
the rectum. Within a week after application, TNBS induces
a fully developed inflammation that presents ulcerative
lesions and transmural inflammation (Anthony et al. 1995,
2007). However, the development of chronic inflammatory
lesions in the TNBS model is highly variable and does
not show good reproducibility (Knollmann et al. 2002).
Furthermore, the short-term and self-limiting nature of these
colitis models is not adequate for the study of the relapsing
and remitting course of IBD. Both acetic acid and TNBS are
introduced as an enema in the rabbit rectum and induce an
inflammation that is usually confined to the distal colon,
whereas T. suis ova hatch and develop in the ileum and cae-
cum. Further colitis models in rabbits are of limited use
either because of the complicated induction procedure
(Hodgson et al. 1978; Hotta et al. 1986) or because of the
high variability of the induced pathology (Watt & Marcus
1970).
Thus, a novel colitis model in the rabbit that allows the
study of the mechanisms underlying the therapeutic effects
of TSO treatment is needed.
In both mice and rats experimental colitis is commonly
induced by the heparin-like polysaccharide dextran sodium
sulphate (DSS). DSS increases the trans-epithelial perme-
ability by decreasing the expression and by inducing the
redistribution of tight junction proteins (occludin, zonula
occludens-1, claudins) and by enhancing epithelial cell
apoptosis (Poritz et al. 2007), (Yan et al. 2009), (Menni-
gen et al. 2009). Furthermore, DSS causes a hyperosmotic
stimulus that leads to the activation of NF-jB in the epi-
thelium (Schwartz et al. 2008). This is consistent with the
accepted role of epithelial barrier dysfunction in the path-
ogenesis of IBD (Clayburgh et al. 2004). In both IBD and
DSS colitis, the damaged epithelium allows the entry of
luminal content into the mucosa, thereby facilitating the
onset of inflammatory processes (Nell et al. 2010). In
mice short-term administration of DSS (1–10% w/v) in
drinking water is used to induce ‘acute’ colitis, whereas
long-term or cyclic administration produces chronic colitis
(Wirtz et al. 2007). The development of pathology can be
easily monitored based on body weight, stool appearance,
rectal bleeding and behavioural changes. Such clinical
changes are usually preceded by alterations in histopatho-
logical parameters including colon shortening, mucosal
injury, immune infiltration and epithelial damage. These
changes initially appear in focal regions of the distal
colonic mucosa and then expand progressively although
the inflammation remains confined to the colon (Melgar
et al. 2005).
The DSS model guarantees low risk of mortality, high
reproducibility and good uniformity of the induced mucosal
inflammation (Melgar et al. 2008). We therefore chose to
develop a DSS colitis model in the rabbit. We found that in
rabbits administration of 0.1% DSS for 5 days induces a
clear caecum-localized inflammation that mimics histological
features of ulcerative colitis and is characterized by a similar
gene expression profile as observed in biopsies from patients
with IBD. Furthermore, we describe a scoring system to cor-
relate clinical parameters with histopathological findings
that should facilitate the evaluation of the tested therapeutic
approach.
Methods
Rabbits
All animal experiments were carried out according to
Swiss animal welfare laws and approved by the veterinary
office of Zurich. Female white Himalayan rabbits and
New Zealand white rabbits (Charles River, Kisslegg, Ger-
many) weighing 1.9–2.1 kg were used for the experiments.
Rabbits were maintained single-housed with water and
food (standard rabbit maintenance diet – Provimi Kliba
AG, CH-4303 Kaiseraugst, hay and straw) ad libitum on
a 12:12 h light/dark cycle. Upon arrival, animals were
kept for at least four days under routine husbandry. One
week prior to DSS exposure, drinking water was substi-
tuted by organic fennel tea (Hipp, Pfaffenhofen, Germany)
ad libitum.
International Journal of Experimental Pathology
2 I. Leonardi et al.
Colitis induction and clinical evaluation
Colitis was induced by DSS (MP Biomedicals, Illkirch,
France) dissolved in cold fennel tea at 0.1% w/v (if not
specified otherwise). Control rabbits received fennel tea as
vehicle. The beverage was prepared freshly and changed at
least every second day. For every animal daily weight, daily
food and fluid intake, daily stool appearance and behaviour
were monitored. A disease activity index was calculated
according to Table 1. The disease activity (range: 0–4) index
represents the sum of individual scores for weight loss, pres-
ence of uneaten cecotrophs, food intake and beverage intake
divided by 4. Euthanasia was performed following sedation
with barbiturates with an overdose of ketamine hydrochlo-
ride (Vetoquinol, Bern, Switzerland) and xylazine (Bayer,
Lyssach, Switzerland).
The abdominal cavity was exposed by a midline laparot-
omy, and samples were collected from the ileum, jejunum,
duodenum, caecum and colon. For RNA extraction and
myeloperoxidase activity analysis, the excised samples
(0.5 cm in length) from the duodenum, jejunum, ileum and
colon were opened by a longitudinal incision and rinsed
with cold PBS. 1 cm2 sections of the caecum were washed
extensively with cold PBS until removal of the luminal con-
tent was complete. The samples were immediately snap-fro-
zen in liquid nitrogen and stored at 80°C until analysis.
For histological analysis samples (0.5 cm2 sections of the
caecum samples or 0.5 cm length sections of the other tis-
sues) were either cut longitudinally or cut into smaller
(0.2 cm) sections for fixation. The samples were carefully
washed and fixed with phosphate-buffered 10% formalin
solution. For genomewide mRNA expression studies, caecal
samples (2 cm2) were washed extensively with cold PBS and
stored on ice in 5% BSA in PBS until further processing.
Whole caecal tissue RNA extraction and quantitative
real-time RT-PCR (qPCR)
Total RNA was isolated using the RNeasy Mini Kit (Qiagen,
Hilden, Germany) and the automated sample preparation
system Qiacube (Qiagen) following the manufacturer’s
recommendations. cDNA was synthesized with the High-
capacity cDNA Reverse Transcription Kit (Life Technologies,
Carlsbad, California, USA).
To study the transcription of immune response markers in
rabbit intestine tissues, sequence-specific primers were
applied (Table 2) and qPCR was performed according to
Schnupf et al. with some modifications (Schnupf & Sanso-
netti 2012). Amplifications were performed in a total
volume of 15 ll including 50 ng of cDNA, primers (0.2 lM
each) and 7.5 ll of Power SYBR Green mix (Life Technolo-
gies). Reactions were run in triplicate on an ABI 7900HT
(Life Technologies) using the universal thermal cycling
parameters (2 min 54°C, 94.5°C 10 min, 40 cycles of 15 s
at 97°C and 60 s at 59.7°C; dissociation curve: 15 s at
95°C, 15 s at 60°C and 15 s at 95°C). Results were analy-
sed with the sequence detection software ABI 7900HT
SDS2.4. For quality control purposes, all samples’ dissocia-
tion curves were acquired and amplification products were
visualized by 2% agarose gel electrophoresis. Primer
sequences are listed in Table 2. The comparative DDCt
method was applied for relative gene expression quantifica-
tion (Ct: threshold cycle).
Isolation of caecal lamina propria mononuclear cells
(LPMC) and intestinal epithelial cells (IEC)
Caecal LPMC and IEC were isolated as previ-
ously described (Weigmann et al. 2007), with some
Table 1 Scoring system for the daily monitoring of the disease activity index
Score Weight loss
Stool appearance
and cecotrophs
Reduction in
food intake
Reduction in
beverage intake Fur appearance
0 None Well-formed solid pellets, 0 cecotrophs None None Clean, bright fur
1 0–2% Easy to smear and loose stool, ≤1 cecotrophs 0–30% 0–30% Dim fur
2 2–5% Loose stool, 2–3 cecotrophs 30–60% 30–60% Shagged fur
3 5–10% Loose smeared stool in cage, 4–5 cecotrophs 60–90% 60–90% Smudgy, unclean fur
4 >10% Loose smeared stool in cage, > 5 cecotrophs >90% >90% Smudgy, stool stains,
smeared anus
Table 2 Primers for qPCR
Marker Forward primer Backward primer Primer location within CDS Target size NCBI Accession
IL-12p35 AAGGCCAGACAAACTCTAGAATTC Exon 3/4 and 4/5 from 8 116 nts XM_002716291
TTGGTTAACTCCAGTGGTAAACAGG
iNOS GACGTCCAGCGCTACAATATCC Undetermined 102 nts XM_002718780
GATCTCTGTGACGGCCTGATCT
IFNc TGCCAGGACACACTAACCAGAG Exon 1 and 2/3 from 4 127 nts NM_001081991
TGTCACTCTCCTCTTTCCAATTCC
GAPDH TGACGACATCAAGAAGGTGGTG Exon 1 of 1 120 nts NM_001082253
GAAGGTGGAGGAGTGGGTGTC
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modifications. Briefly, the dissected mucosa was washed
with Ca+- and Mg+-free PBS; the caecal fold was removed
and discarded. The tissue was cut and incubated in med-
ium containing 20 mM EDTA (Sigma-Aldrich, St. Louis,
MO, USA) for 30 min at 37°C on a shaking platform
(150 rpm). After incubation, the suspension of IEC, villus
cells, subepithelial cells and intestinal epithelial lympho-
cytes was detached by vortexing and passing through
a 70-lm cell strainer (BD Biosciences, Erembodegem,
Belgium). The epithelial cells were washed twice, pelleted,
resuspended in RTL buffer (Qiagen), snap-frozen in liquid
nitrogen and stored at 80°C for later analysis. The
remaining tissue containing LP with muscle layer was col-
lected and incubated in medium containing 1 lg/ml colla-
genase type I CLS (Worthington Biochemical Corp.,
Freehold, New Jersey, USA) at 37°C on a shaking plate
(300 rpm). After 15 min incubation, the suspension was
vortexed and filtered through a 70-ll strainer. The filtered
cells were resuspended in 5% BSA in PBS to stop the
enzymatic digestion. The undigested tissue was incubated
with fresh collagenase solution for additional 15 min. The
collagenase digestion was repeated three times, and the
washed LPMC were pooled. LPC were pelleted twice and
resuspended in DMEM supplemented with 5% FCS.
LPMC were purified using Ficoll-Paque PLUS (GE Health-
care Europe GmbH, Freiburg Germany) gradient centrifu-
gation for 40 min at 1509g. The viability of the cells was
confirmed by tryptan blue staining. Cells were resuspended
in RTL buffer (Qiagen), snap-frozen in liquid nitrogen
and stored at 80°C for later analysis.
RNA isolation and genomewide mRNA expression
analysis
Total RNA was isolated with the Qiacube system using
the RNeasy Mini Kit with DNase digestion (Qiagen) to
eliminate genomic DNA. RNA integrity and quantity
were determined on the Agilent 2100 Bioanalyzer (Agilent,
Palo Alto, CA, USA). Samples with an integrity score
≥6.8 were sent to the Functional Genomic Centre Zurich
(FGCZ) for sequencing on the Illumina platform. The
fold change (FC) was used to express the changes in
average gene expression between studied groups. FC was
normalized against the control group (rabbits receiving
fennel tea only). The ENSEMBLE IDs were annotated
using BetterBunny augmented annotation and analysis of
rabbit genes (http://cptweb.cpt.wayne.edu) (Craig et al.
2012). MetaCoreTM (Thomson Reuters, http://portal.gene-
go.com) was used to perform network and pathway
analyses. The following cut-offs were applied to select
differentially expressed genes for further analysis: P-value
P ≤ 0.01 and fold change ≥|2.0|. The pathways (groups of
genes belonging to the same pathway map in MetaCoreTM
database) and gene families were considered significant with
a P-value ≤0.05 and were further selected on the basis of
their relevance to inflammatory bowel disease pathology.
Additional gene expression data sets for comparison were
obtained from GEO Data Sets (NCBI) of previously pub-
lished studies in colon pinch biopsies from patients with UC
and CD (Granlund et al. 2013).
Validation of the genomewide mRNA expression analysis
The expression profiling results were confirmed by qPCR of
selected genes involved in the highlighted pathways. cDNA
synthesis was performed using a High-capacity cDNA
Reverse Transcription Kit (Life Technologies Ltd). Real-time
PCR was performed using TaqMan Gene Expression Assays
(Life Technologies Ltd) and TaqMan Fast Universal PCR
Master Mix No AmpErase UNG (Life Technologies Ltd) on
a 7900 HT Fast Real-Time PCR System with SDS 2.2
Software (Life Technologies Ltd). TaqMan gene expression
assays were performed for COX-2 (Ptgs2, Oc03398293
_m1), IL-6 (Oc04097051_m1), MMP-1 (Oc04250656_m1)
Table 3 Scoring system for DSS-induced histological changes in the caecum
Morphological features Inflammation
Villous stunting
Villous epithelial
injury Crypt distortion
Intraepithelial
lymphocytes
LP lymphocytes and
plasma cells LP eosinophils
1 Normal mucosa Normal mucosa Normal mucosa 5–10/50 IEL/epithelial
cells
25% of the villous
lamina propria
2–3 cells per 9 40 field
2 Mild villous
stunting
Mild villous
epithelial injury
Mild crypt
distension,
hyperplasia and
distortion
11–30 IEL/50 epithelial
cells.
25–50% of the villous
lamina propria
5–10 per 9 40 field.
3 Moderate villous
stunting
Moderate villous
epithelial injury
Moderate crypt
distension,
hyperplasia and
distortion.
31–50 IEL/50 epithelial
cells
may be focally clustered.
50–75% of the villous
lamina propria.
10–20 per 9 40 field.
4 Marked villous
stunting
Marked villous
epithelial injury
Marked crypt
distension,
hyperplasia and
distortion
51–100 IEL/50 epithelial
cells, may be clustered
and at all levels of the
epithelium
75–100% of the villous
lamina propria.
> 20 per 9 40 field
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and the housekeeping gene GAPDH (Oc03823402_g1)
as an endogenous control. Measurements were performed in
triplicates; relative expression was calculated using the DDCt
method.
Histopathological evaluation of colitis
After careful dissection and fixation, tissues were routinely
embedded in paraffin. Serial sections of 5 lm were cut using
a microtome (Carl Zeiss AG, Feldbach, Switzerland) and
stained with haematoxylin–eosin to investigate epithelial
damage and cellular infiltration. The histological changes in
the caecum were quantified in a blinded manner by two
investigators with a scoring system (range 1–24) for mor-
phological features and infiltration of immune cells accord-
ing to the scoring system described in Table 3 (Cooper et al.
1993; Kojouharoff et al. 1997; Day et al. 2008).
Analysis of myeloperoxidase activity
Myeloperoxidase (MPO) activity was measured in different
regions of the gastrointestinal tract as previously described.
Myeloperoxidase activity was calculated as mean absor-
bance (460 nm) per incubation time per protein content of
(a) (d)
(e)
(b)
(c)
Figure 1 Manifestation of clinical
symptoms upon DSS exposure.
Response to colitis induction was
monitored daily according to a detailed
score sheet. Food intake (a), beverage
intake (b), weight change (c), stool
consistency (d. representative pictures
for control and DSS rabbits at day 10)
were summarized into a disease activity
index (e. DAI, 0–4). DSS rabbits (●,
n = 12) were fed with 0.1% DSS in the
daily beverage (fennel tea) for 5 days.
The control group (○, n = 5) was
maintained under the same conditions
with fennel tea as beverage. Data
represent mean  SD; Mann–Whitney
test, **P ≤ 0.005, *P ≤ 0.05.
(a)
(b)
Figure 2 Absence of histopathology in
the colon and ileum. Representative
HE-stained colon (a) and ileum (b)
sections in control and in DSS-exposed
rabbits at day 10. Scale: 200 lm.
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the sample in grams (indicated as arbitrary units U/g s)
(Bozeman et al. 1990).
Statistical analysis
The results of the 0.1% DSS colitis were obtained in two
different experiments (n = 8 and n = 4). As the experimen-
tal protocol was identical for both experiments, results
were pooled together. The data obtained from this study
were analysed using IBM SPSS statistic 21 (Armonk, NY,
USA). The majority of the examined parameters were
asymmetrically distributed. For the comparison of the treat-
ment groups, the nonparametric Mann–Whitney U-test for
two independent samples was used.
Results
Clinical symptoms of DSS exposure in rabbits
As rabbits have a more sensitive digestive tract in compari-
son with mice, the concentration of DSS to induce colitis
had to be drastically decreased. We observed a reduction of
daily fluid intake that we ascribed to the unpleasant taste of
DSS. To overcome this problem, DSS was dissolved in
organic fennel tea that successfully masked the taste of
the DSS and restored a normal fluid intake during DSS
exposure.
A pilot study (data not shown) showed that administra-
tion of 0.1% DSS in fennel tea for 3 days reduced the
(a)
(d)
(b) (c)
Figure 3 Histopathological changes of
the caecum at different time points
after colitis induction. HE-stained
caecum sections were scored (a, 1–4)
for markers of inflammation
(infiltration of lamina propria
eosinophils, lamina propria
lymphocytes, intraepithelial
lymphocytes) and for the distortion of
morphological features (villous
stunting, villous epithelial injury, crypt
distortion). Single parameters were
summarized to a global score (b). Black
dots represent DSS-treated rabbits (●);
white dots represent control rabbits
(○). Horizontal lines represent the
arithmetical mean; Mann–Whitney test,
**P ≤ 0.05, *P ≤ 0.1. Representative
HE-stained caecal sections of control
rabbits (c) and of DSS-exposed rabbits
at different time points after colitis
induction (d). Scale: 200 lm.
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normal weight gain from day 5 on in the treated animals.
This effect was no longer present from day 14 on, indi-
cating a restitution of the colitis. Other clinical symptoms
were not evident. Histological analysis of HE stained
intestinal samples showed no clear signs of inflammation;
only a slight reduction in the number of goblet cells in
the caecum at day 7 and 10 was observed. Subsequently,
the duration of the DSS phase was increased from 3 to
5 days. Twelve white Himalayan rabbits were fed for
5 days with 0.1% DSS in the daily beverage (fennel tea),
whilst control rabbits (n = 5) housed in the same facility
were given fennel tea without DSS. The earliest symptoms
manifested at day 4, when the rabbits started to gradually
diminish the daily food and beverage intake from the ini-
tial 120 g/day pellet and 210 ml/day beverage intake at
day 1 down to 40 g/day and 100 ml/day at day 7 (Fig-
ure 1a, b).
Exposure to 0.1% DSS markedly reduced the weight gain
(Figure 1c). Further symptoms included the presence of
loose and smeared stool (Figure 1d), behavioural abnormali-
ties such as apathy or aggressiveness and unclean fur. A
combinatorial index of disease, (Figure 1e, disease activity
index DAI, described in the methods section) was used to
quantify the severity of the monitored clinical symptoms.
We found that whilst the DAI of control rabbits remained
Table 4 Genes concordantly upregulated in LPMC of DSS colitis
rabbits and IBD biopsies
Cell adhesion and
cytoskeleton reorganization
Metabolism and biosynthesis
CD38 PTGS2(COX2)
PLEK SLC6A14a
S100A9 TCN1
SELLa
Cytokine and cytokine R genes Development
IL1A EGR2a
IL6
IL8
IRF1
Chemokine and chemokine R genes Tissue remodelling genes
CCR7a MMP3
CXCL10
CXCL11
CXCR4
ENA-78a
Immune response
Innate immune defence BCR and TCR signalling
TMEM173 CD19
DMBT1 LAX1
FAM65Ba
SLC11A1a
List of genes concordantly upregulated in LPMC from the caecum
of DSS-treated rabbit and colonic biopsies of inflamed tissue from
patients with IBD. LPMC: Lamina propria mononuclear cells. adif-
ferentially expressed in patients with UC, only.
Figure 4 mRNA expression of pro-inflammatory cytokines
during colitis induction. mRNA expression of IL-12 p35 in
caecum from DSS-treated (●) or control (○) rabbits. Results
are shown as mean expression relative to GAPDH using the 2
 DDCt method. Dots represent single rabbits; horizontal lines
represent the arithmetical mean. Each sample was analysed in
triplicate.
Figure 5 Process network analysis of differentially expressed
genes in epithelial cells (EC, black bars and line) and lamina
propria mononuclear cells (LPMC, grey bars and line). This
analysis is based on a manually curated database of process
networks, which details more specific biological processes than
GO annotations alone. Most prominent process networks
associated with the identified genes were involved in cell
adhesion and chemotaxis (═) and immune and immune
responses (▬). Analysis was performed with MetaCoreTM. Bars
represent the log(p-value) of enriched pathways, whereas lines
represent the ratio between differentially expressed genes upon
DSS exposure and the total number of genes involved in the
specific process network. Gene expression threshold: fold
change ≥ |2.0|; P-value ≤ 0.05.
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at baseline (DAI <0.5), the DAI of rabbits receiving DSS
increased significantly starting from day 5 (DSS: 0.47 
0.32, n = 12; control: 0.08  0.10. n = 5) and rose up to
2.1 at day 12.
DSS induces a caecum-localized pathology
Histological evaluation of the intestinal tract revealed a
caecum-localized pathology, whereas no clear signs of tissue
damage were observed in other regions of the intestinal tract
(colon and ileum, Figure 2).
Histopathology of the caecum was characterized by infil-
tration of immune cells into the epithelial layer and the
lamina propria and by morphological changes such as vil-
lous stunting, crypt distortion and villous epithelial injury
(Figure 3a,c,d). The global histology score was increased
from day 4 onward (Figure 3b). The severity of the damage
increased progressively even after the removal of DSS from
a baseline value of 7.7  0.9 in control rabbits (n = 5) to
an average score of 13.3  5.0 at day 10 (n = 4) and
further increased until day 14.
Expression analysis of genes involved in the immune
response
To evaluate the inflammatory response in DSS-treated
rabbits, we analysed the mRNA expression of inflammation-
related genes by q-rtPCR. iNOS, IFNc and IL-12 p35 were
chosen as they have been implicated in IBD and have been
shown to be overexpressed in inflamed rabbit tissue
(Schnupf & Sansonetti 2012). Gene expression analysis of
inflammatory markers in the caecum showed a transient
increase of IL-12 p35 in DSS-treated rabbits (Figure 4),
although, owing to the limited sample number in the control
group, the difference did not reach statistical significance.
No difference between the groups was observed for iNOS
and IFNc.
Genomewide gene expression analysis in LPMC and IEC
by RNAseq
Genomewide gene expression analysis identified 470 differ-
entially expressed genes in IEC and 215 differentially
expressed genes in LPMC (FC ≥ |2|, P ≤ 0.05). The pro-
cess networks that were significantly over-represented in
Figure 6 Enrichment of differentially expressed genes in selected
disease categories (by biomarkers) in epithelial cells (IEC, white
bars and line) and lamina propria mononuclear cells (LPMC,
grey bars and line). The Gene IDs of the orthologous genes
assigned to the differentially expressed rabbit mRNAs were
analysed for enrichment in selected disease categories using
MetaCoreTM. Terms relevant for IBD and experimental colitis
are displayed. Bars represent the log (P-values) of enriched
pathways, whereas lines represent the ratio between the
differentially regulated genes upon DSS exposure and the total
number of genes involved in the specific process network. IBD,
inflammatory bowel disease, UC, ulcerative colitis, CD, Crohn’s
disease. Gene expression threshold: fold change ≥ |2.0|; P-value
≤0.05.
Table 5 Genes concordantly upregulated in ECs of DSS colitis
rabbits and IBD biopsies
Cell adhesion and
cytoskeleton reorganization
Metabolism and
biosynthesis
SELLa FCRLAb
PLEK PLA2G7a
VNN1 SLC11A1a
S100A9 SLC2A3
CLEC4A SLC6A14a
CD38 TCN1
Cytokine and cytokine R genes Apoptosis
IL1A UBD
IL1B IER3a
IL6a PEA15a
IL8
Chemokine and chemokine R genes Cell–cell signalling
CCR7a ADM
CXCL10 TNFAIP6a
CXCL11 Tissue remodelling genes
CXCL13 CTSK
CXCL5a MMP1
CXCL6 MMP12
CXCL9 SERPINE2
Immune response
Innate immune defence BCR and TCR signalling
OAS2 CD19
TLR8b CD74
Humoral immune response CD79B
POU2AF1 CD86a
CD83a LYNa
Acute-phase response SLAMF8a
SERPINA1 Inflammatory response
Antigen processing NFKBIZa
HLA-DMA Anti-inflammatory
response
HLA-DPA1 A1F1
HLA-DPB1b
List of genes concordantly upregulated in EC from the caecum of
DSS-treated rabbit and colonic biopsies of inflamed tissue from
patients with IBD. EC: epithelial cells. agenes differentially
expressed in patients with UC, only. bgenes differentially expressed
in patients with CD, only.
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the MetaCoreTM analysis were 58 in LMPC and 49 in IEC
respectively. Among the most relevant process net-
works, there was an over-representation of genes involved
in inflammation, immune response and chemotaxis (Fig-
ure 5).
Furthermore, the disease (by biomarkers) ontology in
MetaCoreTM was used to assess the similarity between the
gene expression in our rabbit DSS colitis model with the
gene expression known to be associated with selected
human diseases. In both LPMC and EC, we found an
enrichment of differentially expressed genes associated with
inflammation, IBD, CD and UC (Figure 6).
To further confirm the results of the disease enrichment
analysis, we compared genes differentially regulated in our
DSS colitis model with a gene set from a genomewide
gene expression analysis in human CD and UC patients
(Granlund et al. 2013). Overall, the majority of the differen-
tially expressed genes were involved in immune response,
cell adhesion, cytoskeleton reorganization and chemokine
signalling (Table 4; Table 5).
Finally, the sequencing results for mRNA expression were
validated for COX-2, IL-6 and MMP1 by qPCR (Figure 7).
In accordance with our transcriptome results, the expression
of the selected genes was higher in both LPMC and EC
isolated from DSS-treated rabbits in comparison with the
non-colitic controls.
DSS transiently increases neutrophil infiltration in the
rabbit caecum
The neutrophil infiltration into inflamed tissues was moni-
tored by analysis of myeloperoxidase (MPO) activity (Brad-
ley et al. 1982). MPO activity in the caecum of DSS-
treated rabbits transiently increased at days 5–7 before
returning to baseline levels at day 14 (Figure 8a), but due
to the low number of animals the change did not reach
statistical significance. Analysis of MPO in the ileum and
the colon showed no significant differences between colitis
animals and the control group (Figure 8b,c). In the ileum,
the basal MPO activity in untreated rabbits was higher
than in the caecum, but no changes occurred upon expo-
sure to DSS. Overall, our results suggest that the DSS-
induced infiltration of neutrophils predominantly localizes
in the caecum.
(a) (b) (c)
Figure 7 Quantitative RT-PCR showing expression of COX-2 (a, d), IL-6 (b, e) and MMP-1 (c, f) in intestinal epithelial cells (IEC,
upper panel) and lamina propria mononuclear cells (LPMC, lower panel) of DSS and control rabbits at day 10 postcolitis induction.
Expression is shown relative to GAPDH in the distal colon, n = 4–9. Values are given as mean  SD and difference between groups
was tested by two-tailed Student’s t-test.
(a) (b) (c)
Figure 8 Myeloperoxidase (MPO) was determined as a marker for neutrophil infiltration in the gastrointestinal epithelium. Values
for MPO activity in caecum (a), duodenum (b) and ileum (c) samples were normalized for the total protein concentration as
determined by BCA assay and for the incubation time (values are represented in arbitrary units U/g s). Dots represent single animals.
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Discussion
The helminth parasite T. suis has shown promising results
for the treatment of IBD in human studies. Unfortunately,
efficacy and safety (in particular in immune-compromised
subjects) as well as the underlying mechanisms cannot be
studied in the well-established mouse and rat models of
IBD as the parasite’s ova fail to hatch in the intestine of
these rodents. TSO are known to hatch in pigs (the natural
host), humans and rabbits. As the life cycle of T. suis in
humans and in rabbits appears similar, a rabbit model of
colitis would represent an adequate model for investigations
into TSO therapy. The aim of the present study was to
develop an IBD model in rabbits by administration of DSS
into the daily fluid intake. This study shows that adminis-
tration of 0.1% DSS for 5 days is sufficient to induce a
clear acute inflammation that is localized in the caecum.
Localization of the pathology in the caecum makes the DSS
model particularly suitable to study the effects of TSO
treatment as the caecum is the site of T. suis colonization
in rabbits.
In accordance with the disease manifestation in other spe-
cies, the clinical symptoms observed in rabbits were reduced
weight gain, reduced food and beverage intake, loose stools
and unclean fur (Wirtz et al. 2007). The strong reduction in
fluid intake began after 5 days only; hence, the daily intake
of DSS remained constant throughout the whole induction
phase.
The reduction in food intake reflects the response to
abdominal discomfort and the disturbances in feeding
behaviour that are seen in patients with inflammation of the
gastrointestinal tract (Rigaud et al. 1994) and are also com-
monly observed in mouse and rat models of gastrointestinal
inflammation (McHugh et al. 1993; McDermott et al.
2006). To facilitate the evaluation of the disease outcome,
we developed a DAI based on the monitoring of the differ-
ent clinical parameters. Starting from day 4 after DSS
administration, rabbits manifested clear symptoms of
pathology that gradually worsened. A peak of disease activ-
ity was reached at day 9. Afterwards, the DAI decreased
and stabilized until the last analysed time point at day 14.
Macroscopical analysis of the internal organs following
euthanasia showed no abnormalities. In contrast, histopath-
ological analysis of the intestinal tract revealed that DSS
causes an inflammation predominantly localized in the cae-
cum. The other sections of the large intestine and the small
intestine remained unaffected.
The caecum localization of the DSS-induced inflammation
is also observed in guinea pigs and in the Mongolian gerbil
model (Iwanaga et al. 1994; Bleich et al. 2010). These spe-
cies possess a functional caecum that is particularly enlarged
and provides a niche for the microbial fermentation of cellu-
lose (Snipes 1982, 1997). The caecum localization of the
DSS-induced inflammation might be due to an increased
permeability of the intestinal barrier to DSS in this particular
section of the intestine (Hoshi et al. 1996). The localization
of the lesions in gerbils has been linked to the increased
absorption of sulphated polysaccharides in this particular
section of the gerbil intestine, and absorption of DSS in the
caecum has also been reported in rabbits (Sharratt et al.
1971) and might explain our observations. In accordance with
DSS models in other species, DSS treatment induced both a
disruption of the mucosal morphology and an infiltration of
immune cells (Melgar et al. 2005). In particular, the histopa-
thology of the caecum displays crypt loss, epithelial damage
and infiltration of immune cells. These manifestations repro-
duce characteristic traits commonly observed in ulcerative
colitis (Okayasu et al. 1990). Despite the progressive amelio-
ration of the clinical symptoms after their peak at day 9, the
histological damage persists longer and displays some charac-
teristics of chronic intestinal inflammation such as the atypi-
cal branching of the crypts.
The initial pathology (day 4–9) presents classical features
of an acute inflammation. From day 7 to day 10, we
observed a transient increase in neutrophil infiltration into
the caecal mucosa accompanied by an increased expression
of the pro-inflammatory cytokine IL-12 p35. This transient
inflammatory activity correlates well with the peak of the
DAI and with the histological findings and suggests an ini-
tial T helper 1-driven acute response. The increased neutro-
phil activity in the caecal mucosa is a common feature with
the guinea pig colitis model. However, the described model
in guinea pigs was performed with high concentration of
DSS (3%) and had a fulminant outcome, with 96% of the
animals dying within 96 h (Iwanaga et al. 1994).
Genomewide mRNA expression profiling in caecum
LPMC and ECs at day 10 showed an enrichment of genes
involved in chemotaxis and immune response. In particular,
the immune response was characterized by genes involved in
Th17 signalling, particularly in epithelial cells. An activation
of the innate immune response is a feature shared by both
patients with CD and UC. In contrast, Th17-associated
cytokines are usually observed in the inflamed mucosa of
patients with CD, only. Our analysis further showed enrich-
ment for IL-4-related cytokines that would rather suggest a
Th2-type response. This type of response correlates well to
the atypical Th2 response (mediated by natural killer cells
producing IL-13) observed in patients with UC (Fuss et al.
2004). A switch into a Th2-type response has been observed
as the colitis matures from an acute towards a chronic phase
(Alex et al. 2009). The features that appear at later stages
of the rabbit colitis might indicate that after an acute phase
characterized by severe clinical symptoms, mucosal damage
and acute inflammation, the pathology acquires a certain
degree of chronicity with a shift towards a Th12 immune
response. A long-term analysis is necessary to investigate
these preliminary observations and to clarify whether the dis-
ease resolves after the acute phase or whether it progresses
to chronicity.
In summary, we report the development and characteriza-
tion of a novel DSS-induced colitis model in rabbits. The
initial pathology has an acute nature and is characterized by
specific clinical symptoms, histopathological changes and
higher mRNA expression of inflammatory markers. Our
International Journal of Experimental Pathology
10 I. Leonardi et al.
model provides a safe and reliable induction of colitis in
rabbits that is particularly suitable to study the effects and
mechanisms of TSO treatment in IBD.
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 4.1 Summary 
BACKGROUND & AIMS: Immunomodulation by helminths can be used to prevent and treat 
immune related diseases. Clinical trials in IBD with T. suis ova (TSO) have shown promising results 
but the underlying mechanisms and the safety in patients with immunosuppressive therapy have not 
been investigated so far. We used a rabbit model of colitis to study the efficacy, mechanisms and 
safety of TSO therapy in immunocompetent and immunosuppressed animals. 
 
METHODS: NZW rabbits received 3x2500 TSO (d1, 14, 21, i.g). Colitis was induced at d26 with 
0.1% DSS for 5 days. Symptoms were monitored daily and rabbits were sacrificed at d35. Lamina 
propria mononuclear cells (LPMC) and epithelial cells (IEC) were isolated from caecal biopsies, for 
RNA extraction and genome wide expression analysis. For immunosuppression, treatment with 
cyclosporine (100 ul/kg/day p.o) and methylprednisolone (1 mg/kg/day p.o) was started 14d prior to 
the first TSO treatment and continued until d35. 
 
RESULTS: TSO treatment significantly reduced the weight loss during colitis (% d10/d0, TSO: 
+4.23±0.98 vs. vehicle: 0.25±1.22; n=8 per group) and reduced the disease activity index (DAI) at 
d35 from 1.6±0.8 (vehicle) to 0.7±0.2 (TSO). TSO partially protected the caecal mucosa from the 
DSS induced morphological changes and reduced the extent of lymphocyte infiltration. Expression 
profiling showed that the effect of TSO mainly influenced LPMC by dampening innate inflammatory 
and Th17 responses and by down regulating cell-adhesion pathways. 
  
In immunosuppressed rabbits, TSO treatment exacerbated the DSS induced colitis: The weight loss 
increased from 0.15±1.20 (vehicle, n=8) to 3.10±1.60 (TSO, n=9). Further, histological examination 
revealed the presence of larvae in the caecal mucosa and a worsening of the histology score by 50%. 
CONCLUSIONS: We show that TSO ameliorates the development of colitis in immunocompetent 
rabbits, where it modulates LPMC immune responses. This preventive effect, however, is lost in 
immunocompromised animals, where TSO treatment exacerbates the colitis. Caution should be 
exercised with regard to TSO treatment in immunosuppressed patients. 
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4.2 Introduction 
The etiology of IBD is complex and is not fully understood. Nonetheless, the increase in IBD 
incidence in developing nations suggests that the environment plays a critical role in the development 
of both UC and CD [1]. In particular, the hygiene hypothesis suggests that the increasing hygienic 
standards of the post-industrial era led to an increase of the incidence of several immune related 
disorders [2]. Among various factors, a clear inverse correlation exists between the distribution of 
IBD and that of soil-transmitted helminthic infections [3].  
According to the old-friends hypothesis, helminths are the intestine-symbionts that co-evolved with 
the adaptive immune system and are thereby essential for its proper maturation and functioning [4]. 
Helminths act on the intestinal homeostasis on several levels: they induce regulatory networks that 
promote anti-inflammatory immune responses, they modulate the composition of the intestinal 
microbiota [5] and they increase the permeability of the intestinal epithelium [6].  
The immune- modulation exerted by helminths has been proposed for the prevention and treatment of 
immune-related diseases [7]. The swine parasite Trichuris suis is the main helminth species tested in 
IBD. The trials in human IBD patients have been performed by administration of different doses and 
dosages of embryonated T. suis ova (TSO)279. The current view is that T. suis can to colonize the 
human intestine where the larvae mature without reaching sexual maturity [9].  
 
The evidence in support of the efficacy and safety of TSO for the treatment of IBD remains 
inconclusive [10]. The initial open-label studies showed promising clinical efficacy and safety [11]. 
Yet, larger multicenter studies failed to show a significant effect of TSO in comparison to placebo in 
mild to moderate IBD patients [10]. Furthermore, the safety of helminth therapy in 
immunosuppressed individuals that constitute the majority of the IBD patients is a major concern. 
Summers and colleagues did not report any severe consequence among the immunosuppressed 
patients involved in their clinical trials [12]. On the contrary, Kradin et al. reported the case of an 
invasive iatrogenic infection in an immunosuppressed patient [13]. It has to be noted, that the nature 
of IBD itself might mask the presence of TSO induced symptoms, thereby complicating the 
assessment of the side effects of TSO-treatment.  
To date, the lack of a suitable animal model has hampered detailed investigation into the mechanisms 
and safety of TSO treatment. We recently developed a colitis model in rabbits by administering 0.1% 
DSS for 5 days in the drinking water [14] since the course of a TSO infection in the rabbit intestine 
parallels the one in humans. Here, we use this model to test the efficacy and safety of a preventive 
TSO therapy in immunocompetent and immunosuppressed animals. 
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4.3 Materials and Methods 
4.3.1 Rabbits 
All animal experiments were carried out according to Swiss animal welfare laws and approved by the 
veterinary office of Zurich (license No. 128-2010 and 231-3013). New Zealand white rabbits (Charles 
River, Kisslegg, Germany) weighing 1.9-2.1 kg (8-10 week of age) were used for the experiments. 
Rabbits were maintained single-housed with water and food (standard rabbit maintenance diet – 
Provimi Kliba AG, Kaiseraugst, Switzerland, hay and straw) ad libitum on a 12:12 hour light/dark 
cycle. Upon arrival, animals were kept for at least 4 days under routine husbandry. Afterwards, 
drinking water was substituted by organic fennel tea (Hipp, Pfaffenhofen, Germany) ad libitum.  
4.3.2 Trichuris suis Ova Administration 
Rabbits were randomly assigned to treatment groups receiving either suspensions of 2500 TSO 
(embryonated T. suis eggs, supplied as ready-to-use inoculation doses) or the vehicle (Phosphoric 
acid buffer pH 5.0 with 0.05% potassium sorbate) in 3 oral doses at day 1, day 14 and day 21. 
Animals were fasted overnight prior to TSO administration and sedated with 0.4 ml Hypnorm 
(VetaPharma, Leeds, UK), s.c. The TSO suspension (volume 15 ml) was completely filled in a 
syringe and administered to the animal using a gastric tube (i.e. Ruesch Katheter, CH14, REF 
402101, Kernen, Germany ). The animals were fed shortly after administration. 
4.3.3 Colitis Induction and Clinical Evaluation 
DSS Colitis was induced at day 26 as described previously [14]. Rabbit received DSS (MP 
Biomedicals, Illkirch, France) dissolved in cold fennel tea at 0.1% w/v for 5 days. Control rabbits 
received cold fennel tea only. Of every animal weight, food and beverage intake, stool appearance 
and behavior were monitored daily. A disease activity index was calculated according to Table C.1.  
4.3.4 Immunosuppression 
Immunosuppressive treatment was started 2 weeks prior to the first TSO gavage. The rabbits received 
oral administration of cyclosporine (100 μl/kg/day, Sandimmun Neoral Trink Lös 100 mg/ml; 
Novartis Pharma Schweiz AG) and methylprednisolone (1 mg/kg/day, 6α-Methylprednisolone 21-
hemisuccinate sodium salt -lyophilized powder, Sigma-Aldrich, Munich, Germany) for 2 weeks daily, 
afterwards the dose was reduced to half and then continued until the end of the experiment. Control 
rabbits received vehicle (12% V/V EtOH). 5 ml of blood were collected from the marginal ear vein 
prior to immunosuppressive treatment and at day 1, 14, 21 and 35 and sent to the clinic of hematology 
(USZ, Zurich, Switzerland) for a complete blood count.  
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4.3.5 Euthanasia and Organ Sampling 
Euthanasia was performed at day 35 (if not otherwise described) after sedation with barbiturates with 
an overdose of ketamine hydrochloride (Vétoquinol, Bern, Switzerland) and xylazine (Bayer, 
Lyssach, Switzerland). The abdominal cavity was exposed by a midline laparotomy and samples were 
collected from the ileum, jejunum, duodenum, cecum and colon. For RNA extraction and 
myeloperoxidase activity analysis, the excised samples (0.5 cm in length) were opened by a 
longitudinal incision and rinsed with cold PBS. 1 cm2 sections of the cecum were extensively washed 
with cold PBS until complete removal of the luminal content. The samples were immediately snap-
frozen in liquid nitrogen and stored at -80° C until analysis. For histology, samples (three 0.5 cm2 
sections from different regions of the cecum or one 0.5 cm length section of the other tissues) were 
collected. The samples were carefully washed and fixed with phosphate buffered 10% formalin 
solution. For genome RNA isolation caecal samples (2 cm2) were extensively washed with cold PBS 
and stored on ice in 5% BSA in PBS until further processing. 
4.3.6 Isolation of Caecal LPMC and IEC 
The dissected specimens were washed with Ca+- and Mg+-free PBS, the caecal fold was removed and 
discarded. The tissue was cut and incubated in medium containing 20 mM EDTA (Sigma-Aldrich) for 
30 min at 37° C on a shaking platform (150 rpm). IECs were detached by vortexing and passing 
through a 70 µm cell strainer (BD Biosciences, Erembodegem, Belgium). The IEC were washed 
twice, pelleted, resuspended in RLT buffer (Qiagen, Hilden, Germany), snap-frozen in liquid nitrogen 
and stored at -80° C for later analysis. The remaining tissue containing LP with muscle layer was 
collected and incubated in 1 μg/ml collagenase type I CLS (Worthington Biochemical Corp., 
Freehold, New Jersey, USA) at 37° C on a shaking platform (300 rpm). After 15 minutes incubation, 
the suspension was vortexed and filtered through a 70 µl strainer. Cells were resuspended in 5% BSA 
in PBS. The undigested tissue was incubated with fresh collagenase solution for additional 15 
minutes. The digestion was repeated three times and the washed LPMC were pooled resuspended in 
DMEM with 5% FCS. LPMC were purified using Ficoll-Paque PLUS (GE Healthcare Europe 
GmbH, Freiburg Germany) gradient centrifugation for 40 min at 1200 rpm. The viability of the cells 
was confirmed by tryptan blue staining. Cells were resuspended in RLT buffer (Qiagen, Hilden, 
Germany), snap-frozen in liquid nitrogen and stored at -80° C for later analysis. 
4.3.7 RNA Isolation and Genome Wide mRNA Expression Analysis 
Total RNA was isolated with the Qiacube system using the RNeasy Mini Kit with DNase digestion 
(Qiagen, Hilden, Germany) to eliminate genomic DNA. RNA integrity and quantity was determined 
on the Agilent 2100 Bioanalyzer (Agilent; Palo Alto, CA, USA). Samples with an integrity score ≥ 
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 6.8 were sent to the Functional Genomic Centre Zurich (FGCZ) for sequencing on the Illumina 
platform. The fold change (FC) was used to express the changes in average gene expression between 
studied groups. FC was normalized against the control group. The ENSEMBLE IDs were annotated 
using BetterBunny augmented annotation and analysis of rabbit genes (http://cptweb.cpt.wayne.edu) 
[15]. MetaCore™ (Thomson Reuters, http://portal.genego.com) was used to perform network 
analyses. The following cut-offs were applied to select differentially expressed genes for further 
analysis: pValue ≤ 0.05 and fold change ≥ |1.0|. Process networks (PN, groups of genes involved in 
main signaling and metabolic processes in the cell in the MetaCore™ database) were considered 
significant with a pValue ≤ 0.05 and were further selected on the basis of their relevance to 
inflammatory bowel diseases pathology. 
4.3.8 Histopathological Evaluation of Colitis 
After careful dissection and fixation, tissues were embedded in paraffin. Serial sections of 5 μm were 
cut using a microtome (Carl Zeiss AG, Feldbach, Switzerland) and stained with hematoxylin-eosin 
(HE). The histological changes in the cecum were quantified in a blinded manner by two investigators 
(range 1 - 24) for morphological features and infiltration of immune cells (Table C.2). 
4.3.9 RNA Extraction and Quantitative real-time PCR 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) following the 
manufacturer's recommendations. cDNA was synthesized with the High-Capacity cDNA Reverse 
Transcription Kit (Life Technologies, Carlsbad, California, U.S.A). Gene expression was determined 
with a TaqMan® Gene Expression Assay (#Oc04097051_m1 IL-6; #Oc04250656_m1 MMP1; 
#Oc03398293_m1 PTGS2 (COX2); #Oc03398448_m1 SLC15A2; #Oc03397715_m1 TNFα; 
Oc03823548_s1 ALOX-15A2; Oc03397217_m1 ARG-1; Applied Biosystems). Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) gene expression was measured as endogenous control 
(#Oc03823402_g1, Applied Biosystems) and used for calculation of relative mRNA expression by 
the ΔΔCt method. All samples were analyzed in triplicate. 
4.3.10 Faecal and Luminal Microbiota Analysis 
Fresh fecal samples were collected ad different time points during the experiments and luminal 
contents were collected from caecum after euthanasia. Samples were snap-frozen in liquid nitrogen 
and stored at -80° C for later analysis. DNA isolation was performed using the PowerLyzer 
PowerSoil Kit (MO BIO Laboratories, Carlsbad, CA USA) using 0.25 g feces or luminal content 
according to the manufacturer protocol. Approximate yield (ng/ml) was first determined by 
spectrophotometry using the NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA). 
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Samples with DNA concentration > 10 ng/ml were sent to a commercial laboratory for metagenomics 
bacterial analysis based on 16S rDNA sequencing (Microsynth Balgach, Switzerland).  
4.3.1 Trichuris suis Detection by PCR 
Tissue samples (colon, ileum, caecum, brain, kidney, spleen) were collected after euthanasia and 
immediately snap-frozen in N2. Samples were sent to IBR Inc (Matzingen, Switzerland) for detection 
by PCR. Primers for the ITS2 gene were used (Table 4.1). The ITS2 copy numbers is proportional to 
the number of T. suis larvae.  
Table 4.1: Primers and standard used for the detection of T. suis. 
 Sequence 
Forward primer 
ITS2-FW1 
5' - CTGCGGAGAGCGGCTAACT – 3' 
 
Reverse primer 
ITS2-RW1 
5' - ATGTAGCGACGACGTAGCCAACT – 3' 
 
Internal Standard Probe 
IntStd-TS-P 
5' - VIC – TGAAAATGCCAAAGTGACAAG – 3' 
 
Trichuris suis Probe 
ITS-P1 
5' - FAM – CAGTACGGAAGCTGCC – 3' 
 
4.3.2 Statistical Analysis 
The data obtained from this study were analysed using GraphPad Prism (version 5.04). If not 
otherwise indicated, Mann-Whitney U-test for two independent samples was used for the comparison 
of the treatment groups, data are shown as mean ± SD. 
  
78 
 4.4 Results 
4.4.1 TSO Prevent Colitis in Immunocompromised Rabbits 
We first tested whether a pre-treatment with TSO could prevent or reduce the development of DSS 
induced colitis in immunocompetent rabbits. TSO treated animals were protected from the DSS 
induced weight loss observed in vehicle (Veh) treated animals (Figure 4.1A).  
 
Figure 4.1: TSO treatment ameliorates the outcome of a subsequent induced DSS colitis. NZW rabbits received 
2500 TSO at day 1, 14 and 21 (intragastrically). At day 26 colitis was induced by administration of 0.1% DSS 
in the daily beverage during 5 days. A) Body weight is shown as percentage of individual weight at the time of 
DSS colitis induction (day 26). B) Clinical symptoms (food and beverage intake, fur cleanliness, weight loss 
and stool consistency), were monitored daily and summed to a disease activity index (DAI).Bars show mean ± 
SEM, *P<0.05, **P<0.01, ***P<0.001, two-sided pValue, Mann-Whitney test relative to vehicle water group if 
not otherwise specified. Data are pooled from 2 independent experiments with 3–4 rabbits in each group in each 
experiment  
Concurrent to weight loss, Veh animals manifested various symptoms including reduced food and 
beverage intake, unclean fur and diarrhea and at day 35 they had reached an average disease activity 
index (DAI, Figure 4.1B,) of 1.6±0.8. In contrast, TSO treatment also delayed the onset of the 
symptoms of 2 days and significantly reduced the disease activity (DAI) at day 34 to 0.7 ±0.2. 
Importantly, TSO treatment did not induce weight loss and no symptoms where observed in healthy 
animals (Figure 1B and Figure C.1). When treated with DSS, the control rabbit showed substantial 
weight loss by day 31 and lost of -0.25% at day 35 (Figure 4.1A).  
4.4.2 TSO Prevent Severe Histopathology in the Caecal Mucosa  
Histologically, the cecum of TSO treated healthy rabbits did not show any sign of epithelial damage 
or villous stunting although a mild crypt disproportionation was visible (Figure 4.2A).  
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 Figure 4.2: TSO treatment reduces the cecum histopathology of the subsequently induced colitis. Caecal 
samples were collected after euthanasia at day 35. A. HE stained cecum section from vehicle or TSO treated 
rabbit with or without subsequent colitis induction. Bars correspond to 100 µm Semi quantitative scores of the 
immune cells infiltrate (B) and morphological changes (C) in the cecum section were summed to a global 
histopathology score (D). (E) Quantification of the average number of eosinophils within 40x field of cecum 
sections. Data are pooled from two independent experiments with n≥3 per group. For the scoring, 3 caecal 
samples per rabbit were collected and evaluated separately in at least three rabbits per group. *P<0.1, **P<0.05, 
two-sided pValue, Mann-Whitney test relative to vehicle water control if not otherwise specified. Dots represent 
single animals, bars represent mean ± SD. 
In Veh animals, DSS triggered a cecum localized pathology characterized by profound morphological 
changes and a marked infiltration of lymphocytes into the lamina propria and in the epithelium, 
leading to a total score of 13.2±2.5 (Figure 4.2B). We found that TSO partially protected the caecal 
mucosa from the DSS induced morphological changes. In addition, it also reduced the extent of 
lymphocyte infiltration into the mucosa. No larvae were visible in the histology section. Nonetheless, 
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 PCR-detection confirmed the presence of T. suis in the caeca of 9 out of 12 TSO DSS animals, 
whereas the TSO water group resulted negative (Table C.3). Blinded semi-quantitative scoring of 
morphological and inflammatory histological parameters confirmed that TSO treatment reduced the 
histological score by 14% to 11.4±3.8. As expected, TSO induced a strong infiltration of eosinophils 
into the lamina propria even in absence of DSS administration (Figure 4.2C).  
  
4.4.3 Transcriptome Analysis of LPMC and IEC 
To gain further insights into the mechanism of TSO treatment, we performed gene wide expression 
analysis on caecal epithelial cells (IEC) and lamina propria mononuclear cells (LPMC) by RNA 
sequencing (RNAseq). Hierarchical clustering (Figure C.3) revealed distinct expression profiles 
between EC and LPMC and highlighted significant effects especially in LPMC, whereas the 
clustering in EC was less clear. 
For further analysis, The LPMC genes were filtered to include genes with fold change |FC|>1 relative 
to the level in the vehicle water group with a FDR corrected pValue < 0.05. We identified 511 
significantly differentially expressed genes in the TSO DSS animals in comparison to the Veh DSS 
group. In the TSO DSS animals, 423 genes were over-expressed and 88 were under-expressed.  
Genes with significantly altered mRNA levels were analyzed with MetaCore to determine the 
biological relevance of their differential expression. Enrichment analysis showed that in the healthy 
mucosa TSO influenced the expression of genes involved in typical features of a parasitic infection 
such as TCR signaling, phagocytosis, innate inflammatory response and MIF (Macrophage migration 
inhibitory factor) signaling. Interestingly, 42% of the genes over-expressed by TSO in IEC and 
LPMC are also over-expressed in the cecum of T. muris infected mice [16] (Figure C.4, Table C.4). 
In the LPMC of DSS treated animals innate inflammatory and Th17 related pathways were 
significantly over-expressed and that TSO treatment partially prevented this over-expression (Figure 
4.3A). Besides, the TSO treatment also led to the down-regulation of genes involved in cell-adhesion 
and in developmental processes (Figure 4.3B). Differential expression of selected transcripts was 
verified by rt-qPCR (Figure 4.3C,D).  
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Figure 4.3: Gene expression signature in caecal LPMC as determined by RNAseq. Hierarchical cluster was used 
to sort expression profiles for the 4 groups (n=3 per group). Left: Visualization of the down- (A) and up- (B) 
expressed genes in the TSO DSS, Veh DSS and TSO Water groups in comparison to the control Veh Water 
group. Right: Top relevant process networks (PN) enriched by genes that were significantly differentially 
expressed in the LPMC of TSO DSS, Veh DSS and TSO water groups relative to the Veh Water group. (A) 
Enrichment for the down regulated genes, PN number 3, 5, 7 are not inserted in the graph because not relevant 
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 for the analyzed cell type. (B) Enrichment for the up regulated genes. Numbers refer to the enrichment ranking; 
genes were selected with fold change FC>|1| and P<0.05. (C) Validation of the genes COX-2, IL-6, MMP-1 in 
LPMC (data pooled from two separate experiment, with n=3-4 per group) was performed by rt-qPCR, 
expression changes were quantified with the ΔΔCt method. *P<0.1, two-sided pValue, Mann-Whitney test 
relative to the vehicle water control, dots represent single animals, bars represent mean ±SEM. The expression 
patterns reflect those observed by GWAS analysis (D) Genes having a fold change value FC>|1| and P<0.05 
were considered differentially expressed genes and were included in the analysis.  
To evaluate the impact of TSO on the subsequently induced innate inflammation, innate leukocyte 
invasion into caecal tissues was assessed by measurement of peroxidase activity. The overall 
peroxidase activity was increased in the TSO treated animals even in the absence of DSS induced 
injury (Figure C.2A). Treatment with the eosinophils’ peroxidase (EPO) inhibitor aminotriazole 
(AMT) reduced the peroxidase activity in the TSO treated animals and reveals a trend toward a 
decreased neutrophil infiltration in the TSO DSS animals although the difference did not reach 
statistical significance (Figure C.2B). 
4.4.4 TSO Exacerbates Colitis in Immunocompromised Animals 
Potential aberrant migration of Trichuris larvae after TSO treatment of immunosuppressed IBD 
patients has been a major concern. We therefore investigated the effect of the preventive TSO 
treatment on DSS colitis in immunosuppressed rabbits. The efficiency of immunosuppressive (IS) 
treatment by Cyclosporine and Methylprednisolone was confirmed by repeated differential blood 
counts (Figure C.5C). After 2 weeks of 2 weeks of IS treatment leukocyte count decreased to less 
than 5.109 cells/µl, with lymphocytes being the most affected cell population. Preventive TSO 
treatment was started, whilst immunosuppression was until the end of the experiment. Interestingly, 
we observed a reduced weight gain in immunosuppressed animals in comparison to the 
immunocompetent controls independently of TSO treatment (Figure C.5A). In immunosuppressed 
individuals without colitis induction, TSO did not induce any clinical symptom and no adverse effects 
were observed (Figure 4.4A). In contrast, colitis induction was followed by severe weight loss in TSO 
treated immunosuppressed rabbits. Furthermore, TSO pre-treatment exacerbated clinical symptoms of 
DSS colitis in immunosuppressed rabbits and led to such a severe course of disease that only six out 
of nine animals survived until the end of the experiment  
Trichuris suis colonizes the caecum of immunocompromised rabbits 
Histological examination (Figure 4.5A), showed increased villous stunting and crypt distortion in IS 
TSO DSS animals as well as enhanced infiltration of lymphocytes into the epithelial layer. As 
expected, the extent of eosinophil infiltration was enhanced in the two TSO DSS groups (Figure 
4.5C). The extent of lymphocyte infiltration into the mucosa (Figure 4.5D) and morphological 
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distortion (Figure 4.5E) an thus the combined histological score were clearly elevated in comparison 
to the control group with immunosuppression and colitis induction.  
 
Further examination revealed the presence of larvae in the caecal mucosa of 5 out of 9 IS TSO DSS 
rabbits. The parasites size and morphological features were characteristic of a late larval or early adult 
stage, in particular a digestive tube with a tripartite esophagus and well-developed reproductive 
organs were distinguishable Figure 4.5B). Larvae were not observed in other parts of the intestine 
(ileum, proximal and distal colon). Still, PCR-detection revealed the presence of T. suis in the colon 
of 4 out of 10 IS TSO DSS and 2 out of 2 IS TSO Water rabbits (Figure 4.4C, Table C.3). The 
presence of T. suis in the colon of IS animals, suggests a failure in the control of the helminth-
infection. To test if the parasite could reach sexual maturity in the immunosuppressed host, we 
regularly tested the feces for the presence of un-embryonated eggs using the fecal sedimentation-
flotation method and no positive samples were detected (data not shown). Analysis of immune 
response markers in the LPMC showed that immunosuppression reduced the increase in the markers 
of alternative macrophage activation ARG-1 and ALOX-15. Similarly, the increased expression in the 
SLC15A2 was abrogated, whereas expression of IL-6 increased in the IS TSO DSS animals, although 
not significantly. On the other hand, the reduction in TNFα observed in the immunocompetent rabbits 
was still observed (Figure 4.5).  
 
Confirming our previous results the global peroxidase activity but not the MPO specific activity was 
augmented in the Ctrl TSO DSS group (Figure C.6). On the contrary, analysis of the peroxidase 
activity in IS animals only showed a small increase after TSO treatment for both the global 
peroxidase activity and the MPO specific activity. This is accordance with the absence of a clear 
significant increase in the eosinophilic infiltrate observed with histology. 
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Figure 4.4: Immunosuppression abrogates the protective effects of TSO and exacerbates the DSS induced 
damage and inflammation of the caecal mucosa. IS was maintained with daily cyclosporine (p.o 100 μl/kg/day) 
and methylprednisolone (p.o 1 mg/kg/day). 2 weeks after the start of the IS NZW rabbits were treated with 2500 
TSO or vehicle at day 1, 14 and 21 (intragastrically). At day 26 colitis was induced by administration of 0.1% 
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DSS in the daily beverage during 5 days. A. Body weight change was calculated relative to the baseline at the 
time of DSS colitis induction (day 26). B. representative HE stained specimens of caecal mucosa (day 35). IS: 
immunosuppressed rabbits, control: immunocompetent rabbits. Bars correspond to 100 µm. 3 specimens per 
rabbit were assessed. Filled arrowhead: T. suis schistosome. C. HE stained section of the caecal mucosa of IS 
TSO-DSS rabbits showing the presence of adult T. suis. The left panel shows a longitudinal section of the 
posterior part; the right panel shows a cross section of the posterior end of the parasite. S: stychosome nucleus; 
Bb: bacillary band; C: cuticle; O: reproductive organs; D: digestive tract; M: muscle layer. Bars correspond to 
20 µm. Empty arrowhead: syncytial tunnel derived from the host’s caecal epithelium. D: Inflammation score 
was calculated on the basis of the lymphocytes’ infiltrate in the lamina propria and in the epithelium (2-8). 
Villous stunting, epithelium damage and crypt distortion were scored independently and summed to a 
morphology score (3-12). Morphology and inflammation score were the summed to a global histology score (5-
20). E. Percentage of animals found positive to Trichuris in different regions of the gastrointestinal tract 
(caecum, colon and ileum). RNA was extracted from homogenized tissue specimens. Trichuris suis was 
detected by PCR amplification of the sequence W: water, D: DSS, V: Vehicle, T: TSO, Ctrl: Control, IS: 
immunosuppressed. (#): number of analyzed animals. Dots represent single animals, bars represent mean ± SD, 
data were pooled from 3 independent experiments. *P<0.1, **P<0.05, two-sided pValue, Mann-Whitney test 
between IS Veh DSS (n=8‡) and IS TSO DSS (n=9‡). ‡: n at the start of the experiment. 3 IS TSO DSS and 1 IS 
Veh DSS animals reached the euthanasia criteria before the end of the experiments and were sacrificed at the 
indicated time point. # Premature death: 1 IS TSO DSS rabbit was found dead unexpectedly at day 34. 
 
Figure 4.5: Effects of immunosuppression of the expression of different immune response markers in LPMC. 
LPMC where isolated from the caecal mucosa of control (ctrl) and immunosuppressed (IS) rabbits. Expression 
of selected genes was determined by qRT-PCR. GAPDH was used as a housekeeping gene. Bars represent 
Mean±SEM form 2 pooled experiments. *p<0.05, Mann-Whitney test.  
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 4.5 Discussion 
The progressive, relapsing, chronic course of inflammatory bowel disease requires a long-term 
treatment that maximizes the anti-inflammatory action while minimizing the systemic effects. 
Unfortunately, the performance of the current therapies is low. The first studies on a therapeutic effect 
of Trichuris suis for both UC and CD were promising. Yet, larger multicenter studies could not show 
a significant effect of TSO in comparison to placebo in mild to moderate IBD patients and the 
available evidence in support of TSO therapy is currently judged insufficient [10]. Furthermore, the 
mechanisms and effects underlying TSO therapy at molecular level as well as the safety in 
immunosuppressed individuals could not be investigated so far due to the absence of a suitable animal 
IBD model. Here, we studied the efficacy and safety of a preventive infection with T. suis ova (TSO) 
in a recently developed rabbit model of colitis [14]. To date - besides the pig host – T. suis has only 
been shown to hatch in humans, primates and rabbits. We chose to use a rabbit model of colitis[14] 
since the course of a TSO infection resembles that observed in humans with T. suis hatching and 
colonizing the gastrointestinal tract for 2-3 weeks but without reaching sexual maturity [9]. 
Consistent with the previous human studies, we found that a preventive treatment with 3 doses of 
2500 TSO protected from colitis induced weight loss and reduced the disease activity index and the 
caecal histology score in our rabbit model of acute DSS colitis. Intriguingly, whole genome 
transcriptome analysis of caecal LPMC and IEC samples, showed a strong effect of TSO treatment on 
the lamina propria cells gene expression, whereas the effect on IEC was less marked. This 
observation, agrees with evidence that T. suis excreted or secreted proteins can bypass the EC barrier 
and directly modulate the lamina propria environment [17]. Recently, Hiemstra et al. showed that T. 
suis produces glycans that reduce the EC permeability thus allowing the passage of soluble 
compounds to the basolateral side [6]. Among the over expressed genes in caecal IEC, several were 
involved in the degradation of connective tissues. Beside a role in enhancing the barrier permeability, 
this might lead to the formation of syncytia that allows the colonization of the cecal mucosa [18]. 
Several proteins excreted/secreted by T. suis have been linked to chemokine, T-cell receptor and 
TGFβ signaling as well as leukocyte transendothelial migration [6]. Accordingly, we could observe a 
TSO induced decrease in expression of genes involved in cell-adhesion, endothelium-leukocytes 
interactions and chemotaxis. Furthermore, TSO treatment also limited the DSS induced increase in 
expression of genes involved in Th17 and was associated with an increase in expression of genes 
involved innate inflammation involved in IL-4 and histamine signalling. Whilst these observations 
largely accord with the typical anti-helminth response, a TSO specific response might occur, 
especially given the profound differences observed when comparing the T. suis transcriptome with 
those of other well studied helminths [19]. The majority of the IBD patients receive an 
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immunosuppressive therapy [20]. As our data suggest that TSO treatment predominantly affects 
infiltrating immune cells, the protective modulation of the immune response could be lost in those 
patients thus rendering the therapy inefficacious. Furthermore, the safety of a curative TSO infection 
in immunosuppressed patients is a crucial concern. Although T. suis is not a human parasite, an 
aberrant migration of Trichuris particularly in an immunecompromised host with impaired gut barrier 
function cannot be excluded a priori. In humans, trichuriasis is caused by T. trichiura and can be 
asymptomatic if the worm burden is low. Symptoms usually appear when the host is infested with 
more than 200 worms and can range from mild digestive tract distress to anemia, dysentery, bleeding, 
abdominal pain and more generalized effects, such as loss of appetite for food, nausea, vomiting, 
anemia, peripheral blood eosinophilia, retarded growth and malnutrition [21]. 
The published clinical trials with IBD patients did not report any TSO induced side effect, even if 
some of the involved patients were receiving immune-modulatory therapy [8,12,22,23]. Nonetheless, 
underlying IBD symptoms might mask the consequences of a chronic Trichurias induced colitis289. In 
fact, symptoms were observed in other studies testing a TSO therapy for non-gastrointestinal diseases, 
even in the absence of an immunosuppressive therapy. In a randomized double-blinded placebo-
controlled clinical trial in allergic rhinitis, patients ingesting TSO had a 3 to 19-fold higher rate of 
gastrointestinal episodes (flatulence, diarrhea and abdominal pain) compared with placebo subjects 
[]25,26]. Similarly, in two small pilot studies in multiple sclerosis, 1 out of 4 [27] and 3 out of 5 [28] 
patients receiving TSO experienced mild transient symptoms at about 30days after the first dose of 
TSO.  
To date no systematic study of TSO in immunosuppressed individuals has been performed. 
Consequently, we tested the preventive TSO administration in immunocompromised rabbits. To 
achieve immunosuppression, we used a combination of cyclosporine and methylprednisolone. 
Cyclosporine acts rapidly and is effective in the management of severe UC, whereas corticosteroids 
are used for moderate to severe relapses of both IBD forms [29]. Importantly, we show that the 
protective effect of TSO is lost in the immunosuppressed individuals where TSO leads to an 
exacerbation of the pathology. The sudden deaths of IS TSO DSS rabbits highlight the dangers of a 
helminth therapy in immunosuppressed hosts. Histology revealed the presence of L4 larvae in the 
cecum of the immunosuppressed rabbits demonstrating a failure in the control of the infection when 
the intestinal barrier function is damaged. The histological findings resemble those observed in an 
immunosuppressed CD patient that developed a iatrogenic Trichuris infection after treatment with 
TSO [13]. Of note, no egg-bearing worms were observed in the cecum of the infected rabbits nor 
were eggs observed in their faces. This suggests that T. suis is not reaching sexual maturity in the 
cecum of the infected rabbits but rather remains in a pre-adult stage. Our results, provide important 
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 evidence that immunosuppression interferes with the TSO treatment and might predispose towards 
adverse effects. Based on these initial findings, the interaction between immunosuppression and TSO 
treatment should be further investigated and caution should be used when treating immunosuppressed 
IBD patients with TSO or other therapeutic parasites. 
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 5 DISCUSSION 
In this work, we describe a rabbit model suitable for the investigation of T. suis ova therapy.  
Using this model we show that TSO is safe and ameliorate a subsequent colitis in immunocompetent 
animals. In contrast, TSO exacerbates the colitis and has no protective effect in immunocompromised 
animals. 
5.1 The need of a DSS Model of Colitis in Rabbits 
The commonly used mouse and rats models of IBD are not suitable for the study of a therapy with 
live T. suis as the ova fail to hatch in these rodents. Instead, rabbits appear a good translational model 
since they are transiently colonised by T. suis in the caecum as it occurs in humans227. 
Unfortunately, the existing rabbit models appear inadequate for the study of T. suis ova (TSO) (Table 
5.1). Acetic acid and TNBS are applied to the rabbit with a rectal enema and induce a pathology 
localized to the rectum and distal colon. The application of an enema is invasive and requires sedation 
of the animals. Additionally research using the acetic acid colitis model decline, since the pathology 
features an initial epithelial cell damage and the immune response is delayed and does not progress to 
chronicity290. 
We successfully established an acute model of colitis in rabbits by administration of 0.1% DSS in the 
daily beverage for 5 days. DSS administration induces a caecum localized colitis, whereas no 
pathology is observed in other parts of the intestine. To permit a longitudinal assessment of the colitis 
progression we defined a disease activity index and we confirmed that the monitored clinical 
symptoms correlated well with the extents of the histologic damage.  
The pathology included morphological changes such as villous stunting, crypt distortion and villous 
epithelial injury as well as infiltration of immune cells (particularly neutrophils) into the epithelial 
layer and the lamina propria. Our DSS model resembles the clinical manifestations and microscopic 
features of the human pathology (especially UC). Further, the observed changes are similar to those 
induced by DSS in mice and rats (Table 5.1).  
The induction protocol via the daily beverage is simple, has a reasonable time frame and the 
outcomes appear highly reproducible. Finally, the localisation of the pathology in the rabbit caecum 
makes the DSS model particularly suitable to study the effects of TSO treatment as the caecum is the 
site of T. suis colonisation in rabbits. 
In other species (mouse, rat, mongolian gerbil and guinea pig), 2-5% DSS is the standard dose for 
induction of acute colitis. The rabbit intestine appears more sensitive as higher doses caused an acute 
and fulminant colitis. This increased sensitivity is also observed in the acetic acid model that is 
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induced in rabbits by a 0.5% whereas in rat and mouse it is induced by a 3-5% acetic acid enema 
(Table 5.1). 
 
Table 5.1: Chemically induced colitis in the rabbit 
Model Application Sedation Localisation Start-peak Dose (rabbit) 
Dose 
(mouse/rat) 
Histology 
Acetic 
Acid 
Rectal enema Yes Colon 1h-1d 0.5% in 1ml 3-5% in <1ml 
loss of IEC, loss of 
GC, crypt 
abscesses, edema, 
neutrophil influx 
TNBS Rectal enema Yes Colon 1h-7d 
40mg in 25% 
EtOH 
20-80mg in 20-
50%EtOH 
Crypt abscesses, 
ulceration, crypt 
distortion 
DSS 
Oral in daily 
beverage 
No Caecum 5d-14d 0.1% DSS, 5d 2-10% 5-7d 
Crypt loss, 
epithelial damage, 
immune cells 
infiltration 
 
Expression profiling of the caecal tissues at day 10 revealed an enrichment of IBD related genes in 
both lamina propria mononuclear cells and intestinal epithelial cells. Most genes belonged to 
pathways involved in chemotaxis and immune response. In particular, genes involved in Th17 
signalling and innate immunity were enriched in the IEC transcriptome.  
Activation of the innate pathway is common in IBD patients. On the other hand, the IL-23/Th17 axis 
has pathogenic relevance in CD only291. For example, transcription and translation of Th17 related 
cytokines are typical in active CD lesions and Th17+ CD4+ lymphocytes are frequent in the lamina 
propria of CD patients42. 
Interestingly, we also observed an enrichment of genes involved in a Type 2 response. This type of 
response is rather observed in UC patients, whose lamina propria T cells produce greater amounts of 
IL-1346. Our observation, correlate with the cytokine profile observed in murine DSS colitis: 
following an initial Th1/Th17 response a Th2 response develops as the colitis progresses toward 
chronicity183.  
Our results suggest that in rabbit DSS colitis, an initial acute phase characterized by severe clinical 
symptoms, mucosal damage and acute inflammation precedes a chronic phase with a shift toward a 
Th2 immune response. A long-term analysis would be necessary to confirm these preliminary 
observations and to clarify if the disease resolves after the acute phase or if it progresses to chronicity.  
An important caveat of DSS colitis in mouse and rat is the dispensability of B and T cells292. 
Although we did not directly address their role in rabbit, the transcriptome analysis suggests a 
secondary role of adaptive immunity also in our model.  
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 5.2 TSO in Immunocompetent Animals 
Using the rabbit model we demonstrate the efficacy and safety of a preventive administration of TSO 
against DSS colitis. The animals receiving 3 doses of 2500 TSO did not experience gastrointestinal 
side effects (diarrhoea, bloody faeces).  
Importantly, T. suis infected rabbits were protected from DSS induced weight loss and developed 
milder clinical symptoms. Our results confirm the positive outcomes of TSO treatment in IBD 
patients and the safety of its administration in immunocompentent individuals287,285.  
At the histological level, T. suis reduced the extent of morphological damage and lymphocytes 
infiltration in the lamina propria and in the intestinal epithelium. The semi-quantitative scoring of the 
histological damage does not reach statistical significance; this might be due to the limited number of 
animals included in the experiment.  
In the TSO-DSS group, half of the rabbits did not experience a clear amelioration of the microscopic 
features. Non-responders are also present in clinical trials with IBD patients where a double blind 
clinical study has shown a non-response rate of 44%282. The New Zealand White (NZW) rabbits used 
for this study belong to an outbred stock: a higher variability is not surprising and the subdivision in 
responder/non-responder groups might be ascribable to inter-individual genetic variation.  
As expected, eosinophils were recruited to the caecum of T. suis infected animals. Infiltration of 
eosinophils into infected tissues has been observed in TSO treated patients125 and in T. trichiura 
treated macaques278. Generally, eosinophilia is a common feature of parasitic infections, although its 
role is not completely understood293,294. 
To explore the mechanisms by which TSO exert their protective effect, we performed a transcriptome 
analyses on the caecal epithelial cells (EC) end lamina propria mononuclear cells (LPMC) at day 10 
post colitis induction by using next generation RNA sequencing (RNAseq). TSO induced distinct 
profiles on IEC and LPMC and exerted a stronger effect on LPMC then on IEC.  
In the healthy mucosa TSO induced changes typically observed upon parasitic infection such as TCR 
signalling, phagocytosis, innate inflammatory response and MIF signalling. It is noteworthy that 26% 
of the genes up-regulated by TSO in IEC and LPMC are also up-regulated in the caecum of T. muris 
infected mice230, confirming the similarities among different Trichuris species230;231.  
In the colitis rabbits, TSO counteracted the DSS induced up-regulation of several genes involved in 
Th17 pathways and in innate immunity. Further, TSO also affected genes involved in cell-adhesion, 
chemotaxis and developmental processes. 
The stronger influence exerted by T. suis on LPMC might be a consequence of several factors:  
1. The effect of T. suis on the intestinal epithelium occurs in the early phases of the infection 
when the larvae start colonising the caecum. Our analysis was performed 10 days after the 
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last TSO administration and might have “missed” the early phases of the IEC-T. suis 
interaction.  
2. Some T. suis secreted products can bypass the intestinal epithelium and directly penetrate the 
mucosa where they act on LPMC. This is in agreement with the finding that T. suis glycans 
increase IEC permeability and allow the passage of soluble compounds to the basolateral 
side.  
3. DSS induced damage of the intestinal epithelium hinders the detection of the changes induced 
by TSO.  
A longitudinal observation of the effects induced by T. suis on the caecal mucosa would help to reveal 
the complex cross talk between T. suis and the intestinal mucosa during the various phases of the 
infection. 
5.3 TSO in Immunocompromised Animals 
The whole genome transcriptome study shows that T. suis influence the response of LPMC to the 
DSS induced injury. In the following studies, we investigated whether the administration of TSO 
would be as efficacious and safe in an immunocompromised host.  
To this end we developed an immunosuppression protocol for NZW rabbits by a combination of 
cyclosporine and methylprednisolone. Cyclosporine inhibits the NF-AT mediated IL-2 production and 
thus affects the proliferation of T lymphocytes. Methylprednisolone is a corticosteroid and has a 
broader effect: it reduces NF-κB activation and down-regulates pro-inflammatory cytokines. The 
reduced weight gain observed in the immunosuppressed groups is a common side effect observed in 
cyclosporine treated rabbit295.  
Prior to the administration of DSS, TSO did not cause any side effects in the immunosuppressed 
rabbits. Our observation, suggest that in presence of an intact intestinal epithelium an 
immunosuppressed host can control the T. suis infection.  
In contrast, in presence of a DSS-induced colitis, TSO exacerbated the weight loss and further 
symptoms and can lead to fulminant colitis and death in immunocompromised animals.  
Similar to the report of an iatrogenic infection in a CD patient by Kradin283, histological examination 
revealed the presence of late stage larvae in the caecum of the immune-suppressed rabbits supporting 
a failure in the control of the iatrogenic infection when the intestinal barrier function is damaged.  
The lack of beneficial effects and the worsening of colitis might be a consequence of the different 
developmental stages reached by T. suis in the immunocompromised host. The transcriptome of T. 
suis changes as the larvae progress toward the adult stadium231, and we can hypothesize that the 
interactions of the early larval stages exerts a beneficial modulation of the intestinal niche. This 
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 positive effect would then be lost as the infection progresses towards chronicity as observed in 
susceptible strains infected with T. muris230,239 (Figure 5.1). 
 
Figure 5.1: Modulation of the caecal niche by different stages of T. suis. In immunocompetent hosts infection 
with T. suis is cleared before the parasite reaches a late larval stages. T. suis larvae exert a beneficial effect on 
the inflamed mucosa and down-regulates the expression of several colitogenic pathways. In 
immunocompromised hosts T. suis develops further and the protective effect is lost. A strong remodelling of the 
caecal mucosa occurs and the persistent Trichuris infection leads to an exacerbation of colitis. Black arrows 
indicate stimulatory pathways; red diamond-tipped arrows indicate inhibitory pathways. 
The existing studies in IBD, reported no side effects, even in immunocompromised patients (Table 
1.10). Yet, the limited number of patients and the absence and the nature of these studies call for 
further larger double blind studies with TSO286.  
To date no study has specifically addressed the concerns of safety and efficacy in the 
immunocompromised patients.  
Our results provide important evidence that immunosuppression interferes with the control of T. suis 
and can predispose towards serious adverse effects.  
5.4 Alternative Approaches to the Live Worm Therapy 
Our study highlights the promises of helminth treatment for IBD and yet, at the same time, evidences 
its perils. Helminth therapy concept warrants more investigation before a widespread clinical use can 
be initiated.  
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Besides the observed beneficial effects, our results evidence the variability of the individual response 
to TSO. The interaction between Trichuris and host is intricate and encompasses all the components 
of the mucosal niche, from bacteria to immune cells.  
Our results show, that TSO therapy can lead to a noxious iatrogenic infection, especially when both 
the host barrier and immune defences are compromised.  
 
Figure 5.2: Different approaches to helminth therapy. Helminth therapy can be applied by using either live 
parasites or parasite derived products. Extracts, Lysates or E/S products can be further purified to identify and 
isolate selected products with improved characteristics. As an alternative, parasite molecules can be used as 
template to generate synthetic drugs. 
As we have remarked in the introduction, a therapy with live parasites is not the sole option, and 
alternative approaches can limit the drawbacks of a live infection (Figure 5.2). E/S products from T. 
suis and other parasites possess immune-modulatory properties103;104 and can be used preventively or 
as a treatment in animal models of several diseases (chapter 1.4).  
E/S products are not completely risk free: they include a variety of components that are still poorly 
characterized and might cause counterproductive effects or possess immunogenic potential. Further, 
the concentrations of the “beneficial” component in the E/S might be low and thus require the 
administration of large doses. For example, the immune-modulatory serpins only constitute the 0.15% 
of the whole T. suis secretome232 
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 The identification and isolation of active compounds from E/S products might allow a 
pharmacologically reasonable dosage and facilitate the translation to the clinic. This approach has 
proven efficacious in different animal models. The glycan LNFPIII from S. japonicum possesses 
beneficial effects in EAE and in a mouse model of psoriasis118,139. Another example is the filaria 
derived glycoprotein ES-62, that is protective in allergy and rheumatoid arthritis models100,131. 
Isolating single components of the E/S products allows for selection and concentration of safe and 
efficacious molecules but limits the range of the targeted pathways. Further, this method probably 
requires frequent administration of the immune-modulatory product.  
A smart solution to this problem comes from a study in the DSS colitis model where an E/S protein 
was cloned into probiotic bacteria to target its delivery into the intestine and ensure a prolonged 
release219. An E. coli Nissle strain modified to secrete AvCys ameliorates colitis in both a mouse and a 
pig model proving that this system is not only effective in small rodents but can also be applied in 
larger animals219.  
Many E/S products with immune-modulatory effects are large, potentially immunogenic molecules 
and appear unsuitable as a standard drug. To avoid this problem, helminth products can be used as a 
basis for novel drugs with improved characteristic. The immune-modulatory site of E6-62, a 
phosphorylcholine, was used as a basis to construct a library of small-molecule analogues that were 
screened in vitro for immune-modulatory properties. This approach allowed the identification of two 
drugs called 11a and 12b that possess a preventive effect in CIA and asthma models101,102. This 
approach is surely promising and for sure warrants further trials with other helmitnths’ E/S products. 
Yet, the development of these analogue drugs is laborious and they will not be readily available to the 
clinic in the near future. 
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 6 CONCLUDING REMARKS AND OUTLOOK 
In this work we show that preventive treatment with Trichuris suis ova (TSO) exerts a preventive 
effect on the development of a DSS induced colitis in a rabbit IBD model.  
This effect is only observed in immunocompetent animals, and TSO administration is detrimental to 
immunocompromised animals as it exacerbated disease.  
In our opinion, our results possess a high relevance to the clinic, since the majority of IBD patients 
are immunosuppressed. Our DSS colitis model mimics the acute flares of colitis in IBD patients and 
the obtained results suggest that TSO administration during the remission period can prevent a relapse 
of the disease.  
We have not yet addressed the effect of TSO in a chronic model. In mice and rats the DSS model can 
be easily adapted to generate a chronic colitis. It is reasonable to hypothesize that a repeated 
administration with a slightly reduced DSS dose should similarly allow for induction of chronic 
colitis in rabbits.  
A further study of a therapeutic administration of TSO would be of interest, but is complicated by the 
delay between the administration of TSO and the colonisation of the caecum. 
 As an alternative, T. suis extracts would easily allow the investigation of a therapeutic administration. 
The mechanisms of action of helminths and in particular of T. suis are still open to question, but 
probably involve several pathways and cellular processes.  
In this work, we have mainly addressed the mechanisms of TSO action at the transcriptional level. We 
can thus only speculate that E/S products secreted in the caecum cross the epithelial barrier and 
modulate the action of LPMC. 
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APPENDIX A 
Summary of the studies on the therapeutic use of helminth infection or helminth derived 
products in rodent model of inflammatory bowel diseases (Figure A. 1). 
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 Figure A. 1: Summary of the studies on the therapeutic use of helminth infection or helminth derived products in rodent model of inflammatory bowel diseases. 
Author Year Effect Species Parasite  Component Disease Model Timing 
Ancylostoma (Nematode) 
Cancado  2001 Live worms not required; attenuation of colitis, live worm not required mouse A. ceylanicum 
ES and crude 
extracts DSS colitis Concomitant 
Ruyssers  2009 Attenuation of colitis. Dose-dependent decrease of inflammation and MPO activity  mouse A. caninum ES TNBS colitis Therapeutic 
Anisakis (Nematode)  
Cho  2011 
Attenuation of colitis. Lower inflammatory CK production and 
higher Treg frequencies. A. simplex MIF II induced in vitro 
expression of IL-10 by EC, DCs, and fibroblasts and TGFβ by 
fibroblasts. 
mouse A. simplex  larvae  DSS colitis Preventative 
Acanthocheilonema (Nematode) 
Schnoeller  2008 Attenuation of colitis. (Mac dependent) mouse A. vitae  cystatin DSS colitis Concomitant 
Whelan 2014 
Attenuation of colitis, ↑ Foxp3+ Tregs, ↓ local IL-6 and IL-17A 
production, ↓ MIP-1α/β, MCP-1/3, and RANTES, ↓ inflammatory 
Macs in colon 
mouse A. vitae  
E. coli 
producing 
A.viteae cystatin 
DSS colitis Concomitant 
Brugia (Nematode) 
Kron 2013 Attenuation of colitis, ↑IL-10 production (by CD3
+ and CPG and 
LPS stimulated splenic cells) mouse B. malayi 
asparaginyl-
tRNA 
synthetase 
T cell transfer 
colitis Therapeutic 
Hymenolepis (Cestode) 
Wang  2015 Attenuation of colitis. ↑ TGFβ by splenic follicular CD19
+ B cells. 
IL-4 and IL-10 indep, T and B cell indep (Rag KO mice). Mac dep. mouse H. diminuta 
CD19+ B cells 
from infected 
mice 
DNBS-, 
oxazolone-, 
DSS-colitis 
Concomitant 
Reardon  2001 Assumed Th2 response. Normalization of colonic ion transport, but no improvement in colonic histopathology mouse H. diminuta  larvae DSS colitis 
Preventive 
Therapeutic  
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Author Year Effect Species Parasite  Component Disease Model Timing 
Hymenolepis (Cestode) 
Hunter 2005 
Preventive: Augmented Th2 response (↑ Il-4, ↑ Il-10 mRNA 
expression), attenuation of colitis. Therapeutic: IL-10 required for 
protective effect. Enhanced recovery of colitis 
mouse H. diminuta  larvae DNBS colitis Preventive 
Hunter 2005 No effect on colitis. Not specified. rat H. diminuta  larvae DNBS colitis Preventive 
Hunter 2007 Worsening of colitis. Augmented Th2 response (↑ IL-4, ↑ IL-5, ↑ IL-13, ↑IL-10), changes in Treg response.  mouse H. diminuta  larvae 
Oxazolone 
colitis Preventive  
Hunter  2010 Attenuation of colitis. ↑Mobilization of alternatively activated macrophages.  mouse H. diminuta  larvae DNBS colitis Preventive  
Melon  2010 
Attenuation of colitis. Diminished Th1 response (↓TNF, ↓IFNγ), 
augmented Th2 response (↑ IL-4, ↑ IL-10, ↑eosinophils), 
augmented Treg response (↑ IL-10).  
mouse H. diminuta  larvae DNBS colitis Preventive  
Heligmosomoides (Nematode) 
Elliott  2004 
Attenuation of colitis. Diminished Th1 response (↓ IL-12, ↓IFNγ), 
Th2 induction. (↑IL-13), Treg response (↑Foxp3 mRNA 
expression). Protection can be transferred with T cells from worm-
infected donors. 
mouse (Il-10 
KO) H. polygyrus larvae 
 Il-10 KO 
spontaneous 
colitis 
Therapeutic 
Sutton  2008 
Attenuation of colitis. Diminished Th1 response (↓Tnf, ↓Ifnγ 
mRNA expression), augmented Th2 response (↑ Il-4, ↑ Il-13 
mRNA expression), mast cell-mediated effects. 
mouse H. polygyrus larvae TNBS colitis Preventative 
Urban 1991 CD4
+ but not CD8+ T cells regulate the IgE response and protective 
immunity in mice. mouse H. polygyrus  larvae healthy  na 
Fox 2000 
Attenuation of colitis. ↓inflammation, gastric immune responses 
and gastric atrophy. ↓IgG1, IFNγ, TNF, IL-1B, IP-10, MIP-1β and 
RANTES ↑IgE, TGFb 
mouse H. polygyrus  larvae H. felis colitis Preventive 
Chen  2005 
↑Th2 response (IL-4, IL-5, IL-10), ↑Treg response (IL-10) Changes 
in Th1 response (↓IFNγ, ↑TNF), STAT6-mediated mechanism. 
worsening of colitis 
mouse H. polygyrus  larvae C. rodentium colitis Preventive 
120 
 Author Year Effect Species Parasite  Component Disease Model Timing 
Heligmosomoides (Nematode) 
Chen  2006 
CD11c+ DC expansion and ↑ IL-10 mRNA expression. Transfer of 
parasite-primed DC exacerbates colitis. No exacerbation with Il-10 
KO DCs. 
mouse H.polygyrus larvae C. rodentium colitis Preventive  
Metwali  2006 Attenuation of colitis. CD8
+ Tregs required, act independently of 
IL-10 or TGFβ signalling mouse H. polygyrus  larvae 
Il-10 KO T cell 
transfer colitis Therapeutic 
Setiawan  2007 
Attenuation of colitis. Diminished Th1 response (↓ IL-12p40, 
↓IFNγ), augmented Treg response (↑ IL-10) IL-10R blockade in 
vitro restores IFNγ and IL-12p40 production by mucosal cells. 
mouse H. polygyrus  larvae TNBS colitis Preventive  
Elliott  2008 
Attenuation of colitis. Suppression of IL-17 production. IL-4 and 
IL-10 block IL-17 production by T cells. IL-10 alone is not 
sufficient. 
mouse H. polygyrus  larvae Il-10 KO T cell transfer colitis Therapeutic  
Massacand 2009 
Tslrp KO normal Th2 cell differentiation, protective immunity and 
memory responses. ES antigen directly suppressed IL-12p40 
production by DC 
mouse H. polygyrus,  larvae and ES antigen healthy  na 
Ince  2009 No effect on colitis. IL-10 secretion requires intact T cell TGFβ signaling.  mouse H. polygyrus  larvae 
TGFβRII DN 
colitis Preventive 
Hang  2010 
Attenuation of colitis. Phenotypical changes of DC ( ↓CD80 and 
CD86, ↑plasmacytoid dendritic cell Ag-1 and CD40). (↓IFNγ, IL-
17). Modulation of innate immune cells is sufficient to suppress 
colitis weeks after abrogation of H. polygyrus infection 
mouse H. polygyrus  larvae Il-10 KO T cell transfer colitis 
Preventive 
Therapeutic  
Walk 2010 Shift in the abundance and relative distribution of bacterial species 
in the ileum of mice. ↑ Lactobacillaceae abundance  mouse H. polygyrus  larvae healthy  na 
Wang  2010 Worsening of colitis. Involvement of Th2 response (↑ IL-5 and 
↑eosinophils recruitment). mouse H. polygyrus  larvae 
Oxazolone 
colitis Preventive  
Li 2011 Selectively induce expansion of the D11c
lowCD45RBmid regulatory 
DC subset that promotes development of Foxp3+ IL-10+ Treg cells. mouse H. polygyrus  larvae healthy  na 
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Author Year Effect Species Parasite  Component Disease Model Timing 
Heligmosomoides (Nematode) 
Blum 2012 
Attenuation of colitis. Block OVA IFNγ/ IL-17 responses of LPMC 
isolated from colitic animals through direct contact. Regulatory T 
cell idep. Block gut Ag-specific IFNγ/ IL-17 T cell response 
mouse H. polygyrus  
Transfer of DC 
from infected 
RAG mice 
Il-10 KO T cell 
transfer colitis Therapeutic 
Donskow-
Lysoniewska  2012 
Attenuation of colitis. ↑Macs infiltration (↑ IL-1β, TNF, IL-6), 
↑expression of MOR1, POMC and β-endorphin mouse H.polygyrus  larvae DSS colitis Therapeutic  
Leung 2012 Attenuation of colitis. ↓IFNγ, ↓ IL-17, induction of Foxp3
+ Treg 
cells, ↑ IL-10 from non-T cells mouse H.polygyrus  larvae 
Antigen-driven 
colitis Preventive  
Hang  2013 
↑ Foxp3+ T cells (mLN). Foxp3+IL-10− T cell transfer form infected 
Il-10 KO mice : attenuation of colitis and reconstitution of 
Foxp3+IL-10− and Foxp3+IL-10+ T cell subsets 
Mouse  H.polygyrus  larvae Il-10 KO T cell transfer model Preventive  
Nippostrongylus (Nematode) 
Massacand 2009 
Tslrp KO normal Th2 cell differentiation, protective immunity and 
memory responses. ES antigen directly suppress IL-12p40 
production by DC 
mouse 
(Tslrp KO) N. brasiliensis 
larvae and ES 
antigens healthy na 
Schistosoma (Trematode) 
Heylen 2014 Attenuation of colitis. ↓IL-17A producing T cells; ↑ IL-4 producing T cells  mouse S. japonicum 
soluble worm 
proteins 
T cells transfer 
colitis Therapeutic 
Heylen 2015 Attenuation of colitis (stronger in preventive). ↓Ifnγ and Il-17a 
expression; ↑ Il-4 expression in the colon mouse S. japonicum 
soluble eggs 
proteins 
T cells transfer 
colitis 
Preventive 
Therapeutic  
Zhao  2009 Attenuation of colitis. ↓IFNγ, ↑ IL-10, ↓Tlr4 mRNA expression 
related to ↓IFNγ and ↑ IL-10.  mouse S. japonicum  eggs TNBS colitis Preventive 
Xia  2010 
Attenuation of colitis. Diminished Th1 response (↓TNF, ↓IFNγ), 
maintaining epithelial barrier function trough augmented tight 
junction proteins  
mouse S. japonicum  eggs TNBS colitis Preventive  
Elliot 2003 Attenuation of colitis. ↓IFNγ, ↑ IL4, ↑ IL-10. STAT6 dep. mouse S. mansoni  eggs TNBS colitis Preventive 
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Schistosoma (Trematode) 
Moreels 2004 Attenuation of colitis. ↑ IL4, changes in smooth muscle contractility  Rat S. mansoni  larvae TNBS colitis Concomitant 
Smith 2007 Worsening of colitis. Not specified mouse S. mansoni  eggs DSS colitis Preventive  
Smith 2007 Attenuation of colitis. Induction of F4/80
+CD11b+CD11c− 
macrophages.  mouse S. mansoni  larvae DSS colitis Preventive  
Bodammer  2010 
Attenuation of colitis. Diminished Th1 response (↓TNF, ↓IL2 
mRNA expression), diminished Th2 response (↓ Il-4 mRNA 
expression).  
mouse S. mansoni  larvae DSS colitis Preventive s 
Trichuris (Nematode) 
Massacand 2009 
TSLP reduces IL-12p40 production and treatment of Tslrp KO 
animals with neutralizing anti-IL-12p40 mAb reversed 
susceptibility and ↓IFNγ production. ES has no effect on IL-12p40 
production by DC. 
mouse 
(Tslrp KO) T. muris  
larvae and ES 
antigens healthy  na 
Taylor 2009 
Ab neutralization of TSLP or deletion of the Tslrp resulted in 
defective expression of Th2 CK and persistent infection. 
Susceptibility: ↑ expression IL-12/23p40, IFNγ, and IL-17A, and 
development of severe intestinal inflammation. neutralization of 
IFNγ in infected Tslrp KO mice restored Th2 responses and 
resulted in worm expulsion (TSLPR indep pathways for Th2 CK 
production) 
mouse T. muris larvae healthy  na 
Wilson  2011 Induction of colitis. Development of a Th1-dominated response. IL-13 reduces pathology in Il-10 KO IL-13rα2 KO mice mouse T. muris eggs 
 Il-10 KO 
spontaneous 
colitis 
na 
Vegas-Sánchez 2014 
Concurrent infection: colitis exacerbation, prolonged parasites 
survival 
Colitis at d54 -62 p.i.(all worms expelled): colitis amelioration. 
Colitis at d27-35 p.i. colitis amelioration, mucosal epithelization 
and regeneration  
mouse T. muris eggs DSS colitis Concomitant Therapeutic 
Wilson  2010 Worsening of colitis. ↑IFNγ, ↑ IL-17A. ↑IL-13Rα2 resulting in ↓ IL-13 activity mouse T. muris  eggs 
 Il-10 KO 
spontaneous 
colitis 
Therapeutic 
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Author Year Effect Species Parasite  Component Disease Model Timing 
Trichuris (Nematode) 
Broadhurst 2012 
Attenuation of colitis. ↑Arachidonic acid metabolism IgE signalling 
(Fcer1aA, Ms4a2), mast cell activation (Cpa3, Cma1), Th2 and 
eosinophil recruitment (Ccl17, Ccl18, Ccl26), aaMacs (Alox5, 
Alox15), CK signalling (Il-5ra, Il9r, Postn), and worm expulsion. 
↓bacterial attachment to the intestinal mucosa and changes in 
composition of attached bacteria.  
macaque 
monkey T. suis larvae 
Idiopathic 
chronic 
diarrhoea 
Therapeutic  
Trichinella (Nematode) 
Adisakwattana  2013 Attenuation of colitis. Changes in Treg response. mouse T. papuae larvae DSS colitis Preventive  
Du  2011 Attenuation of colitis. Induction of Th2 and regulatory response; may involve induction of aaMacs. mouse T. spiralis  53 kDa ES TNBS colitis Preventative 
Khan 2002 Attenuation of colitis, induction of Th2 response. mouse T. spiralis  larvae DNBS colitis Preventive 
Motomura  2009 Attenuation of colitis. Induction of Th2 and regulatory mechanisms mouse T. spiralis  larval antigens DNBS colitis Preventative 
aaMacs: alternative activated macrophages, CK: cytokines, CPG: cytosine phosphate guanosine, D/TNBS: Di/Tri-nitrobenzene sulfonic acid, ES: excretory/secretory antigen, DSS: dextran sodium 
sulphate, IL-13Rα2: IL-13 decoy receptor, in/dep: in/dependent, LPS: lipopolysaccharide, Macs: Macrophages, na: not applicable. 
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APPENDIX B 
Summary of the studies on the therapeutic use of helminth infection or helminth derived 
products in rodent model of different organic diseases (Figure B. 1). 
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 Figure B. 1: Summary of the studies on the therapeutic use of helminth infection or helminth derived products in rodent model of asthma and allergy, Multiple 
sclerosis (MS), Reumathoid arthritis (RA), Transplant rejection, Diabetes, Gastritis, Hepatitis 
Author Year Effect Species Parasite Component Disease Model 
Asthma and allergy 
Herrick 1913 Among the first causal proof linking infection and eosinophilia guinea pigs A. lumbricoides. whole body extracts anaphylaxis 
Cho 2015 Suppress airway inflammation, ↑ IL-10, Treg. Via TLR2 on lung EC on TLR2 mouse A. simplex MIF OVA-airway allergy 
Schnoeller 2008 
↓ Th2-related inflammation, OVA-specific and total IgE, IL-4 
production. When applied during or after sensitization and before 
challenge with the allergen. Macs and IL-10 dep. 
mouse A. vitae Cystatin OVA-airway allergy 
Daniłowicz 2013 decreased levels of Th2 cytokines and mast cell degranulation and increased levels of cystatin-specific IL-10 mouse A. vitae AvCystatin grass pollen-airway allergy 
Rzepecka 2013 Protection associated with restoredTh1/Th2 balance. ↓Th1 mouse A. vitae ES62 OVA-airway allergy 
Rzepecka 2014 Prevent Th2-associated airway inflammation and eosinophil 
infiltration.↓neutrophil infiltration (therapeutic) mouse A. vitae 
11a, 12b ES62 
small molecule 
analogues 
OVA-airway allergy 
Bashir 2002 Attenuation of allergy. ↓ PN-specific IgE, f IL-13 by PN-specific T cells. mouse H polygirus  peanut-allergy model 
wilson 2005 
↓inflammatory cell infiltrates (lung, CD25 dep). mLN cells: 
↑CD4+CD25+Foxp3+ T cells, TGF-β expression, and IL-10 
responses. mLN (Tregs?)can transfer protection (IL-10 indep) 
mouse H. polygyrus larvae OVA-airway allergy 
Kitagaki 2006 ↓eosinophilia, bronchial hyper reactivity, Th2 responses in an IL-10-dependent manner; ↑ IgE mouse H. polygyrus larvae 
OVA-airway allergy and 
transfer of OVA-CD4+ T cells 
McSorley 2012 
At sensitization: ↓esinophilia, ↓ type 2 innate response, ↓Ab 
generation; ↓ effector T-cell reactivity. ↑CD4+Foxp3+ Treg 
At challenge: ↓Eosinophilia 
mouse H. polygyrus E/S antigen OVA-airway allergy 
McSorley 2014 ↑ ILC2, ↑IL-5, IL-13 production (via IL-33, MyD88) mouse H. polygyrus E/S antigen Fungal-airway allergy 
McSorley 2015 ↓ Type 2 CK by ILC2  (at sensitization, MyD88, TRIF indep.) mouse H. polygyrus E/S antigen OVA-airway allergy 
Jarrett EE, Orr TS, 
Riley P. 1971 
Parasite infection interferes with albumine passive sensitization for 
systemic anaphylaxis and skin test reaction rat N. brasiliensis  
Systemic anaphylaxis, skin test 
reaction 
Wohlleben 2004 
↓ allergen-induced airway eosinophilia, eotaxin levels. Infection 1-
2w before: no effect. ↓albumin-specific IgG1 and IgE (BAL). IL-10 
dependent. 
mouse, Il-10 KO N. brasiliensis larvae OVA-airway allergy 
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Author Year Effect Species Parasite Component Disease Model 
Schabussova 2013 
↑ IL-10 TGF-β in BMDC (in vitro) .mouse model of birch pollen 
allergy: ↓allergen-specific antibodies + ↓IgE-dependent basophil 
degranulation. Prevented airway inflammation 
mouse O. dentatum 
Whole body 
extract from 
male worms 
(eMOD) 
OVA-airway allergy 
Mangan 2004 Protection from anaphylaxis. Essential role of IL-10-producing B cells mouse S. mansoni  systemic fatal anaphylaxis 
Smith 2005 ↓ CXCL8-induced neutrophil infiltration and inflammation mouse S. mansoni smCKBP Air pouch; contact hypersensitivity 
Negrao-Correa 2003 
Concomitant infection prolonged airway eosinophilic inflammation 
(BAL), ↓ viable parasites, ↓ AHR (only during the lung migration 
phase) 
rat S. venezuelensis larvae OVA-airway allergy 
Rzepecka 2013 Protective, resetTh1/Th2 balance, ↓Th1 mouse T. suis ES OVA-airway allergy 
Ebner 2014 
↓ OVA specific IFN-γ, IL-4 (in vitro). ↓ MHCII and CD86 TLR-9 
mediated upregulation by BMDC (in vitro).  Mouse: ↓ OVA 
specific IL-4, IL-5, IL-13 (BAL) and IgE (serum), goblet cells and 
RELM-α+ aaMacs, IL-10 mediated. 
↑ T. suis specific Th2 response (systemic) 
mouse T. suis ES OVA-airway allergy 
Multiple sclerosis (MS) 
Walsh 2009 
Concomitant infection reduced severity. ↓ auto-antigen specific Th1 
and Th17 (TGFβ dep). DC induce parasite-specific Treg cells 
expressing IL-10 and TGFβ. 
mouse (WT and 
IL10 KO) Fasciola hepatica larvae EAE 
Sewell 2003 Preventive. Th2 shift (STAT6 dep) mouse (WT and STAT6 KO) S. mansoni OVA EAE 
La Flamme 2003 Preventive. ↓clinical course, ↓ incidence and delayed onset. ↓ IFN-
γ,TNF, IL-12p40 and NO (by splenocytes), ↑IL-10 and TGFβ mouse S. mansoni OVA EAE 
Zhu 2012 Concomitant treatment reduced severity, Th2 shift mouse S. mansoni LNFPIII EAE 
Reyes 2011 
Preventive infection reduced symptoms in 50% of animals, ↓MOG-
specific splenocyte proliferation, ↓IL-17, ↓TNF. ↑IL-4 , IL-10, 
↓leukocyte infiltration (spinal cord, brain) 
mouse T crassiceps larvae EAE 
Reumathoid arthritis (RA) 
Rocha 2008 Protective. ↓ NO, IL-1β, IL-10 rat A. suum Extract ZYA 
Rocha 2009 Protective. ↓ IL-10, but not IL-1β or TNF, levels mouse A. suum larvae CIA 
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 Author Year Effect Species Parasite Component Disease Model 
McInnes 2003 
ES-62 given during collagen priming significantly reduced initiation 
of inflammatory arthritis. Crucially, ES-62 was also found to 
suppress collagen-induced arthritis severity and progression when 
administration was delayed until after clinically evident disease 
onset 
mouse A. vitae ES-62 CIA 
Harnett 2007 PC possess anti-inflammatory activity mouse A. vitae ES-62, PC mojety CIA 
Pineda 2012 
Target IL-17–producing network, (DC γ/δ or CD4+ T cells 
signalling). ↓MyD88 and TLRs (by Th17 cells). modulated γ/δ T 
cells migration (↓CD44), ↓IL-infiltrating cells 
mouse A. vitae ES-62 K/BxN-induced polyarthritis 
Al-Riyami 2013 Protective. ↓IFNγ and IL-17 mouse A. vitae ES62 SMA 11a CIA 
Pineda 2014 Protection, desensitization of the synovial fibroblast responses (IL-
22 dep). ↑IL-22 (serum and joints) mouse A. vitae ES-62 CIA 
Graepel 2013 Worsening. ↑complement C5a and MCP1 (serum) mouse H. diminuta larvae K/BxN-induced polyarthritis 
       
He 2010 Dependent on infection stage mouse S. japonicum larvae CIA 
Song 2011 
Infection 2w before immunization: reduced CIA severity, ↓ nti-CII 
IgG, IgG2a, ↑anti-CII IgG1 +; ↓Splenocyte proliferation (vs. 
polyclonal and Ag-specific stimuli), ↓ IFN-γ, TNF, IL-1β, IL-6 ↑ 
IL10 by CD4+. 
Infection at the onset of CIA: ↑Treg, ↓Th17. 
Infection 1w before immunization: CIA exacerbation. 
mouse S. japonicum 
larvae 
(productive 
infection: ♂+♀ 
larvae ) 
CIA 
Osada 2009 
Infection 2w before immunization: ↓Anti-IIC IgG and IgG2a. 
↓IFNγ, TNFα, IL-17A. ↑ IL-4, IL10 up-regulation. Abrogates up-
regulation of IL-1β, IL-6 and NFκB (inflamed paws ) 
mouse 
 S. mansoni larvae CIA 
Osada 2014 
Severity reduced in males, but not in females. Male: ↓ IL-17, TNF 
reduced, ↑ f IL-4, IL-10 .But: ↑ IgG rheumatoid factor and anti-
dsDNA IgG (serum) 
mouse (IL-1Ra 
KO) S. mansoni larvae Spontaneous RA 
Pearson 1975 Infected mice are protected (incidental finding). After treatment with piperazine: high incidence of adjuvant arthritis rat S. oblevata larvae CIA 
Ortiz-Flores 2013 No effect  T. crassiceps larvae 
adoptive OVA-specific T cell 
transfer 
Psoriasis 
Atochina 2006 Skin lesions prevention;↓Gr1+F4/80+ Macs,↓CD8+ T cells mice [fsn/fsn] S. japonicum LNFPIII (glycan) 
Spontaneous psoriasis-like 
pathology (flaky skin) 
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Author Year Effect Species Parasite Component Disease Model 
Transplant rejection 
Komine-Aizawa 2011 Reduced resorption rate from 42.9% (control) to 11.1% (rDiAg). ↓ IL-4, IL-23 and TNF (serum) mouse 
Dirofilaria 
immitis 
Recombinant 
polyproteins 
(rDiAg) 
immune mediated pregnancy 
loss (abortion-prone 
CBA/J × DBA/2J ) 
Li 2011 Delayed rejection. ↓CD4
+, CD8+, CD28+ T-cells, ↓Fkn mRNA. ↑IL-
10 (serum) rat 
Echinococcus 
multilocularis larvae orthotopic liver transplantation 
ledingham 1996 Delayed rejection. ↓mononuclear cell infiltration (CD4+ and CD8+ 
T cells). ↑ IL-4 expression (leukocytes) rat N. brasiliensis 
larvae and 
soluble worm 
extract 
kidney allografts 
Liwski 2000 
Delayed rejection. ↓cytotoxic T-lymphocyte activity of spleen T 
cells. ↑IL-4, IL-6 and ↓IFNγ and ↓ proliferation by T cells in 
response to allo-antigen. ↑IL-4+ CD8+ Tc2 cells 
rat N. brasiliensis larvae cardiac allograft 
Araujo 1977 Delayed rejection when grafting occurs in the egg-laying phase (60d p.i) mouse S. mansonii larvae skin allograft 
GeorgeJ. Svet-
Moldavsky 1969 Prolonged allogeneic graft survival. mouse T. spiralis larvae skin allograft 
Svet-Moldavsky 1971 Preventive effect 23d before allograft, lost when infection was performed 7d before allograft. mouse T. spiralis larvae skin allograft 
Alkarmi 1995 Larvae and larvae secretory antigens delayed allograft rejection. No effect of soluble larval extracts. mouse 
T.spiralis or 
T.pseudospiralis 
larvae, larvae 
secretory 
antigens and 
soluble larval 
extracts 
skin allograft 
Diabetes 
Imai 2001 Insulitis and diabetes prevention. Impaired islet Ag-specific Th1 response. Th2-type shift mouse (6w old) D.immitis DiAg NOD 
Lund 2014 
Insulitis and diabetes prevention (84% of mice, until 30w). ↓IFN-γ 
by autoreactive T cell. IgG2a to IgG1switch. M2 switch of 
peritoneal Macs (Ym1, Arg-1, TGFβ and PD-L1) 
mouse (4w old) F. hepatica Secreted protein NOD 
Liu 2009 Insulitis and diabetes prevention. CD25 and IL-10-independent mouse (4w old) H. polygyrus larvae NOD 
Mishra 2013 
Infection at 5-7w, inhibited T1D onset (until 40w). ↓ CD4+ T-cell 
STAT6 phosphorylation. ↑ IL-10 by Tregs. IL-10 dep. Transfer of 
CD4+ T cells from Hp NOD IL-4 KO mice to NOD mice prevented 
T1D. IL-10 essential in Th2-deficient environment (not in WT 
mice). 
mouse (IL-4 KO, 
5-7 week old) H. polygyrus larvae NOD 
130 
 Author Year Effect Species Parasite Component Disease Model 
Osada 2013 
Multiple low-dose model: immune mediated 1D: Hp prevented 
decrease in pancreatic islet size, ↓TNF, IL1β (pancreas, IL-10 and 
STAT6 indep). Single high-dose: immune independent T1D: no 
effect of Hp. 
mouse 
(STAT6KO, 
IFN-γKO, Il-10 
KO, 6w old) 
H. polygyrus larvae STZ 
Hubner 2009 
Insulitis and diabetes prevention. Th2 shift in response to main 
diabetes autoAg: ↑IL-4 and IL-5 αCD3/αCD28-stimulated 
splenocytes. ↑ insulin-specific IgG1. 
mouse (6w old) L. sigmodontis larvae NOD 
       
Hubner 2012 
Insulitis and diabetes prevention. Despite lack of Th2 shift 
(NOD.IL4KO). ↑ Treg proliferation (NOD.WT and NOD.IL4 KO). 
TGFβ dep, Treg indep WT, IL-10R indep (tested with Ab blockade 
in NOD.WT) 
mouse (IL-4 
KO) L. sigmodontis larvae NOD 
Yang 2013 Decreased weight gain and improved glucose metabolism. ↓hepatic steatosis (IL13-STAT6 dep). Preventive and therapeutic 
mouse (RIP2-
Opa1β cell KO, 
STAT6 KO, 
IL-13 KO) 
N. brasiliensis larvae HFD 
Ohsugi 1994 ↑ disease incidence in a pathogen free environment mouse (4w old) na  NOD 
Cooke 1999 Th2 shift mouse (4w old) S. mansoni larvae NOD 
Zaccone 2003 Insulitis and diabetes prevention (<4w age). ↑ IL-10 by T cells, 
Vα14i NKT cells mouse (4w old) S. mansoni soluble extracts NOD 
Zaccone 2009 
↑ T regs (pancreas, DC and TGFβ dep).↑ C-type lectins, IL-10 and 
IL-2. by DCs. ↑TGFβ, Iβ8, Galectins by T cells. Prevention by 
transfer of spleonocytes from SEA treated mice is dependent on 
CD25+ T cells. 
mouse (6w old) S. mansoni egg antigen NOD 
Zaccone 2011 ↑ FoxP3 (by CD4+ cells), IL-4, ↑ Th2 polarizing DCs. TGFβ and retinoic acid-dep mouse (5w old) S.mansoni 
glycoprotein ω-
1 (from egg 
antigen) 
NOD 
Zaccone 2010 Induce systemic Th2/Treg response.↑IL-2, IL-6, IL-10, and TGFβ (peritoneal cells), aaMacs (ARG1, FIZZ.1), ↑TGFβ by DC (in vitro) 
mouse (4-6w 
old) 
Schistosoma 
mansoni egg antigen NOD 
Saunders 2007 Th2 response; prevent β-cell disruption. mouse (4w old) T. spiralis or H. polygyrus larvae NOD 
Gastritis 
Martin 2010 
Co-infecction transiently reduced gastritis indices. Effect of 
helminth lost by 42w p.i. ↑ anti-inflammatory mediators mRNA 
(transient) 
gerbils B. filariasis larvae H. pylori induced gastritis 
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Author Year Effect Species Parasite Component Disease Model 
Whary 2014 Reduced development of gastric atrophy, dysplasia and prevented 
changes in the gastric flora. ↑ FoxP3+ cells in the corpus. mouse H. polygirus larvae H. pylori induced gastritis 
Fox 2000 Prevention of corpus gastritis and decreased chronic inflammation. 
↓ Th1 CKs mouse H. polygirus larvae H. felis induced gastritis 
Hepatitis 
Nascimento 2014 
↓ liver weight increase and transaminase levels at 8h, 24h an 7d 
after preventive treatment and at 7d after curative treatment. 
↑survival rate from 38.5 %, to 67 % (therapeutic) and to 100 % 
(preventive). ↓cellular infiltration, ↑IL-4, IL-10, and IL-13. ↑liver 
fibrosis 
Mouse A. suum Asc extract Concanavalin A-induced autoimmune hepatitis 
aaMacs: alternative activated macrophages, AHR: arways hyper responsiveness, BAL: bronchioalveolar lavage, CIA: collagen induced arthritis, CK: cytokines, CPG: cytosine phosphate guanosine, 
D/TNBS: Di/Tri-nitrobenzene sulfonic acid, EAE: experimentally induced autoimmune encephalomyelitis, EC: epithelial cells, ES: excretory/secretory antigen, DSS: dextran sodium sulphate, HFD: 
high fat diet, in/dep: in/dependent, LPS: lipopolysaccharide, na: not applicable, NKT: natural killer cells, NOD: non obese diabetic, OVA: ovalbumin, STZ: streptozotocin 
132 
 APPENDIX C 
Supplementary material for the second manuscript: Administration of T. suis Ova protects 
immunocompetent rabbit from DSS colitis, but is detrimental to immunosuppressed individuals 
 
C.1. Index of Tables 
Table C.1: Scoring system for the daily monitoring of the disease activity index. ............................ 135 
Table C.2: Scoring system for DSS-induced histological changes in the cecum. .............................. 136 
Table C.3: detection of T.suis specific DNA in intestinal samples of TSO treated rabbits ................ 137 
Table C.4: Genes differentially up-regulated in LPMC and IEC from TSO infected rabbits and in the 
caecal tissues of T. muris infected mice.. ........................................................................................... 139 
 
C.2. Index of Figures 
Figure C.1: Preventive treatment with TSO ova in a model of DSS induced acute colitis.. .............. 143 
Figure C.2: Neutrophil and eosinophils infiltration into the caecum.. ............................................... 144 
Figure C.3: Genomic signature for genes differentially expressed in LPMC and EC.. ...................... 145 
Figure C.4: Process network (PN) analysis of genes differentially regulated in LPMC and IEC from 
T. suis infected rabbits and in the caecal tissues of T. muris infected mice.. ..................................... 146 
Figure C.5: Preventive treatment with TSO ova in a model of DSS induced acute colitis in 
immunosuppressed (IS) and immunocompetent (Ctrl) rabbits. .......................................................... 147 
Figure C.6: Neutrophil and eosinophils infiltration in immunosuppressed rabbits ............................ 147 
Figure C.7: Modulation of the caecal niche by different stages of T. suis.. ....................................... 148 
 
  
 
133 
 
C.3. Supplementary Methods 
Analysis of peroxidase activity  
Peroxidase activity in caecal lysates was measured as previously described14. To achieve relative 
specificity for the neutrophils’ MPO the assay was conducted in presence of the EPO inhibitor 
aminotriazole (3-Amino-1H-1,2,4-triazole, 95%; Brunschwieg, Switzerland) at pH 6.0296. MPO 
activity (indicated as arbitrary units U/g.s) was calculated as mean absorbance (460 nm) per 
incubation time per protein content of the sample in grams determined by BCA assay (ThermoFisher, 
Rockford, USA)297. 
Fecal flotation 
5 g of fresh feces were collected 1 day before and 1 day after each TSO-gavage and 9 days after the 
DSS-treatment begin. The samples were immediately suspended in 300 ml water, filtered through a 
1mm sieve and incubated at RT for 30 min. The supernatant was discarded and 1 ml of the sediment 
was resuspended in 10 ml Sheather’s solution (454 g Sucrose in 355 ml water with 6ml 37% 
formalin), mixed briefly and centrifuged 5min at 500 g. 4 drops were collected with a smear loop, 
transferred to a slide and examined at 10x lens objective, (changing the plane of focus during the 
examination). As a positive control, 1 ml of the TSO-gavage solution was suspended in 10 ml 
Sheather’s solution and analyzed as described above.  
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C.4. Supplementary Tables 
Table C.1: Scoring system for the daily monitoring of the disease activity index. 
Score weight loss stool appearance and cecotrophs 
reduction in food 
intake 
reduction in 
beverage intake 
fur appearance 
0 None well-formed solid pellets, 
0 cecotrophs 
none none clean, bright fur 
1 0%-2% easy to smear and loose stool, 
≤1 cecotrophs 
0%-30% 0%-30% dim fur 
2 2%-5% loose stool, 
2-3 cecotrophs 
30%-60% 30%-60% shagged fur 
3 5%-10% loose smeared stool in cage, 
4-5 cecotrophs 
60%-90% 60%-90% smudgy, unclean 
fur 
4 > 10% loose smeared stool in cage, 
> 5 cecotrophs 
> 90% > 90% smudgy, stool-
stains, smeared 
anus 
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Table C.2: Scoring system for DSS-induced histological changes in the cecum. 
 Morphological features  Inflammation 
 Villous 
stunting 
Villous 
epithelial 
injury 
Crypt 
distortion 
 
Intraepithelial 
lymphocytes 
LP lymphocytes 
and plasma cells 
1 Normal mucosa Normal 
mucosa 
Normal mucosa  5–10/50 
IEL/epithelial cells 
25% of the villous 
lamina propria 
2 Mild villous 
stunting 
Mild villous 
epithelial 
injury 
Mild crypt 
distension, 
hyperplasia and 
distortion 
 11–30 IEL/50 
epithelial cells. 
25%–50% of the 
villous lamina 
propria 
3 Moderate 
villous stunting 
Moderate 
villous 
epithelial 
injury 
Moderate crypt 
distension, 
hyperplasia and 
distortion. 
 31–50 IEL/ 50 
epithelial cells may 
be focally clustered. 
50%–75% of the 
villous lamina 
propria. 
4 Marked villous 
stunting 
Marked 
villous 
epithelial 
injury 
 
Marked crypt 
distension, 
hyperplasia and 
distortion 
 51–100 IEL/ 50 
epithelial cells, may 
be clustered and at 
all levels of the 
epithelium 
75% – 100% of the 
villous lamina 
propria. 
Functional annotation was performed usind the David Functional Annotation Tool , 6.7, NIAID/NIH . 
Genes with FDR<0.1 where included in the analysis. Mouse cecum expression data where obtained from 
Foth, 2014230 
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 Table C.3: detection of T.suis specific DNA in intestinal samples of TSO treated rabbits 
 
Treatment IS/Ctrl Colitis No Ileum Caecum prox distal 
TSO 
Ctrl 
DSS 
8.9 - - - - 
8.14 - - - - 
9.4 - - 
 
  
8.1 - + - - 
8.8 - + - - 
9.9 - + 
 
  
9.1 - + 
 
  
9.13 - + 
 
  
10.7 - + - - 
10.9 - + - - 
10.1 - + - - 
10.15 - + + + 
Water 
8.4 - - - - 
8.5 - - - - 
8.12 - - - - 
8.15 - - - - 
IS 
DSS 
7.3 - - - - 
7.2 + - - - 
9.1 - + 
 
  
9.2 - + 
 
  
9.14 - + 
 
  
10.8 - + - - 
9.11 - + + + 
10.3 - + + + 
10.6 - + + + 
10.16 - + + + 
Water 
7.1 - + + + 
7.4 - + + + 
Veh Ctrl DSS 
8.7 na - na na 
8.1 na - na na 
8.11 na - na na 
8.13 na - na na 
9.3 na - na na 
9.5 na - na na 
9.16 na - na na 
10.5 na - na na 
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10.12 na - na na 
10.14 na - na na 
Water 
8.2 na - na na 
8.3 na - na na 
8.6 na - na na 
8.16 na - na na 
IS 
DSS 
7.5 - - - - 
9.7 na - na na 
9.12 na - na na 
9.15 na - na na 
10.2 na - na na 
10.4 na - na na 
10.13 na - na na 
Water 
9.6 na - na na 
9.8 na - na na 
10.1 na - na na 
10.11 - - - - 
Ctrl: control group (immunocompetent), IS: immunosuppressed ; +: positive; - : negative; na: not analyzed.  
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 Table C.4: Genes differentially up-regulated in LPMC and IEC from TSO infected rabbits and in the caecal 
tissues of T. muris infected mice. 
Gene ID KEGG pathway Biocarta Gene name 
adam8   a disintegrin and 
metallopeptidase domain 8 
alox15 Arachidonic acid metabolism,  arachidonate 15-
lipoxygenase 
arg1 Arginine and proline metabolism, Catabolic Pathways for 
Arginine , Histidine, Glutamate, 
Glutamine and Proline, 
arginase, liver 
arhgdib Neurotrophin signaling pathway, Caspase Cascade in Apoptosis, 
D4-GDI Signaling Pathway, 
FAS signaling pathway (CD95), 
HIV-I Nef, TNFR1 Signaling 
Pathway 
Rho, GDP dissociation 
inhibitor (GDI) beta 
arid5a   AT rich interactive domain 
5A (MRF1-like) 
basp1   brain abundant, membrane 
attached signal protein 1 
c1qb Complement and coagulation 
cascades, Prion diseases, Systemic 
lupus erythematosus, 
 complement component 1, 
q subcomponent, C chain 
c1qc Complement and coagulation 
cascades, Prion diseases, Systemic 
lupus erythematosus, 
 complement component 1, 
q subcomponent, beta 
polypeptide 
ccrl2   chemokine (C-C motif) 
receptor-like 2 
cd14 MAPK signaling pathway, Toll-
like receptor signaling pathway, 
Hematopoietic cell lineage, 
Regulation of actin cytoskeleton, 
Inactivation of Gsk3 by AKT 
causes accumulation of 
b-catenin in Alveolar 
Macrophages, 
CD14 antigen 
cfp  Alternative Complement 
Pathway, 
complement factor 
properdin 
chi3l1   chitinase 3-like 1 
ciita Antigen processing and 
presentation, Primary 
immunodeficiency, 
 class II transactivator 
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csf1r Cytokine-cytokine receptor 
interaction, Endocytosis, 
Hematopoietic cell lineage, 
Pathways in cancer, 
CBL mediated ligand-induced 
downregulation of EGF 
receptors, METS effect on 
Macrophage Differentiation, 
colony stimulating factor 1 
receptor 
csf2rb Cytokine-cytokine receptor 
interaction, Apoptosis, Jak-STAT 
signaling pathway, 
IL 3 signaling pathway, colony stimulating factor 2 
receptor, beta, low-affinity 
(granulocyte-macrophage) 
dhrs9 Retinol metabolism,  dehydrogenase/reductase 
(SDR family) member 9 
fgr Chemokine signaling pathway, Roles of αβγ -arrestin-dependent 
Recruitment of Src Kinases in 
GPCR Signaling, 
Gardner-Rasheed feline 
sarcoma viral (Fgr) 
oncogene homolog 
gpr141   G protein-coupled receptor 
141 
hck Chemokine signaling pathway, Fc 
gamma R-mediated phagocytosis, 
Roles of αβγ-arrestin-dependent 
Recruitment of Src Kinases in 
GPCR Signaling, 
hemopoietic cell kinase 
hdc Histidine metabolism,  histidine decarboxylase 
hk3 Glycolysis / Gluconeogenesis, 
Fructose and mannose 
metabolism, Galactose 
metabolism, Starch and sucrose 
metabolism, Amino sugar and 
nucleotide sugar metabolism, 
Insulin signaling pathway, Type II 
diabetes mellitus, 
 hexokinase 3 
il1b MAPK signaling pathway, 
Cytokine-cytokine receptor 
interaction, Apoptosis, Toll-like 
receptor signaling pathway, NOD-
like receptor signaling pathway, 
Cytosolic DNA-sensing pathway, 
Hematopoietic cell lineage, Type I 
diabetes mellitus, Alzheimer's 
disease, Prion diseases, Graft-
versus-host disease, 
Signal transduction through 
IL1R, IL 5 Signaling Pathway, 
Msp/Ron Receptor Signaling 
Pathway, NFkB activation by 
Nontypeable Hemophilus 
influenzae, 
interleukin 1 beta 
il1r2 MAPK signaling pathway, 
Cytokine-cytokine receptor 
interaction, Hematopoietic cell 
lineage, 
 interleukin 1 receptor, type 
II 
il1rl1   interleukin 1 receptor-like 1 
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 il6 Cytokine-cytokine receptor 
interaction, Toll-like receptor 
signaling pathway, NOD-like 
receptor signaling pathway, 
Cytosolic DNA-sensing pathway, 
Jak-STAT signaling pathway, 
Hematopoietic cell lineage, 
Intestinal immune network for 
IgA production, Prion diseases, 
Pathways in cancer, Graft-versus-
host disease, Hypertrophic 
cardiomyopathy (HCM), 
Cytokine Network, Erythrocyte 
Differentiation Pathway, Role of 
ERBB2 in Signal Transduction 
and Oncology, IL-10 Anti-
inflammatory Signaling 
Pathway, IL 17 Signaling 
Pathway, Signal transduction 
through IL1R, IL 5 Signaling 
Pathway, IL 6 signaling 
pathway, Cytokines and 
Inflammatory Response, 
Regulation of hematopoiesis by 
cytokines, 
interleukin 6 
irf5 Toll-like receptor signaling 
pathway, 
 interferon regulatory factor 
5 
itgb7 Focal adhesion, ECM-receptor 
interaction, Cell adhesion 
molecules (CAMs), Intestinal 
immune network for IgA 
production, Regulation of actin 
cytoskeleton, Hypertrophic 
cardiomyopathy (HCM), 
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC), Dilated 
cardiomyopathy, 
 integrin beta 7 
itk Chemokine signaling pathway, T 
cell receptor signaling pathway, 
Leukocyte transendothelial 
migration, 
The Co-Stimulatory Signal 
During T-cell Activation, 
IL2-inducible T-cell kinase 
lcp2 Natural killer cell mediated 
cytotoxicity, T cell receptor 
signaling pathway, Fc epsilon RI 
signaling pathway, 
 lymphocyte cytosolic 
protein 2 
lpcat2   lysophosphatidylcholine 
acyltransferase 2 
lrrc33   leucine rich repeat 
containing 33 
plek   pleckstrin 
ptafr Calcium signaling pathway, 
Neuroactive ligand-receptor 
 platelet-activating factor 
receptor 
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interaction, 
ptpn7 MAPK signaling pathway,  protein tyrosine 
phosphatase, non-receptor 
type 7 
sell Cell adhesion molecules (CAMs), Adhesion Molecules on 
Lymphocyte, Monocyte and its 
Surface Molecules, Neutrophil 
and Its Surface Molecules, 
selectin, lymphocyte 
serpinb2  Fibrinolysis Pathway, serine (or cysteine) 
peptidase inhibitor, clade 
B, member 2 
sh3kbp1 Endocytosis, CBL mediated ligand-induced 
downregulation of EGF 
receptors, 
SH3-domain kinase 
binding protein 1 
sla   src-like adaptor 
slc45a3   solute carrier family 45, 
member 3 
srgn   serglycin 
tgm1   transglutaminase 1, K 
polypeptide 
tnf MAPK signaling pathway, 
Cytokine-cytokine receptor 
interaction, Apoptosis, TGF-beta 
signaling pathway, TLR signaling 
pathway, NLR signaling pathway, 
RIG-I-like receptor signaling 
pathway, Hematopoietic cell 
lineage, … 
Cadmium induces DNA 
synthesis and proliferation in 
macrophages, Cytokine 
Network, Free Radical Induced 
Apoptosis, HIV-I Nef, … 
tumor necrosis factor 
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 C.5. Supplementary Figures 
 
 
Figure C.1: Preventive treatment with TSO ova in a model of DSS induced acute colitis. A. Experimental 
layout. B. Weight progression from day 0 (first TSO/Vehicle treatment) to day 35 (day of euthanasia and organ 
sampling). Colitis was induced at day 26 by administration of 0.1% DSS (w/v) in the daily beverage for 5. Dots 
represent mean ± SD. 
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 Figure C.2: Neutrophil and eosinophils infiltration into the caecum. Infiltration was determined indirectly by 
measuring the caecal peroxidase activity. Caecal specimens were excised and homogenized. The supernatants 
were assayed for the determination of the peroxidase activity with or without the selective eosinophil-
peroxidase inhibitor aminotriazole (AMT), activity was normalized for the total protein content as determined 
by BCA test. Dots represent single animals, bars show mean ± SEM, *P<0.05, unpaired t test.  
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Figure C.3: Genomic signature for genes differentially expressed in LPMC and EC. RNA was prepared from 
cells isolated from rabbit ceca (n=3 per group) and subjected to genome wide expression analysis. Hierarchical 
cluster analysis was used to sort expression profiles for the 4 treatment groups. (A) Heatmap of the altered 
expression of gens in the different groups compared. Each column displays the genomic signature for 1 subject. 
Genes up regulated are displayed in red, whereas down regulated genes are displayed in blue, as indicated on 
the accompanying expression scale. (B) Visualization of the under- (left) and over- (right) expressed genes in 
the TSO DSS, Veh DSS and TSO Water groups in comparison to the control Veh Water group. Genes having a 
fold change value FC>|1| and P<0.05 were considered differentially expressed genes and were included in the 
analysis. 
. 
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 Figure C.4: Process network (PN) analysis of genes differentially regulated in LPMC and IEC from T. suis 
infected rabbits and in the caecal tissues of T. muris infected mice. Black bars show the percentage of genes 
found in both rabbit and mice. The percentage of unique genes is showed in white bars for rabbit and in grey 
bars for mouse. MIF: Macrophage migration inhibitory factor, PEL: Platelet-endothelium-leucocyte 
interactions, TCR: T cell receptor. Analysis was performed with metacore. Genes with FDR<0.1 where included 
in the analysis. 
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Figure C.5: Preventive treatment with TSO ova in a model of DSS induced acute colitis in immunosuppressed 
(IS) and immunocompetent (Ctrl) rabbits. A. Experimental layout: IS rabbit received daily Cyclosporine A 
(CycA) and Methylprednisolone (MP). B. Weight progression from day -14 (start of IS treatment) to day 35 
(day of euthanasia and organ sampling) Data show mean± SD from one representative experiment. C. total 
WBC was measured before the experiment begin (d0) and at day 1, 14, 21 and 35. Dots represent single 
animals, lines connect arithmetic mean. Data are pooled from 3 independent experiments. 
 
Figure C.6: Neutrophil and eosinophils infiltration in immunosuppressed rabbits. Infiltration into the caecum 
was determined indirectly by measuring the caecal peroxidase activity. Caecal specimens were excised and 
homogenized. The supernatants were assayed for peroxidase activity with or without the selective eosinophil-
peroxidase inhibitor aminotriazole (AMT); activity was normalized for the total protein content as determined 
by BCA test. D: DSS, W: water, V: Vehicle, T: TSO, IS: immunosuppressed, Ctrl: control. Dots represent 
single animals, bars show mean ± SEM, *P<0.05, two-sided pValue, unpaired t test 
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Figure C.7: Modulation of the caecal niche by different stages of T. suis. In immunocompetent hosts infection 
with T. suis is cleared before the parasite reaches a late larval stages. T. suis larvae exert a beneficial effect on 
the inflamed mucosa and down-regulates the expression of several colitogenic pathways. In 
immunocompromised hosts T. suis develops further and the protective effect is lost. A strong remodelling of the 
caecal mucosa occurs and the persistent Trichuris infection leads to an exacerbation of colitis. Black arrows 
indicate stimulatory pathways; red diamond-tipped arrows indicate inhibitory pathways. 
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